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General introduction 
 
Cystic fibrosis (CF) is an autosomal recessive lethal multi-organ disorder. Over 1000 
mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene 
have been described and there is a wide range of phenotypical expressions even 
within one CFTR genotype. Morbidity and mortality in CF patients are primarily 
related to lung disease that is characterized by thick mucus of abnormal composition 
in the airways. The resultant chronic airway infection and inflammation leads to 
structural and functional abnormalities early in life and eventually to death from 
respiratory insufficiency. Very little is known, however, about the mechanisms by 
which early chronic airway infection and inflammation affect growth of airways and 
alveoli in CF patients. Lung growth will become a relevant issue in the light of 
possible early intervention and improved survival. The structural lung abnormalities 
in CF predominantly occur in the airways and consist of airway wall thickening and 
bronchiectasis.  
 
For clinical management of CF related lung disease to be effective, onset and 
progression of the lung disease is commonly closely monitored, either indirectly by 
monitoring lung function or more directly by monitoring lung structure. Pulmonary 
function tests (PFTs), such as spirometry and body plethysmography, are considered 
the most important tools for monitoring lung function from the age of 5-6 years 
onwards. Chest radiography at least once a year is one of the tools to monitor lung 
structure. Another tool is computed tomography (CT) scanning. CT scanning 
provides information of structural lung damage that is not only more detailed but also 
more closely related to the pathologic changes in CF compared to that obtained from 
chest radiography. Studies in the early nineties have shown that CT scans are more 
sensitive than chest radiographs in the early detection of CF related structural lung 
abnormalities. CT scoring systems were also found to correlate moderately to good 
with PFTs. Moreover, CT scans revealed structural abnormalities in some CF patients 
with normal PFTs.  
 
Various scoring systems have been developed to quantify the structural lung 
abnormalities on CT scans of CF patients. Unfortunately, for several of these the 
interobserver and intraobserver reproducibility is not tested or not described. As a 
comparative evaluation is lacking as well, it is hard to determine which scoring 
system(s) would best serve the purpose.  
 
In addition to scoring, CT scans are also used for quantitative measurements of 
airway wall and lumen dimensions. Quantitative CT analysis techniques have been 
validated for other lung diseases, such as chronic obstructive pulmonary disease 
(COPD), but have not yet been systematically studied in CF. Longitudinal studies in 
CF comparing changes in CT scores or quantitative CT measures with PFTs are still 
lacking.  
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Repetitive CT scanning introduces radiation exposure. It is unknown, however, 
whether the risk of radiation exposure outweighs the potential benefit of monitoring 
CF patients using CT scans.  
 
The issues outlined above need to be addressed in order to determine the risk/benefit 
ratio of monitoring CF related lung disease using CT scans. 
 
 
Aim of the study 
 
The aims of this thesis are:  
1) To evaluate the reproducibility of present CT scoring systems for the detection of 
structural lung abnormalities in CF 
2) To evaluate quantitative airway measurements in CF  
3) To assess in longitudinal studies the sensitivity of CT scans and PFTs for the 
monitoring of onset and progression of lung damage in children and adults with CF 
4) To develop a computational model for studying the risks associated with CT 
scanning in CF and to evaluate if the dose per CT scan can be reduced 
5) To evaluate the potential of CT scanning to measure lung dimensions throughout 
the growth period 
 
The studies addressing these aims are described in this thesis. First, chapter 2 
presents the available knowledge of monitoring lung disease in children and adults 
with CF at the time of the start of the studies. Chapter 3 describes the validation of 
five published CT scoring systems for CF patients. In addition, it describes the use of 
quantitative CT measurements of airways and arteries in CF patients. In chapter 4 
the studies on the sensitivity of CT and PFTs for monitoring onset and progression 
of CF lung disease are described. Chapter 4.1 describes longitudinal changes in CT 
and PFTs in a Dutch cohort of 48 children with CF detected with the use of CT 
scoring systems. Chapter 4.2 describes those changes in a Swedish cohort of 72 
children and 47 adults with CF. Chapter 4.3 describes in a smaller sample of the 
Dutch cohort the use of quantitative CT measurements of airway wall thickening and 
bronchiectasis in addition to the CT scoring systems. Chapter 5 is focused on 
radiation risks associated with CT scanning in CF. In chapter 5.1 the computation 
model to study radiation risks related to repetitive CT scanning in CF is described. 
Chapter 5.2 describes a study to determine whether the number of CT images and 
therefore the dose per CT scan could be reduced without any significant loss of 
information in children with CF. In Chapter 6 two studies are described (chapters 6.1 
and 6.2) in which CT scans of control subjects were used to study the relationship 
between airways, arteries, airspaces (alveoli) and subject height throughout the growth 
period. These studies provide normative data that can be used to study lung growth 
in disease. In chapter 7.1 of chapter 7 a summary of the studies described in this 
thesis is given. In chapter 7.2 the implications of our findings are discussed. Chapter 
7.3 provides directions for future research. 
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Chapter 2.1 Cystic Fibrosis 
 
Cystic fibrosis (CF) is an autosomal recessive genetic disorder, with a prevalence of 
approximately one in 3000-3500 in live-born Caucasians in the United States of 
America 1. The genetic defect leads to a dysfunctional or absent chloride channel 
protein; i.e. the cystic fibrosis transmembrane conductance regulator (CFTR) protein 
2. Over 1000 causative mutations in CF have been described. The relationship 
between genotype and phenotype is weak 2. Hence, genotyping is of little help in 
predicting the course of disease. Even within one CFTR genotype there is a wide 
variability in clinical expression. The dysfunctional or absent CFTR protein leads to 
multi-organ dysfunction and to shorter life expectancy 2. Lung abnormalities are the 
major cause of the morbidity and mortality 2. Advances in patient management and 
improvements in nutritional, antibiotic 3, anti-inflammatory 4 and mucolytic 5, 6 
treatment of CF lung disease have improved median survival from less than 1 year in 
1940 to over 32 years in 2000 7-9.  
 
Pathophysiology of CF lung disease 
CF lung disease starts and remains predominantly located in the airways. Parenchymal 
changes are less frequent and tend to occur later in the disease process. The 
characteristic mucous plugging, infection and inflammation in the airways lead to 
structural changes such as airway wall thickening and bronchiectasis 2, 10, 11. The 
structural changes eventually lead to functional abnormalities of the lungs. This 
translates into reduced exercise tolerance, cough and dyspnea, decline in quality of life 
and shorter life expectancy 12, 13 (Figure 1).  
 
Inflammation and infection 
In most CF patients the onset of neutrophil mediated inflammation occurs in the first 
few years of life. In addition, most patients show chronic bacterial infection of the 
lower airways early in life 14-16. Common pathogens found early in life include: 
Staphylococcus aureus; Haemophilus influenzae; Pseudomonas aeruginosa; and less 
frequently Aspergillus fumigatus 2. It is generally accepted that the inflammatory 
response is excessive and contributes to the structural lung damage in CF 2, 10. 
However, it is still debated whether infection always precedes the inflammatory 
response 14-16, 19-23, possibly because there is considerable regional heterogeneity of the 
early infection 17, 18.  
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Figure 1 Pathogenesis of CF airway disease 
 
In cystic fibrosis (CF), two mutations in the cystic fibrosis transmembrane (CFTR) gene lead to an 
absent or dysfunctional CFTR protein. This in turn results in abnormally thick mucus of abnormal 
composition and mucous plugging in the airways, thereby creating a beneficial environment for 
chronic bronchial bacterial and fungal infections. In addition the airways show abnormal 
inflammatory responses. All three – mucous plugs, infection and inflammation – lead to structural 
abnormalities, mainly in the airways, which then interact in a vicious circle. The structural 
abnormalities, such as bronchiectasis and airway wall thickening, eventually lead to functional 
abnormalities of the airways. Finally, CF lung disease leads to lung transplantation or premature 
death. 
 
Changes in airway structure 
Only few (quantitative) pathology data are available concerning airway abnormalities 
in CF. As most pathologic studies were done on end-stage lungs, these data have 
limited validity for early lung disease. Over the last two decades the management of 
CF lung disease has substantially improved. It is likely, therefore, that consecutive 
generations of CF patients show different structural abnormalities. Autopsy studies 
have shown that at birth CF patients have macroscopically normal airways 2, 24-29. 
Then the earliest manifestation of airway disease is mucous plugging of bronchi and 
bronchioles in the first weeks of life 2, 24, 30, 31. Autopsy data suggest that airway 
abnormalities start in the peripheral airways 11, 30, 32, 33. The mucous plugging and 
abnormal mucus composition are likely to facilitate bacterial infection and the 
ensuing bronchiolectasis, bronchiectasis and thickening of the airway walls 11, 24, 31, 34-
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36. Autopsy specimens revealed that the prevalence of bronchiectasis increases with 
age from 20% at 0-4 months to 75% at 2-6 years and 100% at older ages 37. In 
addition, 67% of children in the 0-4 month old group had mucopurulent plugging of 
the airway lumen and all children in that age group had inflammation of the bronchial 
walls 37. These findings suggest that the onset of abnormalities in the larger airways 
occurs early in life. The bronchiectasis seen in autopsy specimens was characterized 
by widely dilated central bronchi with obliterated peripheral airways 38-40. The airway 
wall thickening was correlated to the severity of airway inflammation 35, 41. The 
severity of airflow obstruction in lung diseases such as chronic obstructive pulmonary 
disease (COPD) and asthma is proportional to the severity of airway wall thickening 
41, 42. A similar correlation was reported in CF. Airway wall thickness was increased 
threefold compared to COPD 35. In addition, the smooth muscle area and epithelial 
height were markedly increased and the area of cartilage was decreased. Furthermore, 
like in other studies, a marked destruction of the epithelial layer was described 43, 44. 
Airway wall thickening, destruction of the epithelial layer and loss of cartilage are all 
likely to contribute to the airflow obstruction in CF patients 35.  
 
Changes in lung parenchyma 
The lung parenchyma is relatively little affected in CF. Even at later stages of the 
disease the extent of parenchymal abnormalities remains relatively small. Parenchymal 
abnormalities consist of emphysema, bullae and consolidations or atelectasis. 
Although uncommon, emphysema has been observed in two-year-old children and 
also in 41% of 10 to 24-year-old patients in an autopsy study 37, 40.  
 
Changes in lung vasculature 
The bronchial arterial circulation is markedly hypertrophied in CF 45. In contrast, the 
major branches of the pulmonary arterial circulation are reduced in size and there are 
fewer small pulmonary arteries (diameter< 500 µm) 34, 36, 46. It was hypothesized that 
the pulmonary arterial system fails to develop completely and that it is hypoxia that 
makes small arterial branches disappear as the disease progresses 46. 
 
CF lung disease and lung growth 
The available pathology data indicate that the structural abnormalities in CF lungs 
start to develop in the first weeks or months after birth. Noteworthily, the human 
lungs are not fully developed at birth 47. Most of the alveoli develop in the first two 
years of life 48. In addition, both airways and alveoli increase in size throughout 
childhood 47. Early CF lung disease is likely to affect postnatal growth of airways and 
alveoli, but this has not yet been shown and requires further investigation.  
 
Clinical monitoring of CF lung disease 
For clinical management of CF lung disease to be effective, it is believed that the 
onset and progression of lung abnormalities must be closely monitored. Therefore in 
routine clinical practice close attention is paid to the following components of CF 
related lung disease: infection; inflammation; lung structure; and lung function. 
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Adequate monitoring enables to individualize treatment. Lung infection can be 
monitored by sputum, throat swabs and bronchoalveolar lavage fluid cytology and 
cultures and blood serology 49-51. For monitoring of lung inflammation, blood 
markers, induced sputum and bronchoalveolar lavage fluid can be used 2, 52, 53. In the 
remainder of this chapter we will focus on the evaluation of lung function (chapter 
2.2) and lung structure using chest radiographs (chapter 2.3) and computed 
tomography (CT, chapter 2.4) as tools to monitor lung disease in CF patients. 
 
 
Chapter 2.2 Monitoring of lung function 
 
Traditionally, parameters derived from pulmonary function tests (PFTs) are 
considered the gold standard to monitor CF related lung disease. Spirometric or flow 
volume parameters such as forced expiratory volume in one second (FEV1), forced 
vital capacity (FVC), and mid-expiratory flow (FEF25-75) are used both in clinical 
management and in clinical studies 2. Most children aged five-seven years or older will 
be able to perform a flow volume maneuver. Even a high proportion of three-year-
olds were found to be able to do so with training 54. In children aged six years or 
older lung volumes can be measured using whole body plethysmography and 
spirometry. Most clinics will perform a flow volume measurement at each clinical 
visit and more extensive lung function measurements, including whole body 
plethysmography, (once yearly) at the annual check up.  
 
Spirometry 
The use of PFTs as a monitoring tool has several advantages. The flow-volume 
maneuver is inexpensive, fast and carries no risk for the patient. Yet there are several 
limitations as well.  
 
• Firstly, the signal-to-noise ratio for the obtained parameters is relatively low 
since the measurement depends on the patient’s co-operation. For this reason 
it is a challenge to do a flow volume maneuver in children younger than six 
years of age. In addition, the results of PFTs are expressed as percent 
predicted of reference values obtained in a sample of the general population. 
The use of these reference values introduces variability especially in the years 
of the pubertal growth spurt 55.  
• Secondly, PFTs are insensitive to localized or focal disease.  
• Thirdly, most PFTs parameters, such as FEV1 and FVC, are insensitive to 
early lung disease which occurs especially in the peripheral airways. The FEF25-
75 is a relatively more sensitive parameter to early changes 6, 11, but has a higher 
variability compared to FEV1 and FVC.  
• Fourthly, PFTs do not inform on the nature of the structural abnormalities 
since PFTs parameters are influenced by many factors, e.g. effort by the 
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patient; mucous plugging; bronchiectasis; atelectasis; airway dimensions; and 
airway and parenchyma mechanics. PFTs parameters can be considered a 
composite score of all these factors.  
• Fifthly, many CF children nowadays show normal spirometry at the age of five 
or six years 56, 57 and functional tests can remain stable over several years, 
limiting its usefulness in monitoring early disease in children with CF.  
• Finally, on the other end of the spectrum PFTs are weak predictors of the 
two-year mortality in CF 58. 
 
 
Alternative lung function tests 
Apart from spirometry, various other lung function tests have been proposed for the 
detection and follow-up of lung disease in CF. Body plethysmography is a more 
demanding technique in comparison with flow volume measurements. It allows to 
measure lung volumes such as total lung capacity (TLC) and residual volume (RV). 
The ratio of RV to TLC is thought to be a sensitive test of air trapping and a 
relatively early sign of small airway disease 2. A more recent and promising 
development is the use of gas mixing techniques to detect inhomogeneity of 
ventilation within the lungs. Abnormalities of ventilation can be found early in the 
disease by measuring lung clearance indices using multiple breath inert gas washout 
tests of helium or sulphur hexafluoride (SF6) 59. These tests, however, have not yet 
been widely used to monitor CF patients. A variety of other functional tests have 
been developed to study CF lung disease in an early phase 19-21, 54, 59-67. A discussion of 
these tests is beyond the scope of this thesis, but they have been reviewed by others 
61. 
 
 
Chapter 2.3 Monitoring of lung structure using 
chest radiography 
 
Chest radiographs are widely used to monitor lung structure, both for the annual 
check up and for the monitoring of exacerbations. This routine is mostly started from 
the time when CF is diagnosed.  
 
The advantage of chest radiography over other structural imaging techniques such as 
CT scanning is the lower radiation exposure to the patient and the low costs. Cross-
sectional studies reported a strong correlation between chest radiograph scores and 
surrogate end-points for CF such as the FEV1 68-72. 
However, chest radiography has some major limitations.  
 
• Firstly, the terminology used by radiologists to describe, for instance, linear 
markings or nodular cystic lesions does not closely correlate with the 
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pathology seen in CF. Correct interpretation of the nature of the structural 
lung abnormalities on chest radiographs is difficult since a chest radiograph is 
a two-dimensional superimposed projection of a three–dimensional, complex 
structure.  
• Secondly, the prognostic value of chest radiograph abnormalities is unknown.  
• Thirdly, there are conflicting results concerning the reproducibility of the 
various chest radiograph scoring systems for CF 57, 68-74. While some studies 
reported good inter- and intraobserver agreement 69, 70, 72, others found a poor 
reproducibility 57, 68, 71, 74. Comparison between these studies is hampered by 
differences in statistical methods used to calculate reproducibility. For 
example, one study reported intraclass correlation coefficients of 0.74, 0.73 
and 0.61 for three scoring systems (intraclass correlation <0.8 represents less 
than good agreement) 71. In contrast, another study reported a very low 
interobserver variability of only -1.0 to 6.7% of the mean of the observers for 
six scoring systems 69.  
• Fourthly, longitudinal data have consistently shown that the annual rate of 
worsening in FEV1 is greater than the annual rate of worsening in chest 
radiograph scores 70, 73.  
• Fifthly, data on the sensitivity of chest radiograph scores to detect CF lung 
disease at an early stage are limited and conflicting. While in one study chest 
radiographs were found to show abnormalities at an earlier stage than FEV1 57, 
in another study this was the other way round 73.  
• Finally, quantitative measurements of airway lumen dimensions are limited to 
the first two generations of the airway tree and measurements of airway wall 
dimensions are not possible on chest radiographs.  
 
Since the early nineties high-resolution CT (HRCT) has frequently been reported to 
be more sensitive than chest radiographs to detect structural lung abnormalities in 
CF. In 1989 Hansell and Strickland 75, two radiologist, stated HRCT to be more 
accurate than chest radiographs in locating the disease process in CF 75. Others 
reported normal chest radiographs in 17 of 38 adult CF patients and only 3 of those 
38 had a normal HRCT 76. Bronchiectasis could be demonstrated on HRCT in 23 of 
the 38 patients, whereas it was observed with chest radiographs in only 3 patients. A 
similar phenomenon was observed in CF children 77, with 25% of them having a 
normal chest radiograph co-occurring with an abnormal HRCT scan. Later studies all 
have confirmed the limited ability of chest radiographs to detect early CF lung disease 
relative to HRCT 78-82. 
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Chapter 2.4 Monitoring of lung structure  
using computed tomography 
 
Technical advances in CT allow direct assessment of airway structure in vivo (Figure 
2). The first report of this technique in CF was published in 1986 83 and followed by 
several cross-sectional studies 20, 75, 76, 78-81, 84-98. One cross-sectional study showed that 
12 of 34 CF patients had a normal FEV1 despite evidence of focal areas of airway 
lesions on their CT scans 79, which would suggest that CT may be more sensitive than 
the gold standard FEV1 for the detection of early lung disease in CF patients.  
 
Figure 2 CT estimated dimensions of airway and accompanying pulmonary artery 
 
This schematic representation shows the various measurements that can be made on CT images of 
airways and the accompanying vessels. Linear measurements include the airway perimeter (Pi), the 
long and short axes of the outer airway area (Ao) and the lumen area (Ai), wall thickness (Awt), 
airway lumen diameter (ALD), airway outer diameter (AoD = ALD + 2 * Awt) and arterial diameter 
(AD). Ratios of various linear dimensions include the airway lumen diameter to arterial diameter 
(ALD/AD), airway wall thickness to arterial diameter (Awt/AD), airway wall thickness to airway 
lumen diameter (Awt/ALD) as well as long to short axis ratios which are measures of the obliquity 
of the section. The area dimensions include the airway lumen area (Ai), airway wall area (Aaw), outer 
airway area (Ao = Aaw + Ai) and arterial area (AA). Ratios of various areas include the airway lumen 
area to arterial area (Ai/AA), airway wall area to arterial area (Aaw/AA) and percent wall area 
(WA%= Aaw/Ao*100%). The square root of wall area (SqrtAaw) is often derived since it is relatively 
linearly related to Pi. Finally, airway dimensions can be referenced to body surface area (eg Aaw/BSA 
and Awt/BSA).  
 
MONITORING OF CYSTIC FIBROSIS LUNG DISEASE 
 
  
 
14
 
CT scan acquisition 
CT scans designed to assess airway structure involve thin slice images (typically 1-2 
mm axial) acquired using a “stop and shoot” protocol and reconstructed using an 
edge-enhancing algorithm, known as the HRCT protocol (Figure 3). To reduce the 
radiation burden as well as the scanning time, a gap of 10 millimeters is kept between 
images. For full-lung helical CT scanning, the images are acquired while the CT 
scanner table moves continuously. Until the recent introduction of multi-detector 
row CT scanners, the usefulness of this technique was limited by a relatively long 
scanning (breath-hold) time and high radiation exposure. These scanners allow much 
faster scanning at lower radiation dose relative to the old single detector scanners and 
will be useful in future studies in CF.  
 
Figure 3 ‘Stop and shoot’ high-resolution CT protocol  
 
Common CT protocols for imaging of the airways include thin sections and an edge-enhancing 
algorithm commonly referred to as high-resolution CT (HRCT). These scans are performed during 
breath-hold. The patient in supine position on the CT scanner table is asked to take a deep breath 
and to hold it. During the breath-hold a 1-mm thick CT section is taken, the table is moved 10 mm 
and a second section is taken. Then the patient is given the opportunity to breathe normally for a 
short period and the procedure is repeated till the lungs are fully covered (approximately 25 sections). 
In more recent protocols the patient is then asked to exhale as far as possible and hold breath. 
During this breath-hold three expiratory images are taken at specified locations. 
 
HRCT scoring systems 
The data provided by a CT scan are a series of images. For use in clinical trials and in 
clinical research these graphic data must be converted to numerical data. In CF, 
various HRCT scoring systems have been used for this conversion since 1991 78-81, 91-
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95, 98. These all make use of a composite score systematically evaluating a number of 
features on CT scans (Table 1). HRCT scoring studies have been useful in studying 
CF lung disease. They have confirmed pathologic studies by demonstrating that in 
many patients the onset of airway disease occurs early in life (Table 2). Several cross-
sectional studies demonstrated a strong correlation between lung function parameters 
and HRCT scoring systems 80, 94, 95, 98. However, in young children lung function 
parameters and HRCT scoring systems were found to correlate only weakly or not at 
all 84, 93 (Table 3). All studies were cross-sectional in design. A variety of semi-
quantitative scoring systems was used of which the intra- and interobserver variation 
was often poorly defined (Table 4). The components of the scoring systems are ill-
defined and there is no consensus on which system is to be preferred to follow up 
CT scans of CF patients.  
 
Table 1 Overview of components of the various CT scoring systems for CF 
System: 
Year: 
Bhalla 
1991 
Nathanson 
1991 
Maffesanti 
1996 
Santa-
maria 98 
Helbich 
1999 
Brody 
1999 
Robinson 
2001 
Scoring per: BPS 12 zones 4 zones BPS BPS Lobes lobes 
Bronchiectasis * * * * * * * 
Airway wall 
thickening 
*  * * * * * 
Mucous plugging * *  * * * * 
Sacculation or 
abscess 
*    *   
Bullae *   * *   
Emphysema *    *   
Atelectasis or 
consolidation 
*   * *  * 
Air trapping    *   * 
Acinar nodules    *    
Septal thickening    *    
Ground glass 
opacities 
   *    
Mosaic perfusion     *   
Alveolar 
consolidation 
  *   *  
Atelectasis, bullae 
and cysts 
  *   *  
Overinflation   *   *  
BPS = broncho-pulmonary segments 
* Included in the scoring system
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Table 2 Prevalence (%) of airway abnormalities on CT in CF 
Study Year Mean age ± 
SD (range) 
N BE AWT MP 
central 
MP 
Peri-
pheral 
GG AT 
Helbich 1999 2.4 ± 1.5 
(0-5) 
20 45 40 10 NI 50 NI 
Stiglbauer 1992 4.8 (0.3-9.7) 24 65 91 48 NI 4.2 NI 
Shah 1997 8.9 (6-12) 8 100 100 88 50 13 NI 
Marchant 2001 9.3 (2.8-11.9) 16 100 0 50 NI NI NI 
Helbich 1999 9.4 ± 3.1 
(6-16) 
61 80 77 52 NI 59 NI 
Demirkazik  2001 6 (0.4-18) 40 65 97.5 30 NI NI 100 
Dakin 2002 12.2 ± 4.3  
(6-19.4) 
34 91 79 77 58 72 NI 
Santamaria 1998 13.2 (6.75-24) 30 90 53 63 17 13 NI 
Maffessanti 1996 13 ± 6 (5-28) 36 89 43 26 80 81 NI 
Nathanson 1991 14.1 ± 1.7 
(0.5-35) 
28 96 NI 61 NI NI NI 
Taccone  1992 19.1 (9-39) 39 87 100 NI NI NI NI 
Robinson 2001 17.3 ± 7.2  
(9-33) 
17 100 100 76 NI NI 100 
Helbich 1999 22.1 ± 4.1 
(17-32) 
36 100 98 72 NI 69 NI 
Bhalla 1991 5-42 14 85.7 92.9 64.3 NI NI NI 
SD is standard deviation, N is number of patients studied, NI not included in the scoring system, BE 
is bronchiectasis, AWT is airway wall thickening, MP is mucous plugging, GG is ground glass 
pattern, AT is air trapping 
 
Patient selection criteria were the following: Helbich prospectively and retrospectively studied all 
stable patients from their outpatient clinic. Stiglbauer studied CF patients prospectively, inclusion 
criteria were not reported. Shah prospectively included 8 stable patients and 19 patients during an 
exacerbation, inclusion criteria were not reported. Marchant included 16 stable CF patients who were 
diagnosed through neonatal screening, inclusion criteria were not reported. Demirkazik prospectively 
included 40 CF patients followed at their clinic, inclusion criteria were not reported. Dakin included 
their routine annual and biennial check up CT scans, other inclusion criteria were not reported. 
Santamaria included 30 CF patients when they had mild or moderate symptoms, other inclusion 
criteria were not reported. Maffessanti included 36 stable CF patients, other inclusion criteria were 
not reported. Nathanson included 25% of the CF patients in their clinic, inclusion criteria were not 
reported. Taccone did not report any inclusion criteria. Robinson prospectively included patients 
who had a clinically defined acute excacerbation and who were older than 8 years and had a FEV1 
greater than 30% predicted. Bhalla prospectively included 14 CF patients, inclusion criteria were not 
reported.  
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Table 3 Correlation of CT-score with pulmonary function tests in CF 
Study Year Mean age ± 
SD (range) 
N FEV1 MEF RV/TLC 
    R2 P R2 P R2 P 
Logan 1990 17 (15-19) 30 0.41 <0.01 NE NE NE NE 
Nathanson 1991 18.8 ± 1.6 19 0.77 <0.01 0.74 <0.01 0.69 <0.01 
Bhalla  1991 5-42 14 0.18 NS NE NE NE NE 
Stiglbauer  1992 4.8 (0.3-9.7) 24 NG NS 0.55 0.02 NE NE 
Maffessanti 1996 13 ± 6 (5-28) 36 0.43 <0.01 NE NE NE NE 
Shah 1997 8.9 (6-12) 8 0.11 0.04 NE NE NE NE 
Santamaria 1998 13.2 (6.75-24) 30 0.25 <0.1 NE NE 0.16 0.02 
Helbich 1999 12.2 ± 3.1  
(0-32) 
117 0.49 0.01 0.71 0.001 0.23 0.001 
Demirkazik 2001 6 (0.4-18) 14 0.44 0.01 0.26 NS NE NE 
Marchant  2001 9.3 (2.8-11.9) 16 0.42 0.01 NE NE NE NE 
Robinson  2001 17.3 ± 7.2  
(9-33) 
17 0.29 0.03 0.52 0.001 0.38 0.01 
NE not evaluated in the study, NG correlation was evaluated but the coefficient was not given, MEF 
included FEF25-75, MEF50 and MEF25, NS not a significant correlation (p>0.05) 
 
Patient selection criteria were the following: Logan randomly selected patients from the outpatient 
clinic. Patients were excluded when they had intravenous antibiotics or hospitalisation in the past six 
weeks for respiratory complications. Nathanson included 25% of the CF patients in their clinic, 
inclusion criteria were not reported. Bhalla prospectively included 14 CF patients, inclusion criteria 
were not reported. Stiglbauer studied CF patients prospectively, inclusion criteria were not reported. 
Maffessanti included 36 stable CF patients, other inclusion criteria were not reported. Shah 
prospectively included 8 stable patients and 19 patients during an exacerbation, other inclusion 
criteria were not reported. Santamaria included 30 CF patients when they had mild or moderate 
symptoms, other inclusion criteria were not reported. Helbich prospectively and retrospectively 
studied all stable patients from their outpatient clinic. Demirkazik prospectively included 40 CF 
patients followed at their clinic, inclusion criteria were not reported. Marchant included 16 stable CF 
patients who were diagnosed through neonatal screening, other inclusion criteria were not reported. 
Robinson prospectively included patients during a clinically defined acute exacerbation who were 
older than 8 years and had a FEV1 greater than 30% predicted.  
 
Table 4 Inter- and intraobserver variability of CT-score in CF 
Study Year Interobserver 
variability 
Intraobserver 
variability 
Bhalla  1991 SD = 1.02 NA 
Nathanson 1991 R=0.82, 0.85, 0.76 NA 
Santamatia  1998 COV = 4.9% NA 
Nasr 2001 COV = 49.1% NA 
Robinson 2001 R=0.94 R=0.78 
SD = standard deviation, COV = coefficient of variation = absolute mean differences x 100 / overall 
mean, R = correlation coefficient, NA = not assessed 
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Quantitative airway analysis 
The quantitative nature of CT enables measurements of airway, arterial and 
parenchymal dimensions. Several quantitative CT analysis techniques to measure 
airway dimensions have been developed and employed in asthma and COPD 99-102. In 
the initial studies of airway dimensions by CT, the investigators used manual tracing 
of the airway images 103-106. Manual tracing, however, is extremely time-consuming 
and prone to bias and error. Computer aided and automated techniques are now 
available to measure airway wall and lumen and arterial dimensions, the most 
commonly reported of which relies on the “Full-Width-At-Half-Maximum” or “half-
max” technique (Figure 4) 100, 107. Although this method provides a standardized and 
unbiased measurement it has its limitations. For instance, comparison of CT scan 
measurements using this method with phantoms of tubes embedded in material 
resembling lung parenchyma and animal and human lung specimens 107, reveals that 
the CT scans consistently over-estimate airway wall area and underestimate lumen 
area. These systematic errors arise from factors including:  
 
• The limited spatial resolution of the CT scanner 
• The angle of orientation of the airway within the CT slice 
• The inability of the scanner to detect edges (the point spread function)  
• The reconstruction algorithm used  
• The analysis technique used 
• The inability to visualize the folding of the epithelium.  
 
Quantitative studies of airway dimensions in children with CF will be challenging as 
airway size changes with lung growth, and because mucous plugging or lack of 
comparable CT sections preclude the identification of airways on subsequent scans. 
To our knowledge, no CF studies have been reported that used quantitative 
techniques to measure airway wall and lumen dimensions on CT. The most important 
potential benefit of quantitative CT analysis would be the reduction of observer 
variability relative to that of the HRCT scoring systems. In addition the time required 
to analyze a CT scan can potentially be reduced. 
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Figure 4 An airway wall measurement using the full-width at half-maximum 
algorithm. 
 
A representative x-ray attenuation (hounsfield units (HU)) curve for a ray that passes from the lumen 
through the airway wall and into the parenchyma is shown. The thickness of the wall is determined 
using the half-maximum point of the change in x-ray attenuation as the ray enters and exits the wall. 
The inset shows a magnified view of an airway. The rays can be seen to start at the lumen boundary 
of the wall and extend to the outer edge. Note that some rays extend into the pulmonary artery 
because the artery has similar x-ray attenuation values as the airway wall. Those rays can be manually 
deleted and the airway outer border is extrapolated from the remaining rays using a mathematical 
spline function.  
 
Quantitative small airway analysis 
CT can indirectly visualize small airways abnormalities. To that purpose expiratory 
CT scans are performed to assess the extent and degree of gas trapping (Figure 5) 108-
114. The extent of gas trapping can be quantified on expiratory scans with techniques 
similar to those used to quantify low attenuation areas in emphysema 108, 111, 112, 115, 116. 
A limitation of the use of expiratory CT scans is that patients have difficulty holding 
their breath at low lung volume. The feasibility of this technique may be improved by 
using spirometric gating 117. No studies have been reported that quantified gas 
trapping on CT scans of CF patients.  
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Figure 5 Gas trapping on an expiratory CT scan in a CF patient 
 
An expiratory high-resolution CT of the lung base in a CF patient demonstrates bilateral areas of air 
trapping. The image clearly shows black areas in both lower lobes where air is trapped. 
 
Radiation Risk 
Radiation exposure is an important issue for any studies that include repetitive CT 
scanning. Infants and young children are at higher risk of radiation induced cancer 
than older children, who are more susceptible than adults 92, 118-124. Therefore, most 
airway research has been restricted to older adults (over 55 years of age) whose risk is 
very low 122. Data comparing radiation exposures from different sources are available. 
In a Swiss survey the dose of a lateral plus antero-posterior chest radiograph was 
about 0.17 milli Sievert (mSv) and that of a chest CT scan with contiguous 10-mm 
thick slices was 9.0 mSv 125. The dose of the CT scans reported in the Swiss survey is 
10 times higher than the dose of a HRCT 122. The radiation dose for a HRCT would 
therefore be 0.9 mSv or five times the dose of the chest radiograph. To put these 
numbers in perspective: 140-350 transatlantic flying hours with a subsonic aircraft or 
60-150 transatlantic flying hours with a Concorde result in a radiation exposure of 1 
mSv 126. Natural background radiation in the USA to cosmic radiation, natural 
radioactivity and domestic radon results in an average exposure of ~3 mSv / year. 
Model data to estimate the risk of inducing lethal cancers using various CT protocols 
are needed to determine the risk/benefit ratio. In addition studies are needed to 
determine the CT protocol that produces the lowest possible dose per CT 
examination with acceptable image quality and diagnostic yield. 
 
Use of CT in Clinical Care 
CT scanning as a tool to monitor lung structure in CF patients has received little 
attention. Most CF centers monitor their patients using chest radiographs and PFTs. 
However, both the Erasmus MC-Sophia Children’s Hospital (Rotterdam, the 
Netherlands) and the Queens Silvia Children’s Hospital (Göteborg, Sweden) have 
been using repetitive CT to monitor lung structure since 1996, replacing the antero-
posterior and lateral chest radiographs applied until then. This new routine was 
initiated because the literature had documented that chest radiographs were not 
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sensitive enough to detect early CF lung disease. Hence, the aim was to monitor not 
only lung function but also to adequately monitor lung structure. As CF patients had 
shorter life expectancy it was assumed at that time that the benefits of a more 
sensitive monitoring would outweigh the disadvantages of the higher radiation 
exposure from CT compared with chest radiographs. The possible benefits of this 
strategy were evaluated in cohorts in both hospitals (this thesis). 
 
Use of CT in Research Trials 
CT must have been shown to provide a valid outcome surrogate before it can be used 
as a primary endpoint in clinical trials of CF lung disease. An outcome surrogate is a 
laboratory measurement or physical sign used as a substitute for a clinically 
meaningful endpoint. In CF the only outcome surrogate currently accepted by the 
Food and Drug Administration (FDA) is FEV1. Outcome surrogates must meet strict 
criteria in order to ensure accurate results from clinical trials 127. For CT scanning to 
become an outcome surrogate, data are needed on 1) the reproducibility of CT 
scoring systems and 2) the extent to which CT scoring systems and quantitative 
airway measurements in relation to PFTs are sensitive to detect onset and progression 
of CF lung disease. To our knowledge, at the start of our evaluation in 2001 only one 
small clinical trial included CT in the protocol 97.  
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Chapter 3.1 Computed tomography in children 
with cystic fibrosis: comparison of scoring systems 
and measurements of bronchi and arteries 
 
 
 
 
 
 
The purpose of this study was to retrospectively compare thin-section computed 
tomographic (CT) scores obtained with five scoring systems for assessment of 
pulmonary disease in children with cystic fibrosis and to determine additional value 
of bronchial and arterial dimension measurements. Scores obtained with five thin-
section CT scoring systems were compared. A score of 0 indicated the absence of 
abnormalities; a higher score meant that more structural abnormalities were seen. 
Three observers assigned scores and then reassigned scores after intervals varying 
from 1–2 weeks to 1–2 months at review of thin-section CT scans obtained in 25 
children with cystic fibrosis. Interobserver and intraobserver reliability was 
calculated with intraclass correlation coefficients. Quantitative measurements of 
bronchial and arterial dimensions were obtained. Thin-section CT scores were 
correlated (Spearman correlation) with bronchial and arterial dimensions and with 
results of pulmonary function tests (PFTs), such as forced expiratory volume in 1 
second (FEV1). Scores with all five scoring systems were reproducible, with 
intraclass correlation coefficients of 0.74 and higher (P <.05), and showed 
significant correlations with FEV1 (R = -0.73 to -0.69, P <.01). Ratio of bronchial 
diameter to accompanying pulmonary arterial diameter was correlated with thin-
section CT scores but not with FEV1. Ratio of bronchial wall thickness to 
accompanying pulmonary arterial diameter was not correlated with thin-section CT 
scores or PFT results. We concluded that thin-section CT scores were reproducible 
and were correlated with PFT results and that measurements of bronchial 
dimensions were not significantly related to scores or PFT results. 
 
 
 
 
 
 
Based on: 
 
Pim A. de Jong, Mark D. Ottink, Simon G.F. Robben, Maarten H. Lequin, Wim C.J. 
Hop, Johan J.E. Hendriks, Peter D. Paré and Harm A.W.M. Tiddens. Pulmonary 
Disease Assessment in Cystic Fibrosis: Comparison of CT Scoring Systems and Value 
of Bronchial and Arterial Dimension Measurements. Radiology 2004; 231: 434–439. 
 
Reprinted with permission of the Radiologic Society of North America 
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Introduction 
 
Cystic fibrosis is the most frequently inherited autosomal recessive disease in whites, 
with an incidence of one in 3,600 in the Dutch population. Cystic fibrosis is a lethal 
disease; when it was described by Fanconi 1 and Andersen 2 more than 60 years ago, 
the median survival was less than 1 year. Presently, median survival is 32.3 years and 
is increasing 3. Despite increased longevity, pulmonary dysfunction causes major 
morbidity in cystic fibrosis, and more than 90% of the mortality is caused by 
pulmonary complications 4. It is therefore critically important to monitor progression 
of lung disease for clinical treatment and to evaluate new treatments. The standard for 
assessment of lung disease in cystic fibrosis is pulmonary function tests (PFTs); 
however, conventional PFTs are not very sensitive in the detection of early lung 
damage 5. In addition, the conventional PFTs are reliable only in children older than 5 
years. There is evidence that pulmonary disease starts early in life in the majority of 
patients 6, 7, and this suggests that therapy should be started before routine PFTs can 
be performed. These facts illustrate the need for a relatively noninvasive and sensitive 
test for lung disease that can be applied in infancy.  
 
In the last decade, the use of thin-section computed tomography (CT) in cystic 
fibrosis has increased. In 1991, Bhalla et al 8 published a scoring system designed to 
quantify structural lung abnormalities in patients with cystic fibrosis by using thin-
section CT. Since then, a number of additional scoring systems and modifications of 
scoring systems have been proposed, and they are frequently used for both clinical 
treatment and research purposes 9. Thin-section CT scoring systems are a potentially 
useful outcome measure surrogate in patients with cystic fibrosis 10. To date to our 
knowledge, there is limited experience with the use of these scoring systems for 
assessment of pulmonary disease in children with cystic fibrosis, and there have been 
no systematic comparisons of the scoring systems. In addition, the quantitative nature 
of thin-section CT allows precise measurements of bronchial and arterial dimensions, 
and these may have added value in the assessment of lung abnormalities in patients 
with cystic fibrosis.  
 
Thus, the purpose of our study was to retrospectively compare thin-section CT 
scoring systems of Bhalla et al 8, Helbich et al 11, Santamaria et al 12, Brody et al 10, and 
Castile et al 13 for assessment of pulmonary disease in children with cystic fibrosis and 
to determine the additional value of measurements of bronchial and arterial 
dimensions.  
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Methods 
 
Study Population 
Twenty-five children and adolescents with cystic fibrosis (17 male patients, eight 
female patients) were randomly selected for this study. The mean age was 10.7 years 
(range, 5.5–17.3 years). All patients were followed up at Sophia Children’s Hospital, 
Erasmus Medical Center Rotterdam, the Netherlands, where biennial thin-section CT 
scans and PFTs are part of our routine clinical protocol. Cystic fibrosis was diagnosed 
with a positive sweat test, the presence of a genotype for known cystic fibrosis 
mutations, or an abnormal potential difference measured across the nasal mucosa (to 
determine the function of the cystic fibrosis transmembrane conductance protein), or 
all of these. The ethics review board of the hospital approved the retrospective study 
and did not require informed consent.  
 
Thin-Section CT and Evaluation 
Thin-section CT scans were obtained (Prospeed SX; GE Medical Systems, 
Milwaukee, Wis) with the patients in the supine position after they were instructed to 
take a deep breath and hold their breath for at least 5 seconds. During each breath 
hold, approximately two lung sections were obtained. A complete thin-section CT 
series included on average 25 (range, 16–34 sections) 1.0-mm-thick sections that were 
acquired with 10-mm intervals from the lung apex to the lung base. Scanning 
parameters were as follows: 120 kV, 160 mA (120 mA in children younger than 9 
years), 1-second scanning time, and a field of view of 350 mm (250 mm in children 
younger than 9 years). Scans were reconstructed with a reconstruction algorithm 
(Detail; GE Medical Systems) and printed with window settings appropriate for the 
imaging of pulmonary parenchyma (window width, –600 HU; window level, 1,500 
HU).  
 
We selected five thin-section CT scoring systems 8, 10–13 for evaluation. These systems 
can be categorized into two groups: lobar scoring systems 10, 13, in which a score is 
assigned to each lung lobe separately, and segmental scoring systems 8, 11, 12, in which a 
score is assigned to each bronchopulmonary segment separately. With all systems, a 
score is assigned in a semiquantitive way to a subset of the following abnormalities: 
bronchiectasis; peribronchial thickening; mucous plugging; sacculations or abcesses; 
bullae; emphysema, air trapping, or hyperinflation; collapse or consolidation; mosaic 
perfusion or ground-glass opacities; acinar nodules or alveolar consolidation; and 
thickening of intralobular and interlobular septa. These abnormalities were considered 
to be the variables and were assigned scores that ranged from 0 to 3. The total scores 
were derived as composites of the variables that were assigned these scores. The 
scores assigned to the variables were used in the calculation of the Kappa (κ) statistic. 
The total scores ranged from 0 (indicating absence of abnormalities) to 92, 100, 27, 
29, and 25 (indicating maximal abnormalities) for scoring systems of Castile et al 13, 
Brody et al 10, Helbich et al 11, Santamaria et al 12, and Bhalla et al 8, respectively. 
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Hereafter, these scores will be referred to as the Castile, Brody, Helbich, Santamaria, 
and Bhalla scores.  
 
Thin-section CT scans were assigned scores by three observers. Observers 1 and 2 
were 5th-year medical students who underwent intensive training in how to score the 
thin-section CT scans. Observer 3 was a senior radiologist. After the training period, a 
consensus meeting was held to further standardize the scoring between the three 
observers. For the scoring methods used in this study, no reference images were 
available. All 25 scans were assigned scores in random order, and observers assigned 
scores independently and were blinded to patient characteristics. To evaluate 
intraobserver variability, random subsets of 10 scans were assigned scores a second 
time after 1–2 weeks (observer 1), 2–4 weeks (observer 2), and 1–2 months (observers 
1 and 3).  
 
Measurements of bronchial dimensions on the CT scans were performed by using a 
workstation (GE Medical Systems, Milwaukee, Wis) with software (version AW 3.1; 
GE Medical Systems) that supported the CT scanner used in this study. All visible 
bronchus-artery pairs that appeared to be round were magnified five times, and two 
perpendicular lines were traced through the center of each bronchus and the 
accompanying pulmonary artery. One line was vertical and the other was horizontal 
to the plane of gravity. The software program constructed a profile of the Hounsfield 
units along the lines, and the observer calculated the cutoff level for the inner and the 
outer wall according to the full-width-at-half-maximum principle 14.  
 
Since bronchial diameter and bronchial wall thickness change as a function of airway 
generation, we calculated ratios of bronchial and arterial dimensions rather than 
absolute values. One of the ratios was calculated by dividing the mean outer bronchial 
diameter by the mean diameter of the accompanying pulmonary artery, and this was 
the bronchus-artery ratio. This ratio has previously been reported as an indicator of 
bronchial dilatation or bronchiectasis 8. In the case of bronchiectasis, the simple 
measurement of bronchial wall thickness divided by bronchial luminal diameter could 
cause spurious underestimation of intrinsic bronchial wall thickening. Thus, to obtain 
an estimate of bronchial wall thickness, we used the ratio of the mean bronchial wall 
thickness divided by the mean diameter of the accompanying pulmonary artery, and 
this was the thickness-artery ratio. This calculation was determined with the 
assumption that there is no change in arterial diameter as pulmonary disease 
progresses in cystic fibrosis. On average, an observer assigned scores on each scan in 
10 minutes for the lobular systems 10, 13 and in 15 minutes for the bronchopulmonary 
systems 8, 11, 12.  
 
PFT Results 
The PFT results used for this study were obtained with PFTs performed most closely 
in time to the time that the thin-section CT scans were obtained. Twenty children 
were evaluated with PFTs and thin-section CT on the same day. For three children, 
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thin-section CT was performed on a different day from that on which the PFTs were 
performed for logistic reasons (intervals between CT and PFTs were 5, 12, and 23 
days).  
 
PFT results were obtained by using a diagnostic system (MasterLab; Jäger, Wurzburg, 
Germany). The results were expressed as the percentage of predicted values for 
forced expiratory volume in 1 second (FEV1) 15, forced vital capacity (FVC) 15, and 
forced expiratory flow between 25% and 75% of expiratory vital capacity (FEF25–75) 
16. The ratio of FEV1 to FVC was calculated and expressed as a percentage. 
Additional measurements included airway resistance (Raw), residual volume (RV), and 
total lung capacity (TLC). Values for these measurements were obtained by using a 
body plethysmograph. The RV/TLC ratio was calculated and expressed as a 
percentage.  
 
Statistical Analysis 
Interobserver and intraobserver reliability of the scoring systems was tested with the 
intraclass correlation coefficient (Ri) and Bland-Altman plots. Values of Ri greater 
than 0.80 are generally considered to represent good agreement between observers. 
Interobserver and intraobserver reliability of the various scoring system variables of 
each of the five scoring systems was evaluated with the κ-statistic. The κ-values of 
<0.20, 0.21–0.40, 0.41–0.60, 0.61–0.80, and 0.81–1.00 are generally considered to 
represent poor, fair, moderate, good, and very good agreement, respectively. The 
mean and individual scores of three observers were used to calculate the Spearman 
correlation, or R, between the scoring systems and that between the scoring systems 
and PFT results. Furthermore, the Spearman correlation was calculated for the 
quantitative thin-section CT measurements (thickness-artery and bronchus-artery 
ratios) with mean thin-section CT scores and with PFT results. Normal distribution 
of all ratios (thickness-artery, bronchus-artery, FEV1/FVC, and RV/TLC) was tested 
by using the Shapiro-Wilk test. A software package (SPSS, version 10.0; SPSS, 
Chicago, Ill) was used for statistical analysis. Data were expressed as the mean ± SD 
and range. A difference with a P value less than .05 was considered significant.  
 
 
Results  
 
Study Population 
Table 1 shows age and PFT data. Table 2 shows the prevalence of abnormalities 
observed at thin-section CT in this study population. Technically satisfactory thin-
section CT scans were obtained in children who could hold their breath for at least 5 
seconds. Although motion artifact was present on some scans, no scans were 
excluded because of motion artifact. Two patients were too young to perform reliable 
PFTs. Thus, all comparisons between CT scores and PFT results were limited to 23 
patients.  
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Table 1 Patient characteristics and PFT results 
Characteristic and PFT* mean SD Range 
age (years) 10.7 3.6 5.5 - 17.3 
male/female 17/8   
FEV1 76 23 36 – 118 
FVC 86 17 48 – 118 
FEV1/FVC 76 13 45 - 95 
FEF25-75 63 38 8 - 140 
Raw 141 75 56 – 310 
RV 143 48 88 – 256 
TLC 100 9 78 – 114 
RV/TLC ratio (%) 34 10 20 – 60 
* Unless specified otherwise, data are expressed as percentage predicted 
 
Table 2 Prevalence of abnormalities at thin-section CT 
Abnormality Prevalence (%)* 
Bronchiectasis 76 
Peribronchial thickening 85 
Mucous plugging 79 
Sacculations or abcesses 11 
Bullae 8 
Emphysema, air trapping, or hyperinflation 1 
Collapse or consolidation 51 
Mosaic perfusion or ground-glass opacities 12 
Acinar nodules or alveolar consolidation 42 
Thickening of interlobular and intralobular septa 4 
* Data were calculated as follows: 100 times the number of subjects with the abnormality divided by 
the total number of subjects 
 
Thin-Section CT Scoring Systems 
 
Interobserver variability of scoring systems: Interobserver variability was generally 
good (Table 3). The Bland-Altman plots illustrated that the most important 
differences between the observers were at the lower scores. The κ-coefficients were 
less than 0.61 for most scoring system variables. For mosaic perfusion, acinar nodules, 
and airspace disease, κ-coefficients were less than 0.40 for all comparisons.  
 
Intraobserver variability of scoring system: Intraobserver variability was good (Ri 
> 0.80) when the interval was shorter than 1 month. Even when the interval was 
longer than 1 month, correlations were generally good (Ri > 0.74). Intraobserver 
variability for the variables of the scoring systems was good; all κ-coefficients were 
greater than 0.61.  
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Table 3 Interobserver and intraobserver variability  
 Interobserver variability Intraobserver variability* 
Scoring 
system 
Observer 
1 vs 2 
Observer
1 vs 3 
Observer
2 vs 3 
Observer 
1 at 1-2 
weeks 
Observer 
2 at 2-4 
weeks 
Observer 
1 at 1-2 
months 
Observer 
3 at 1-2 
months 
Castile 0.76 0.74 0.93 0.95 0.92 0.74 0.80 
Brody 0.80 0.80 0.98 0.96 0.87 0.91 0.93 
Helbich 0.80 0.86 0.95 0.97 0.96 0.92 0.86 
Santamaria 0.80 0.86 0.94 0.94 0.95 0.90 0.81 
Bhalla 0.78 0.85 0.95 0.97 0.94 0.92 0.87 
Note.—Data are intraclass correlation coefficients 
* Data are scores reassigned after intervals noted 
 
Thin-section CT scoring and PFT results: All five scoring systems showed a 
strong and highly significant correlation with values for FEV1, FVC, FEF25–75, and 
FEV1/FVC ratio (Table 4). The relationship between Bhalla score and FEV1 is shown 
in Figure 1. The correlation coefficients were highest for the relationships between 
thin-section CT scores and the FEF25–75 value and lowest for the relationships with 
the FVC value; R values for the relationships between scores and values for FEV1 and 
FEV1/FVC ratio were intermediate. Raw and TLC values were correlated significantly 
with scores achieved with all scoring systems. Values for RV and RV/TLC ratio did 
not show significant relationships (Table 4). The correlation coefficients did not differ 
substantially when individual scores from the three observers were used rather than 
mean scores. The correlation between the scoring systems was strong; R values 
ranged from 0.94 to 0.99. There was no significant correlation between mean scores 
and bronchial wall thickness, expressed as the thickness-artery ratio. The marker for 
the estimate of the severity of bronchiectasis (bronchus-artery ratio) was correlated 
significantly with scores achieved with all five scoring systems. The R values were as 
follows: Castile score, 0.59; Brody score, 0.60; Helbich score, 0.50; Santamaria score, 
0.51; and Bhalla score, 0.50. Neither the thickness-artery ratio nor the bronchus-artery 
ratio showed a significant correlation with PFT results, although the relationship 
between the bronchus-artery ratio and values for FEV1 and FEV1/FVC ratio 
approached significance (P = .07). All ratios, except the thickness-artery ratio, could 
be described with normal distributions. We used the Spearman correlation coefficient, 
which is adequate for nonnormal distributions.  
 
COMPUTED TOMOGRAPHY SCORING SYSTEMS AND QUANTITATIVE MEASUREMENTS 
 
  
 
36
 
Table 4 Thin-section CT scoring systems and PFTs 
PFT* Castile 
score 
Brody 
score 
Helbich 
score 
Santamaria 
score 
Bhalla 
score 
FEV1 -0.69† -0.69† -0.72† -0.70† -0.73† 
FVC -0.54† -0.52‡ -0.58† -0.54† -0.57† 
FEF25-75 -0.76† -0.79† -0.83† -0.82† -0.82† 
FEV1/ FVC -0.72† -0.73† -0.75† -0.74† -0.78† 
Raw 0.67† 0.59‡ 0.56‡ 0.58‡ 0.65‡ 
RV 0.13 0.07 0.06 0.16 0.11 
TLC -0.63‡ -0.71† -0.65† -0.57‡ -0.66† 
RV/TLC-ratio (%) 0.37 0.27 0.33 0.28 0.33 
Note.—Data are Spearman correlation coefficients 
* Unless specified otherwise, data are expressed as percentage predicted 
† P < .01, ‡ P < .05 
 
Figure 1 Graph shows relationship between Bhalla score and FEV1 value (R = –0.73, 
P < .01). 
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Discussion 
 
The results of this study show that the semiquantitative scoring systems that are 
frequently used to detect pulmonary abnormalities with thin-section CT in patients 
with cystic fibrosis are comparable and robust. There was good interobserver and 
intraobserver variability, and this observation indicated that these measurements are 
reliable and reproducible. Furthermore, there was good correlation between scores 
achieved with these thin-section CT scoring systems and PFT results, especially the 
FEV1, FEF25–75, FEV1/FVC ratio, Raw, and TLC values. Correlation of the scoring 
systems with each other was very good. The agreement between the total score of the 
radiologist and that of the students illustrates that it is possible for nonqualified 
observers to be trained in the use of thin-section CT scoring systems. These data do 
not allow the selection of a best scoring system. Such selection will depend not only 
on the reproducibility but also on the sensitivity of the system to early changes, its 
ability to track the progression of pulmonary abnormalities over time, and the time 
required for an observer to assign an adequate score to a scan. In the present study, 
10–15 minutes was needed for each observer to assign a score to a scan; because of 
the time required, it seems unlikely that routine use of scoring systems, at least as 
implemented by a radiologist, will be adopted. Despite the excellent correlations 
between PFT results and the scores derived with the thin-section CT scoring systems, 
abnormalities may be observed on CT scans in patients with normal PFT 
measurements (Figure 2) 17. These observations suggest that at least in some instances 
thin-section CT may be more sensitive to early lung damage in patients with cystic 
fibrosis.  
 
Figure 2. Abnormal transverse thin-section CT scans  
 
Obtained in a 13-year-old boy with normal PFT results as follows: FEV1, 99 percentage predicted; 
FVC, 92 percentage predicted; FEV1/FVC ratio, 90%; and FEF25-75, 95 percentage predicted. Thin-
section CT scores were as follows: Castile score, 22 (range, 0-92); Brody score, 17 (range, 0-100); 
Helbich score, 12 (range, 0-27); Santamaria score, 13 (range, 0-29); Bhalla score, 12 (range, 0-25). 
Left: Scan shows bronchiectasis with a diameter of the artery that was two to three times that of the 
artery at an intermediate location (1). Center: Scan shows cysts in the periphery of the lung (2), 
bronchiectasis with a diameter of the artery that was one to two times that of the artery at a central 
location (3), and mucus-plugged bronchus (4). Right: Scan shows cysts in the periphery of the lung 
(5). 
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Although the scoring systems were reliable and the scores were correlated well with 
PFT results, we were concerned about three observations in our study.  
First, our data showed a lower reproducibility with longer intervals (1–2 months) 
between repeat measurements. In part, this finding may be related to the fact that 
there were gaps between the scoring sessions during which the observers were not 
routinely scoring CT scans. These gaps might have caused some loss of recall of the 
scoring systems, as well as of the findings of the consensus meeting. This result 
suggests that a new training period for observers may be needed after a 1–2-month 
interval. In addition, it might be useful to develop standardized definitions and 
reference images to reduce intraobserver and interobserver variability even further.  
Second, our results showed a lower interobserver reproducibility for most scoring 
system variables than for the total score. Many variables had a low κ-coefficient, even 
after the consensus meeting. An example of one such variable is mosaic perfusion. 
When we examined the thin-section CT scans closely, almost all scans had some signs 
of mosaic perfusion, and there was no description of how other authors defined this 
abnormality. Although all scoring systems except that of Castile et al 13 were designed 
for inspiratory thin-section CT scans, some investigators designated a low-attenuation 
area as "hyperinflation" and others identified such an area as "gas trapping." The 
prevalence of air trapping reported in this study is lower than that previously reported 
10–12, 17. In the routine follow-up of our patients, we restricted ourselves to the use of 
inspiratory thin-section CT scans, which are less sensitive in the depiction of air 
trapping relative to expiratory thin-section CT scans. Currently, we measure air 
trapping in children who are 6 years old and older by using the combination of 
helium spirometry and body plethysmography. It is unclear whether it is worthwhile 
to add more radiation to our standard clinical CT protocol to obtain expiratory CT 
scans on which air trapping could be scored more reliably. Because of the large 
variability in nomenclature, we believe that a uniform nomenclature and clear 
definitions of abnormalities must be developed for use in thin-section CT scoring 
systems to obtain objective and reproducible thin-section CT data for follow-up of 
patients and for clinical trials.  
The third concern is the increased variability between observers that was evident 
when the scores were low. If these systems are to be useful in the early detection and 
longitudinal assessment of lung abnormalities in cystic fibrosis, they should have 
sufficient resolution of the lower end of the scoring system scale.  
 
An additional way to quantify structural lung damage is with the measurement of 
bronchial dimensions on thin-section CT scans. We measured the size of the bronchi 
relative to the accompanying artery (bronchus-artery ratio) and the thickness of the 
bronchial wall relative to the accompanying artery (thickness-artery ratio). The 
bronchus-artery ratio, which is a well-recognized measure of bronchiectasis 8, was 
correlated significantly with thin-section CT scores, presumably because a subjective 
assessment of bronchial dilatation is an important component of all the scoring 
systems. However, bronchial wall thickness was not correlated significantly with thin-
section CT scores. None of these measurements was correlated significantly with PFT 
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results, although the relationship between the bronchus-artery ratio and values for 
FEV1 and FEV1/FVC ratio approached significance. These data suggest that, with the 
technology and algorithms we employed, quantitative bronchial measurements did 
not add value to the scoring systems. Further research is necessary to determine the 
role of bronchial measurements and their correlation with disease severity, as well as 
their interobserver and intraobserver variability.  
 
It has been shown that thin-section CT scans are superior to chest radiographs to 
monitor structural aspects of pulmonary disease in cystic fibrosis 18. Radiation dose is 
of concern, however, since life expectancy is increasing in patients with cystic fibrosis 
19. The radiation dose of the thin-section CT protocol we used is approximately 12 
times that of a chest radiograph 20. Although this dose is not as high as has been 
suggested by some authors 21, one needs to exercise caution. Because of concern 
regarding the balance between radiation and benefits from the additional information 
about lung structure, clinical centers for cystic fibrosis are performing biennial rather 
than annual thin-section CT examinations. New ways to further reduce the dose of 
radiation at thin-section CT must be found, and optimal scanning parameters for the 
pediatric age group have to be determined 19. Researchers in several studies have 
already shown that low-dose thin-section CT, with a 40%–50% reduction of radiation 
dose, is possible without affecting image quality 22–25.   
 
To conclude, the results of this study show that adequate thin-section CT scans can 
be obtained in young children who have cystic fibrosis. Structural abnormalities 
observed on thin-section CT scans can be assigned scores in a reproducible fashion 
with currently available scoring systems. These findings support the use of thin-
section CT to monitor progression of structural lung abnormalities in cystic fibrosis. 
Such use can be important for both patient treatment and therapeutic studies.  
 
 
References 
1. Fanconi G. Das coeliakie syndrom bei angeborener zystischer pancreas fibromatose und 
bronchiektasen. Wien Med Wochenschr 1936; 86: 753-756.  
2. Andersen D. Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and 
pathologic study. Am J Dis Child 1938; 56: 344-399.  
3. Nasr SZ. Cystic fibrosis in adolescents and young adults. Adolesc Med 2000; 11: 589-603. 
4. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229-
1256. 
5. Becklake MR, Permutt S. Evaluation of tests of lung function for "screening" for early 
detection of chronic obstructive lung disease In: The lung in the transition between health and 
disease. New York, NY: Marcel Dekker, 1979.  
6. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary 
inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.  
7. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: 
onset and etiology. Pediatr Pulmonol 1997; 24: 137-142; discussion 159–161.  
COMPUTED TOMOGRAPHY SCORING SYSTEMS AND QUANTITATIVE MEASUREMENTS 
 
  
 
40
 
8. Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. 
Radiology 1991; 179: 783-788.  
9. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM, Strouse PJ. Use of computerized 
tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase 
in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 2001; 
31: 377-382.  
10. Brody AS, Molina PL, Klein JS, Rothman BS, Ramagopal M, Swartz DR. High-resolution 
computed tomography of the chest in children with cystic fibrosis: support for use as an 
outcome surrogate. Pediatr Radiol 1999; 29: 731-735.  
11. Helbich TH, Heinz-Peer G, Eichler I, et al. Cystic fibrosis: CT assessment of lung involvement 
in children and adults. Radiology 1999; 213: 537-544.  
12. Santamaria F, Grillo G, Guidi G, et al. Cystic fibrosis: when should high-resolution computed 
tomography of the chest be obtained? Pediatrics 1998; 101: 908-913.  
13. Castile RG, Long FR, Flucke RL, Hayes JR, McCoy KS. Correlation of structural and 
functional abnormalities in the lungs of infants with cystic fibrosis (abstr). Pediatr Pulmonol 
2000; 20: A427.  
14. Amirav I, Kramer SS, Grunstein MM, Hoffman EA. Assessment of methacholine-induced 
airway constriction by ultrafast high-resolution computed tomography. J Appl Physiol 1993; 75: 
2239-2250.  
15. Quanjer PH, Borsboom GJ, Brunekreff B, et al. Spirometric reference values for white 
European children and adolescents: Polgar revisited. Pediatr Pulmonol 1995; 19: 135-142.  
16. Wang X, Dockery DW, Wypij D, Fay ME, Ferris B, Jr. Pulmonary function between 6 and 18 
years of age. Pediatr Pulmonol 1993; 15: 75-88.  
17. Maffessanti M, Candusso M, Brizzi F, Piovesana F. Cystic fibrosis in children: HRCT findings 
and distribution of disease. J Thorac Imaging 1996; 11: 27-38.  
18. Taccone A, Romano L, Marzoli A, Girosi D, Dell’Acqua A, Romano C. High-resolution 
computed tomography in cystic fibrosis. Eur J Radiol 1992; 15: 125-129.  
19. Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer 
from pediatric CT. AJR Am J Roentgenol 2001; 176: 289-296.  
20. van der Bruggen-Bogaarts BA, Broerse JJ, Lammers JW, van Waes PF, Geleijns J. Radiation 
exposure in standard and high-resolution chest CT scans. Chest 1995; 107: 113-115.  
21. DiMarco AF, Briones B. Is chest CT performed too often? Chest 1993; 103: 985-986.  
22. Lucaya J, Piqueras J, Garcia-Pena P, Enriquez G, Garcia-Macias M, Sotil J. Low-dose high-
resolution CT of the chest in children and young adults: dose, cooperation, artifact incidence, 
and image quality. AJR Am J Roentgenol 2000; 175: 985-992.  
23. Ambrosino MM, Genieser NB, Roche KJ, Kaul A, Lawrence RM. Feasibility of high-
resolution, low-dose chest CT in evaluating the pediatric chest. Pediatr Radiol 1994; 24: 6-10.  
24. Mayo JR, Hartman TE, Lee KS, Primack SL, Vedal S, Muller NL. CT of the chest: minimal 
tube current required for good image quality with the least radiation dose. AJR Am J Roentgenol 
1995; 164: 603-607.  
25. Zwirewich CV, Mayo JR, Muller NL. Low-dose high-resolution CT of lung parenchyma. 
Radiology 1991; 180:413-417.  
   
 
41
 
 
Chapter 4 
 
Sensitivity of computed tomography and lung 
function 
 
 
 
 
 
 
 
 
 
4.1 Progressive damage on high resolution computed tomography 
despite stable lung function in cystic fibrosis 
4.2 Computed tomography is more sensitive than pulmonary 
function tests for monitoring lung disease progression in children 
and adults with cystic fibrosis 
4.3 Changes in airway dimensions on computed tomography scans 
of children with cystic fibrosis 
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Chapter 4.1 Progressive damage on high resolution 
computed tomography despite stable lung 
function in cystic fibrosis 
 
 
 
 
 
 
 
For effective clinical management of cystic fibrosis (CF) lung disease it is important 
to closely monitor the start and progression of lung damage. The aim of this study 
was to investigate the ability of high-resolution computed tomography (HRCT) 
scoring systems and pulmonary function tests (PFT) to detect changes in lung 
disease. CF children (n=48) had two HRCT scans in combination with two PFT 2 
yrs apart. Their scans were scored using five scoring systems (Castile, Brody, 
Helbich, Santamaria and Bhalla). "Sensitivity" was defined as the ability to detect 
disease progression. In this group of children, HRCT scores worsened and PFT 
remained unchanged or improved. Of the HRCT parameters, mucous plugging and 
the severity, extent and peripheral extension of bronchiectasis worsened 
significantly. Relationships between changes in HRCT scores and PFT were weak. 
Substantial structural lung damage was evident in some children who had normal 
lung function. These data show that high-resolution computed tomography is more 
sensitive than pulmonary function tests in the detection of early and progressive 
lung disease, and suggest that high-resolution computed tomography may be useful 
in the follow up of cystic fibrosis children and as an outcome measure in studies 
that aim to reduce lung damage. 
 
 
 
 
 
 
 
 
Based on: 
 
Progressive damage on high resolution computed tomography despite stable lung 
function in cystic fibrosis. P.A. de Jong, Y. Nakano, M.H. Lequin, J.R Mayo, R. 
Woods, P.D. Paré´, H.A.W.M. Tiddens. Eur Respir J 2004; 23: 93±97 
 
Reprinted with permission of the European Respiratory Society 
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Introduction 
 
In cystic fibrosis (CF), chronic bacterial infection leads to progressive structural lung 
damage and to pulmonary dysfunction. It is generally accepted that early and 
aggressive therapy could delay the progression of lung disease. To evaluate the 
efficacy of such treatment it is important to monitor the progression of lung damage 
closely. Pulmonary function tests (PFT) are considered the gold standard for the 
monitoring of lung disease in children of aged >6 yrs. However, since lung function 
is only indirectly related to lung structure, it is likely that high-resolution computed 
tomography (HRCT) is more sensitive than PFT in the detection of structural 
changes 1. Some CF centres have adapted periodic HRCT on a routine basis to 
evaluate the progression of CF lung disease in combination with PFT. However, it is 
unclear what method should be used to analyse the HRCT and whether HRCT is 
more sensitive in detecting pulmonary disease progression in CF. It could be that 
PFT and HRCT provide complementary information and should be performed in 
parallel to assess progression.  
 
The aim of this study was to investigate the sensitivity of five different HRCT-scoring 
systems and PFT to detect changes in CF structural lung disease over time. 
 
 
Methods 
 
Study population 
Since 1996, Sophia Children’s Hospital (Rotterdam, The Netherlands), a tertiary 
academic hospital, has monitored CF patients using annual PFT and biennial HRCT 
scans. All children with CF who had two HRCT scans (HRCT1 and HRCT2) in 
combination with two routine PFT (PFT1 and PFT2) were selected for this follow-up 
study (n=48). CF was diagnosed by a positive sweat test and/or genotyping for 
known CF mutations and/or an abnormal potential difference measured across the 
nasal mucosa. The ethical review board of the hospital approved the study. 
 
Lung structure 
All HRCT scans were acquired using a GE Prospeed SX scanner (General Electric 
Medical Systems, Milwaukee, WI, USA). During the scanning procedure, children 
were not sedated, they were scanned in the supine position, and instructed to take a 
deep breath and hold it for ≥5 s. A complete HRCT series contained ~ 25 1-mm 
thick slices at 10-mm intervals from lung apex to lung base. Scanning parameters 
were 120 kV, 160 mA (≤9 yrs of age 120 mA), 1-s scanning time and a field of view 
of 350 mm (≤9 yrs of age 250 mm). Scans were reconstructed with a detail recon-
struction algorithm (General Electric Medical Systems) and printed using window 
width 1,500 Hounsfield units (HU) and window level -600 HU. All HRCT scans were 
scored in random order by an experienced single observer blinded as to the date of 
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the scan, patient identification and the PFT. Five different HRCT-scoring systems 
were used: Castile et al 2, Brody et al 3, Helbich et al 4, Santamaria et al 5, and Bhalla et al 
6. In a previous study, in which the observer of this study participated, these five 
scoring systems were shown to be reliable between and within observers 7. All slices 
were used to score the lung lobes and the lingula 2, 3 or the bronchopulmonary 
segments of the lung 4-6. The systems score bronchiectasis, bronchial wall thickening, 
mucous plugging, atelectasis, bulla, cysts, consolidation, acinar nodules, septal 
thickening and/or air trapping in a semiquantitative fashion. A score of zero means 
"no abnormalities" in each system. Maximal scores are 92, 100, 27, 29 and 25 for 
Castile, Brody, Helbich, Santamaria and Bhalla scores, respectively. 
 
Lung function 
All PFT were done within 1 month of the HRCT scanning using a Jaeger diagnostic 
system (MasterLab, Jaeger, Germany). Most scans were performed on the same day 
(71 of 96 scans) as the PFT. All HRCT scans were done as part of a routine check-up 
and thus patients were scanned in a relatively stable condition and not during an 
exacerbation. PFT results were expressed as percentage of predicted values: forced 
expiratory volume in one second (FEV1) 8, forced vital capacity (FVC) 8, forced 
expiratory flow between 25% and 75% of expiratory vital capacity (FEF25-75) 9, airway 
resistance (Raw) 10, residual volume (RV) 10, total lung capacity (TLC) and RV/TLC 
10. The ratio FEV1/FVC and the ratio RV/TLC were expressed as a percentage 
(FEV1/FVC % and RV/TLC %). Twelve patients were younger than patients studied 
by Wang et al 9 in the development of the prediction equation for FEF25-75. Body 
plethysmography (TLC, RV and Raw) was performed in 33 of the 48 children. 
Normal lung function was defined as a FEV1 of >85% predicted. 
 
Lung structure and lung function over time 
Data obtained at the first evaluation are reported as HRCT1 and PFT1, and data 
obtained at the second evaluation are reported as HRCT2 and PFT2. ∆HRCT is the 
annual change for a scoring system ((HRCT2-HRCT1)/time interval). To compare 
the annual changes of the five HRCT-scoring systems, ∆HRCT was also expressed as 
a percentage of the maximal obtainable HRCT score for that system. ∆PFT is the 
annual change expressed as % pred for a lung function parameter ((PFT2-
PFT1)/time interval). A positive value for ∆HRCT indicates an increase of structural 
abnormalities and for ∆PFT an improvement in lung function. ∆HRCT and ∆PFT 
were evaluated for the whole group and separately for children younger than and 
older than 10 yrs of age. ∆HRCT and ∆PFT were also evaluated as a function of age 
and baseline disease severity (HRCT1 and first FEV1 % pred). 
 
Statistical analysis 
For the purpose of this article, the term sensitivity is not used in the statistical sense 
but rather as a measure of the techniques’ ability to track pulmonary disease 
progression in CF. It was assumed that, on average, CF lung disease would be 
progressive over 2 yrs and that the method that detected the largest change was most 
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"sensitive". The relationships between HRCT1 and PFT1, HRCT2 and PFT2, 
between ∆HRCT and ∆PFT and between ∆HRCT, ∆PFT, HRCT1, PFT1 and age 
were evaluated using the Spearman correlation coefficient. T-tests (unpaired) were 
performed for ∆HRCT and ∆PFT to determine whether HRCT and/or PFT changed 
significantly in the whole group and for children below and above 10 yrs of age. 
Wilcoxon-signed ranks tests were used to determine which of the HRCT 
abnormalities changed significantly. Statistical significance was set at a p-value of > 
05. Data are presented as mean±SD and range.  
 
 
Results 
 
Study population 
Characteristics of the 48 children (28 male) are shown in Table 1. At HRCT1, 15 
children had normal lung function (31%). HRCT scores were 13.7±8.7, 8.1±6.8, 
6.1±2.9, 6.4±3.2 and 6.1±2.9 for Castile, Brody, Helbich, Santamaria and Bhalla, 
respectively. 
 
Table 1 Patient characteristics 
 Mean ± SD 
HRCT1 
Mean ± SD 
HRCT2 
Mean annual change
Age yrs 11.05 ± 3.3 13.04 ± 3.3 Interval: 1.99 
Body height m  1.37 ± 0.21 1.47 ± 0.20 0.047 * 
Body weight kg  32.5 ± 12.1 38.6 ± 13.9 3.46 * 
FEV1 % pred 74.3 ± 18.2 76.0 ± 21.0 1.24 
FVC % pred 
85.5 ± 15.7 85.1 ± 16.2 - 0.11 
FEF25-75 % pred 58.8 ± 31.2 59.9 ± 32.0 -1.30 
FEV1/FVC % 75.4 ± 10.6 77.6 ± 9.8 0.39 
Raw % pred 136.1 ± 61.8 143.4 ± 76.0 0.10 
RV % pred 
136.6 ± 42.1 129.9 ± 40.2 - 8.49 * 
TLC % pred 98.0 ± 13.2 96.8 ± 11.2 - 1.06 
RV/TLC %  33.2 ± 9.4 31.6 ± 9.7 - 2.11 * 
Castile score  17.7 ± 9.7 22.4 ± 11.4 2.39 * 
Brody score  12.1 ± 8.7 16.3 ± 10.2 2.21 * 
Helbich score  8.4 ± 3.7 10.1 ± 3.8 0.88 * 
Santamaria score  8.9 ± 4.0 10.7 ± 4.1 0.91 * 
Bhalla score  8.2 ± 3.4 10.0 ± 3.6 0.87 * 
Data are presented as mean±SD. HRCT: high-resolution computed tomography; FEV1: forced 
expiratory volume in one second; % pred: % predicted; FVC: forced vital capacity; FEF25-75: forced 
mid-expiratory flow; Raw: airway resistance; RV: residual volume; TLC: total lung capacity *: p<05 in 
1 yr with the one-sample t- test (unpaired) 
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Lung structure and lung function over time 
All HRCT scores worsened significantly. The mean changes for the whole group 
expressed as a percentage of the maximal scores were 2.6, 2.2, 3.3, 3.1 and 3.5% per 
year for Castile, Brody, Helbich, Santamaria, and Bhalla, respectively. Spirometric 
parameters (∆FEV1, ∆FVC, ∆FEF25-75 and ∆FEV1/FVC) did not change 
significantly. RV % pred, RV/TLC % and RV/TLC % pred decreased by 8.9% 
(p=0.004), 2.4% (p=0.0005) and 0.66% (p<0.0001) per year, respectively. Raw and 
TLC did not change significantly. The subgroup analysis of children below and above 
10 yrs of age showed the same results, with the exception that RV % pred remained 
unchanged in the children >10 yrs of age. ∆HRCT and ∆PFT did not differ as a 
function of baseline disease severity or age, with the exception of significant 
relationships between age and ∆RV % pred (R=0.53, p=0.001) and between age and 
∆RV/TLC % (R=0.46, p=0.008). Of the HRCT scan parameters only mucous 
plugging (p=0.001) and the severity (p=0.005), extent (p<0.0001) and peripheral 
extension (p=0.02) of bronchiectasis worsened significantly. Of the 48 patients, the 
severity of bronchiectasis increased in 15, the score for the extent of bronchiectasis 
increased in 19 and the score for the peripheral extension of bronchiectasis increased 
in eight. In only three patients there was a reduction of the severity of bronchiectasis 
(in all three cases, the airway lumen diameter changed from ~ 2 times vessel diameter 
to ~ 1-2 times vessel diameter). One patient showed a reduction in the peripheral 
extension score. 
 
Correlation between lung structure and lung function 
Cross-sectional data showed a significant correlation between HRCT1 and first FEV1 
(R<-0.49, p<0.0001), and between HRCT2 and second FEV1 (R<-0.58, p<0.0001). 
Longitudinal data showed significant but weak correlation between ∆PFT and 
∆HRCT: ∆FEV1/FVC versus ∆Santamaria (R=-0.31, p=0.04), ∆Raw versus ∆Helbich 
(R=0.37, p=0.04), ∆Raw versus ∆Santamaria (R=0.38, p=0.03), ∆RV versus ∆Brody 
(R=0.35, p=0.04), ∆RV/TLC versus ∆Brody (R=0.38, p=0.03), and ∆RV/TLC versus 
∆Helbich (R=0.41, p=0.02). The relationship between ∆FEV1/FVC and ∆Santamaria 
is shown in Figure 1. 
 
SENSITIVITY OF COMPUTED TOMOGRAPHY AND LUNG FUNCTION 
 
 
  
 
48
 
Figure 1 The weak correlation (R=-0 31, p=0 04) between changes in lung function 
(forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)) over a 
1-yr period and structural changes on high-resolution computed tomography (HRCT; 
Santamaria score) is shown.  
 
Patients with improved lung function have a change in FEV1/FVC above 0, and patients with 
progressive structural lung damage have a Santamaria score above 0. 
 
 
Discussion 
 
In this study, the ability of five different HRCT-scoring systems and pulmonary 
function tests were compared to detect and monitor progression of lung damage in 
48 children with CF.  
 
The most striking finding of this study is that structural abnormalities as scored on 
HRCT scans increased significantly, independently of the scoring system used, while 
lung function parameters remained unchanged or even improved. This shows that 
HRCT was more sensitive than PFT in monitoring CF lung disease under the 
assumption that CF lung disease is progressive. In addition, the authors showed that 
it was predominantly the severity, extent and peripheral extension of bronchiectasis 
that worsened significantly. The bronchiectasis most likely represents irreversible 
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structural damage. The irreversibility of bronchiectasis is supported by the fact that 
none of the patients who had bronchiectasis on HRCT1 were without bronchiectasis 
on HRCT2. There are a number of possibilities why the structural abnormalities on 
HRCT were not reflected by the PFT. Firstly, the signal-to-noise ratio for PFT is 
likely to be less than that of HRCT since PFT depend more on patient co-operation 
than HRCT, especially for the younger children, and since PFT are more difficult to 
perform than a breath-hold on the HRCT table. Indeed, the HRCT can be scored 
even when there is minor motion artefact or some variation in inflation level. 
Furthermore, the results of PFT are expressed as % pred with reference to a large 
population sample and this can introduce variability related to the pubertal growth 
spurt 11. In addition, HRCT can detect local abnormalities such as small areas of 
atelectasis and bronchiectasis that may be functionally insignificant. PFT provide a 
global estimate of the lung integrity 1.  
 
In this study RV % pred improved for the whole group, but remained unchanged for 
the children >10 yrs of age. The improvement in RV may, therefore, be a reflection 
of patient effort. For the young children it is more difficult to reach RV during 
expiration. However, the RV/ TLC % and RV/TLC % pred improved slightly in the 
children >10 yrs of age. This suggests that the improvement in RV/TLC % pred is 
only partially caused by an effect of age.  
 
The second important finding of this study is that the structural damage was 
irreversible in most patients irrespective of their change in PFT. In many patients the 
change in HRCT was dissociated from changes in PFT. Approximately one-half of 
the patients who had improved lung function had progressive structural lung disease.  
 
The third important finding is that substantial structural lung damage was present on 
HRCT scans even in children who had lung function within the normal range. This 
supports the conclusions of earlier studies that conventional PFT are relatively 
insensitive to detect the onset and early progression of lung disease in CF 1, 7, 12. 
These results indicate that the current monitoring strategy using PFT may fail to 
detect disease progression and suggest that studies using PFT to monitor treatment 
response may underestimate treatment effects. Therefore, it is possible that because 
of flawed outcome measures, the optimal treatment regime to minimise the 
progression of structural lung damage in CF patients is as yet unknown.  
 
In this study, the HRCT features that changed most over the 2-yr observation period 
were the severity score for bronchiectasis and mucous plugging. Selective scoring of 
these parameters, instead of the full range of parameters included in the currently 
used complex scoring systems, may be more efficient and reproducible. A simplified 
scoring system may prove to be adequate for patient management and therapeutic 
trials. Clearly, such a system should be tested in further studies against the complex 
scoring systems to test this hypothesis.  
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Monitoring CF patients using HRCT carries potential risk due to the associated 
radiation exposure. Since the probability of cancer induction from ionising radiation 
is highest in the paediatric age group 13 and increases with each successive scan, the 
proposal to employ serial HRCT scans must be balanced against the potential 
radiation risk. Further research to determine the optimal scan parameters and 
frequency of HRCT scans for CF monitoring is required.  
 
This study has some limitations. First, only one observer did the scoring. However, in 
a previous study, in which this observer participated, it was shown that the within- 
and between-observer variability for the five scoring systems was good 7. Secondly, 
clinical outcomes were not measured in these patients and thus it cannot be assessed 
whether the worsening on HRCT scans affected the clinical management of the 
patients. However, a case scenario (Figure 2) illustrates how CT scoring could be 
used in a clinical setting. In this patient more aggressive therapy may have affected 
disease progression if it had been detected earlier. Larger prospective clinical studies 
in which CT scans are used in clinical decision making are required to test the 
importance of this conjecture.  
 
To the best of the authors’ knowledge, this is the first study that shows that HRCT 
can reveal progressive, irreversible structural damage in the lungs of cystic fibrosis 
patients over a 2-yr period; changes that are not associated with deterioration in lung 
function. Since the evolution of lung function over time may be dissociated from 
changes in the lung structure it may be advantageous to include high-resolution 
computed tomography in the standard follow-up of cystic fibrosis patients. 
Furthermore, these data support the use of high-resolution computed tomography as 
a measurement tool in therapeutic trials for cystic fibrosis patients, where the 
outcome measure is a slowing of progression of lung disease. Conversely, high-
resolution computed tomography involves significant radiation exposure and in this 
era of prolonged patient survival in cystic fibrosis, the risk-benefit ratio for routine 
high-resolution computed tomography assessment needs to be more fully explored. 
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Figure 2. Patient with cystic fibrosis with improvement of lung function but 
detoriation of lung structure.  
 
The top panels (a and b) show high-resolution computed tomography (HRCT) scan 1 in a patient of 
10 yrs of age. Lung function (% predicted) is as follows: forced expiratory volume in one second 
(FEV1) of 86, forced vital capacity (FVC) of 93, forced mid-expiratory flow (FEF25-75) of 80, and 
FEV1/FVC of 80. HRCT scores are: Castile 17, Brody 16, Helbich 9, Santamaria 10, and Bhalla 9. 
The lower panels (c and d) show HRCT2 at 13 yrs of age. Lung function (% pred) is: FEV1 96, FVC 
91, FEF25-75 105, and FEV1/FVC 90. HRCT scores are: Castile 22, Brody 17, Helbich 12, Santamaria 
13, and Bhalla 12. 
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4.2 Computed tomography is more sensitive than 
pulmonary function tests for monitoring lung 
disease progression in children and adults with 
cystic fibrosis 
 
 
 
 
 
 
Structural lung abnormalities in children with cystic fibrosis (CF) from a single CF 
centre could be more sensitively monitored with computed tomography (CT) 
compared to pulmonary function tests (PFTs). The aims of the study were to 
investigate whether CT scores would also be more sensitive than PFTs to monitor 
structural disease progression in adults with CF and to investigate whether previous 
results in children with CF could be reproduced. CT scans and PFTs were 
retrospectively studied in a cohort of CF-patients aged 5 to 52 years for whom 2 or 
3 CT scans in combination with PFTs (FEV1, FVC, FEV1/FVC, MEF25, MEF50, 
RV, TLC and RV/TLC) with a 3-year interval between CT scans were available. All 
CT scans were scored by two observers. PFTs were expressed as percentage 
predicted and Z-score. The ethical review board of the hospital where the subjects 
were followed approved this retrospective study. Of 119 patients included, 92 
patients had two and 24 had three CT scans. CT (composite and components 
scores) and PFTs both worsened significantly (p<0.02). However, peripheral 
bronchiectasis worsened most by 1.7% per year in children (p<0.0001) and by 1.5% 
per year in adults (p=0.0003). CT score and its components and PFTs showed 
similar worsening rates for adults and children (p>0.09). Peripheral bronchiectasis 
score was more sensitive than PFTs or composite CT score and other component 
scores for monitoring lung disease progression in this cohort of children and adults 
with CF. 
 
 
 
 
 
 
Based on: 
 
Pim A de Jong, Anders Lindblad, Lorenzo Rubin, Wim CJ Hop, Johan C de Jongste, 
Mela Brink, Harm AWM Tiddens. Computed Tomography Is More Sensitive than 
Pulmonary Function Tests for Monitoring Lung Disease Progression in Children and 
Adults with Cystic Fibrosis 
 
Resubmitted to Thorax 
SENSITIVITY OF COMPUTED TOMOGRAPHY AND LUNG FUNCTION 
 
 
  
 
54
 
Introduction 
 
Patients with cystic fibrosis (CF) show progressive worsening in lung structure and 
function due to chronic infection and inflammation 1-3. Pulmonary function tests 
(PFTs) are considered the gold standard for monitoring structural and functional 
changes 2. It was found, however, that functional changes can be preceded by 
structural changes detected on computed tomography (CT) scans 4-8. CT scoring 
systems can quantify structural abnormalities in CF in a reproducible fashion 5, 9-13. A 
recent study in children from a single CF centre demonstrated that structural lung 
abnormalities were monitored more sensitively with composite CT scores compared 
to PFTs, with component CT scores for only bronchiectasis and mucous plugging 
being progressive and irreversible 6.  
 
The first aim of the present study was to investigate whether CT scores would also be 
more sensitive than PFTs to monitor structural disease progression in adults with CF. 
The second aim was to investigate whether the results in children with CF could be 
reproduced. We hypothesized firstly that CT scores and PFTs would show worsening 
in adults with equal sensitivity, and secondly that in concordance with previous 
findings in children CT scores would show worsening whereas PFTs would remain 
stable. 
 
 
Methods 
 
Study population 
Since 1997, the Swedish CF centre has added CT scans to PFTs in the annual check 
up for patients aged 5 years and older. The first CT scan was done when the patient 
obtained reliable PFT results, and CT scans were repeated every third year after. The 
annual check up was postponed if CF patients had an exacerbation, as evidenced by 
change in antibiotics regimen necessitated by acute worsening of CF lung disease. 
Therefore, CT scans and PFTs were performed only when patients were clinically 
stable. We included all routine CT scans up to April 2004. Patients were diagnosed as 
having CF when they had a positive sweat test and/or 2 known CF mutations. The 
cohort was divided in subjects ≤18 years at first scan (children) and >18 years 
(adults). Pancreatic status and prevalence of chronic Pseudomonas aeruginosa infection 
were assessed at first CT. Chronic Pseudomonas infection was defined as sputum or 
nasopharyngeal cultures positive for Pseudomonas at 2 or more occasions in 6 
months. In all subjects cultures had been obtained monthly. The ethical review board 
of the hospital where the subjects were followed approved this retrospective study. 
 
Lung structure  
Lung structure was evaluated using CT scans. For children a single detector CT 
scanner (Philips LX, Philips Medical Systems, Best, Netherlands) was used from 1997 
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to 1999, and a multi-detector row (4 or 8 rows of detectors) CT scanner after 1999 
(General Electric light speed ultra, GE Medical Systems, Milwaukee, WI). Scans were 
obtained using a beam current of 120 mA, an exposure time of 0.5 sec and a beam 
potential of 120 kV from lung apex to base at 15 mm intervals using 1.25 mm thick 
slices. For adults a PQ 6000 scanner (Picker International Inc., Highland Heights, 
OH) was used throughout the study period. Scans were obtained using a beam 
current of 160 mA, a 1 sec exposure time (160 mAs) and a beam potential of 120 kV 
from lung apex to lung base at 10 mm intervals using 1.5 mm thick slices.  
 
All scans were reconstructed with a high-spatial frequency algorithm (bone), printed 
(window width 1400 Hounsfield Unit, window level –400 Hounsfield Unit), blinded 
to date and patient identification and scored in random order by two independent 
experienced observers using an adapted scoring system recently developed by Brody 
et al 13. This scoring system evaluates the 5 lung lobes and the lingula as a sixth lobe 
for severity and extent of central and peripheral bronchiectasis, extent of central and 
peripheral mucous plugging, severity and extent of central and peripheral airway wall 
thickening, extent of opacities (atelectasis or consolidation) and extent of cysts and 
bullae. Hyperinflation (gas trapping) was excluded from scoring since not all scans 
had expiratory images and mosaic perfusion was scored instead. Ground glass pattern 
was not scored in this study. The maximum composite CT score without air trapping 
and ground glass pattern and with mosaic perfusion was 180 13. In addition, 
component CT scores were calculated by adding the component scores from the 6 
lobes. Maximal component scores for central bronchiectasis, peripheral 
bronchiectasis, central mucus, peripheral mucus, central airway wall thickening, 
peripheral airway wall thickening, opacities, mosaic perfusion and cysts or bullae were 
18. For statistical analysis the average composite CT score and component CT scores 
of both observers were expressed on a 0-100 scale (percentage of maximum possible 
score). 
 
Lung function 
Conventional PFTs were done using a dry rolling seal spirometer (MasterLab, Jaeger, 
Würzburg, Germany). Forced vital capacity (FVC), forced expiratory volume in the 
first sec (FEV1), mid expiratory flow at 25% and 50% of VC (MEF25 and MEF50), 
residual volume (RV) and total lung capacity (TLC) were expressed as percentage of 
predicted values and as Z-scores. The ratio between FEV1 and FVC and between RV 
and TLC was calculated and expressed as a percentage, as percent predicted and as a 
Z-score. For children, prediction equations developed by Quanjer and colleagues 14 
were used for FEV1 and FVC and prediction equations developed by Zapletal and 
colleagues 15 were used for MEF25, MEF50, RV and TLC. For adults prediction 
equations from the European Respiratory Society 16 were used for all parameters. 
Spirometry (FEV1, FVC, MEF25 and MEF50) was done in all patients at each annual 
check-up. Plethysmography (RV and TLC) was done in 106 out of 119 (89%), 81 out 
of 92 (88%) and 21 out of 24 (88%) of the patients at the first, second and third 
check-up, respectively. 
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Statistical analysis  
Interobserver agreement of composite and component CT scores was calculated 
using intraclass correlation coefficients. An intraclass correlation coefficient >0.8 
represents good agreement. Systematic errors in component scores were detected 
using Bland and Altman plots that express the difference between two observers as a 
function of their mean 17. Descriptive statistics for children and adults were calculated 
for the time of the baseline CT scan. For the purpose of this paper the term 
sensitivity was not used in the statistical sense but rather as a measure of the 
techniques’ ability to track pulmonary disease progression in CF. We assumed that, 
on average, CF lung disease is progressive and that the method that detects the 
largest worsening can be considered the most “sensitive”. Annual changes in CT 
composite score, CT component scores and PFTs over time were evaluated 
separately for children and adults using repeated measurements analysis of variance 
(RMANOVA). This analysis includes all measurements in the patients with one, two 
or three evaluations. Because distributions of MEF25 (Z-score) and MEF50 (Z-score) 
were not normal, we used percent predicted values transformed to a 10logaritmic scale 
for analysis of MEF25 and MEF50. For all other PFTs we found it more adequate to 
use Z-scores as these account for variability of test scores. A positive slope (annual 
change value) for CT score, RV, TLC and RV/TLC and a negative value for other 
PFTs indicates worsening of disease. Data are expressed as mean ± SD, and p<0.05 
was considered significant. 
 
 
Results 
 
Study population 
We included scans of 119 CF-patients, 72 children and 47 adults at the time of first 
scan. Two scans were available for 92 patients (53 children) and 24 patients had a 
third CT scan. Baseline characteristics are given in Table 1.  
 
Reproducibility of the scoring system 
Intraclass correlation coefficients (r-value) between both observers for CT score 
were: composite 0.92; bronchiectasis 0.88; opacities 0.80; mucous plugging 0.72; 
airway wall thickening 0.67; bulla and cysts 0.53 and mosaic perfusion 0.27. Bland and 
Altman plots evidenced no systematic errors in scoring between both observers for 
bronchiectasis and bulla or cysts. While for mosaic perfusion and mucous plugging 
observer 1 (PdJ) scored systematically higher than did observer 2 (LR), for airway wall 
thickening observer 2 scored higher than did observer 1.  
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Table 1 Patient characteristics at baseline for children and adults  
 Children Adults 
Age (years) 11 ± 4 28 ± 8 
Sex (male / female) 37/35 24/23 
Pancreatic status (sufficient / insufficient) 11/61 14/33 
Chronic Pseudomonas infection (yes / no) 14/58 18/29 
FVC (% predicted)  97 ± 18 94 ± 19 
FEV1 (% predicted) 97 ± 21 78 ± 24 
RV (% predicted) 98 ± 42 126 ± 47 
TLC (% predicted) 95 ± 18 102 ± 12 
MEF50 (% predicted) 96 ± 34 51 ± 30 
MEF25 (% predicted)  84 ± 46 41 ± 33 
FEV1/FVC (%) 88 ± 9 70 ± 13 
FEV1/FVC (% predicted)  98 ± 10 84 ± 16 
RV/TLC (%) 26 ± 11 33 ± 13 
RV/TLC (% predicted ) 104 ± 43 120 ± 42 
Composite CT-score (points, %) 9 ± 11 17 ± 13 
Data given are mean ± SD (standard deviation) 
 
Sensitivity of CT and PFTs for children versus adults 
Table 2 shows the slopes of the RMANOVA regression equations of CT and PFTs 
with age, representing annual changes in CT and PFTs. Interestingly, FEV1 worsened 
by 0.07 Z-score in the children (p=0.03) and FEV1/FVC worsened by almost 0.1 Z-
score per year in both children (p=0.002) and adults (p=0.02). Also MEF25 and 
MEF50 worsened in children (p=0.005 and 0.006, respectively) and adults (p=0.007 
and 0.005, respectively) and RV worsened in adults (p=0.01). All other PFTs 
remained unchanged (p>0.07). Composite CT scores and all CT components scores, 
except mosaic perfusion score in children and adults and peripheral mucous plugging 
score in adults, worsened significantly over time in children (p<0.004) and adults 
(p<0.03). The strongest worsening rate was observed for peripheral bronchiectasis 
score in children (1.7% per year, p<0.0001) and in adults (1.5% per year, p=0.0003). 
Slopes for none of the parameters did significantly differ between children and adults 
(p>0.09), but composite CT score and RV tended to worsen faster in adults relative 
to children.  
SENSITIVITY OF COMPUTED TOMOGRAPHY AND LUNG FUNCTION 
 
 
  
 
58
 
Table 2 Annual changes in pulmonary function test results and composite and 
component CT-scores in children and adults  
 Children Adults Statistical 
difference 
between adults 
and children 
 Change p-value Change p-value  p-value 
FVC (Z-score) -0.0006 0.98 0.0051 0.88 0.89 
FEV1 (Z-score) -0.0734 0.03 -0.0397 0.23 0.47 
RV (Z-score) 0.0105 0.77 0.1025 0.01 0.09 
TLC (Z-score) -0.0028 0.89 0.0294 0.18 0.28 
MEF50 (10log%pred) -0.0119 0.005 -0.0159 0.006 0.53 
MEF25 (10log%pred) -0.0133 0.007 -0.0155 0.005 0.75 
FEV1/FVC (Z-score) -0.0944 0.002 -0.0748 0.02 0.63 
RV/TLC (Z-score) 0.0231 0.62 0.0763 0.07 0.39 
Composite CT-score (%) 1.007 <0.0001 1.547 <0.0001 0.09 
Central bronchiectasis (%) 1.253 0.0002 0.978 0.03 0.60 
Peripheral bronchiectasis (%) 1.721 <0.0001 1.521 0.0003 0.66 
Peripheral mucous plugging 
(%) 
0.652 0.004 0.391 0.08 0.38 
Central AWT (%) 1.389 0.0003 1.076 0.008 0.54 
Peripheral AWT (%) 0.931 0.002 0.807 0.02 0.76 
Opacities (%) 0.733 0.002 0.737 0.006 0.99 
Mosaic glass pattern (%) -0.354 0.58 0.264 0.38 0.38 
Data were obtained using repeated measurement analysis of variance (RMANOVA). Lung structure 
or function = slope times age plus intercept. MEF50 and MEF25 (% predicted) were 10log 
transformed. Being rare, central mucous plugging and bulla or cysts were excluded from analysis. 
Composite-score adapted from Brody et al 13. AWT is airway wall thickening 
Figure 1 presents the changes over the three evaluations for composite CT score and 
FEV1 in the 24 patients who had 3 scans. It is evident that for many patients 
composite CT score worsened while FEV1 remained stable. Figure 2 gives an 
example of progression of structural abnormalities over 4 years despite stable lung 
function. Forty-six of the 92 patients in this study who had two CT scans (50%) 
demonstrated stable or improving FEV1 over three years. Twenty-one of these (46%) 
showed simultaneously worsening in composite CT score up to 9 percent over three 
years. On the other hand, 42 (46%) of the patients showed stable composite CT 
scores over 3 years, 15 of whom (36%) showed worsening in FEV1 up to 22% 
predicted over 3 years.  
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Figure 1 Changes in FEV1 (a) and composite CT score (b) over 6 years in 24 patients 
who had three evaluations  
 
 
Of the 24 patients most demonstrated a stable FEV1 over six years while the composite CT score 13 
demonstrated the expected disease progression. 
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Figure 2 Worsening of irreversible structural abnormalities and improvement in lung 
function parameters over 4 years in a patient with cystic fibrosis 
 
 
 
Female CF patient, age at CT1=9.5 years (1999 I), at CT2 12.0 years (2001 II) and at CT3 13.9 years 
(2003 III). Composite CT scores 13 worsened from 21 to 37 to 40. FEV1 improved from 51 to 61 to 
70 % predicted. FVC improved from 67 to 78 to 85 % predicted. FEV1/FVC improved from 75 to 
78 to 82 %. FEF25-75 improved from 11 to 14 to 20 % predicted. Arrows in the upper three images 
(2aI-III) represent increase in severity of bronchiectasis and airway wall thickening in both upper lobes. 
Arrows in the middle three images (2bI-III) show decrease in central mucous plugging and increase in 
size of central bronchiectasis. Encircled areas show decrease in central mucous plugging and an 
increase in the bronchiectatic size of the airway in the lower lobe. The encircled areas in the lower 
three images (2cI-III) show increased number and size of peripheral bronchiectasis, although there was 
some motion artefact on the CT scan of 1999. 
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Discussion 
 
In this retrospective clinical study we firstly hypothesized that in adults CT score and 
PFTs would be equally sensitive for monitoring structural disease progression. 
However, in disagreement with our hypothesis we found that peripheral 
bronchiectasis CT score (1.5% per year) and composite CT score (1.5% per year) 
showed more worsening than PFTs, and thus CT scoring is more sensitive than PFTs 
to monitor disease progression in adults. 
 
Our second hypothesis was that in concordance with previous findings in children 
CT would show worsening while PFTs would remain stable 6. In contrast to previous 
findings, however, we found that FEV1 worsening (0.07 Z-score is approximately 1% 
predicted) equalled that of the component CT score. The peripheral bronchiectasis 
CT score nevertheless decreased 70% faster than did both the FEV1 and the 
composite CT score. We feel, therefore, that CT in this cohort of children CT was 
more sensitive than PFTs to detect disease progression, even if this was not reflected 
in the composite CT score.  
 
There are two possible explanations why the peripheral bronchiectasis CT scores 
worsened faster than the composite CT scores in the children but not in the adults. 
First, potentially reversible abnormalities, such as mucous plugging 18, 19, airway wall 
thickening and mosaic perfusion, might have been more reversible in the children. 
This would lead to less change over time in the partly reversible composite CT score 
in relation to the irreversible bronchiectasis CT score. Second, changes in airway wall 
thickening and mosaic perfusion were more subtle in the children and therefore more 
difficult to score. Less reproducible scoring of these abnormalities could have 
introduced more noise and subsequently have reduced the ability to detect disease 
progression in the children’s composite CT scores.  
The most likely explanation for discrepancies in PFT findings between this cohort 
and the previously published cohort is duration of follow-up. The latter was followed 
for 2 years only, the former for up to 6 years. Furthermore there might be differences 
between CF centres and between patient populations.  
 
We can only speculate why composite CT scores in the children in this study 
worsened similarly to PFTs. As the children in the previous study had on average 
more advanced disease (lower PFTs at baseline), the CT abnormalities might have 
been less reversible and could therefore have been scored more reproducibly as 
discussed previously. On the other hand, while in the present study CT images were 
acquired at 15 mm intervals, the previous study obtained them at 10 mm intervals. As 
CF airway disease starts heterogeneous, the greater interval between images is likely 
to have resulted in less sensitive composite CT scores in this study.  
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Overall, the major finding of this study is that both in children and adults CT was 
more sensitive than PFTs in monitoring CF lung disease progression, with the 
peripheral bronchiectasis CT score as the most sensitive parameter. For several 
reasons the latter is an attractive outcome parameter, both clinically and in trials. 
First, bronchiectasis can be evaluated relatively easily on CT, witness the good 
interobserver agreement in this and other studies 5, 13. Second, while bronchiectasis is 
argued to be reversible in other diseases 20, 21, it is an irreversible feature in CF 6. 
Third, we believe that airway wall thickening (related to airway inflammation), 
mucous plugging and consolidations all are risk factors for the development of 
bronchiectasis and bronchiectasis is therefore a highly relevant ‘end stage’ feature of 
CF lung disease.  
 
There are several reasons why PFTs worsened less than bronchiectasis on CT. First, 
PFTs have a high noise to signal ratio and Z scores or percent-predicted values are 
calculated using reference equations based on a large population. Second, CT can 
clearly demonstrate focal areas of bronchiectasis that can be scored reproducibly, 
whereas PFTs values can fluctuate for reasons other than structural airway damage, 
such as viral infections and patient effort. That PFTs and CT measure different 
aspects of CF lung disease is also reflected by our observation that composite CT 
scores worsened in 46% of the patients with stable or improving PFTs. In addition, 
PFTs worsened in 36% of the patients with stable composite CT score. This 
discrepancy between lung function and CT findings supports the view that both are 
needed to adequately determine the state of CF related lung disease. The 
bronchiectasis CT score appeared to be more sensitive than lung function to monitor 
disease progression, both in children and adults. 
 
The PFTs findings in this study warrant further consideration. First, we found a 
significant worsening in MEF25 and MEF50, which may be consistent with early lung 
disease 7. Unfortunately, MEF25 and MEF50 have a relative large standard deviation, 
and changes in Z-scores, that we could not use in this study, may not have been 
significant. Second, the FEV1/FVC-ratio changed significantly. Although this 
parameter is usually not included in the analysis of large clinical trials in CF 22-25, our 
findings suggest that it may be a relatively sensitive PFT measurement in CF.  
 
Expectedly, the adults in this study were a selected group of long term survivors. 
Accordingly, the proportion of pancreatic sufficient patients in adults was higher than 
that in children.  
 
Our study is limited by the fact that we did not evaluate air or gas trapping, while this 
is an early marker of CF lung disease 13, 26-28. The sensitivity of this CT abnormality to 
track disease progression in CF is at present unknown which requires further study.  
 
In conclusion, this study shows in adults and children with CF that routine CT scans 
worsened while PFTs remained unchanged or worsened less. The CT worsening was 
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best reflected in peripheral bronchiectasis CT score, which can be scored 
reproducibly and is irreversible in CF. Our findings indicate that a composite CT 
score may be less useful than a peripheral bronchiectasis CT score since a composite 
CT score consists of reversible and irreversible components, and not all components 
were scored reproducibly in this study. Therefore peripheral bronchiectasis CT score 
is important to monitor CF patients clinically and it may gain an important role as an 
outcome parameter in clinical studies in CF.  
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4.3 Changes in airway dimensions on computed 
tomography scans of children with cystic fibrosis 
 
 
 
 
 
 
In cystic fibrosis (CF), chronic bacterial infection and inflammation lead to 
progressive airway wall thickening and lumen dilatation. We aimed to quantify 
airway wall thickening and lumen dilatation in children with CF over a 2-year 
interval. Children with CF (n = 23) who had two computed tomography (CT) scans 
(CTcf1 and CTcf2) combined with pulmonary function tests (PFTs), with a 2-year 
interval between measurements, were compared with control subjects (n = 21) who 
had one CT (CTcontrols). On cross-sectional cut airway–artery pairs, airway wall area 
(WA), airway lumen area (LA) and perimeter, and arterial area (AA) were quantified. 
LA/AA (= marker of bronchiectasis), airway wall thickness (AWT), and WA/AA (= 
markers of wall thickness) were calculated. CT scans were scored using four 
different scoring systems. PFTs were expressed as percent predicted. Airway WA-
to-AA ratio was 1.45 (p < 0.001) and airway LA-to-AA ratio was 1.92 times higher 
(p < 0.001) in children with CF compared with agematched control subjects. 
LA/AA and WA/AA remained unchanged from CTcf1 to CTcf2 and did not increase 
with age. AWT as a function of airway size increased from CTcf1 to CTcf2 by 2% 
(0.03 mm; p = 0.02). The change in AWT was inversely related to the change in 
forced expiratory flow between 25 and 75% of expiratory VC (p = 0.002). In 
conclusion, in CF, quantitative measurements of airways on CT scans show an 
increased ratio between airway LA and AA and progressive airway wall thickening. 
Scoring systems show progression of bronchiectasis but unchanged AWT. PFTs 
remained stable. 
 
 
 
 
 
 
 
 
Based on: 
 
Pim A de Jong, Yasutaka Nakano, Wim C Hop, Frederick R Long, Harvey O 
Coxson, Peter D Paré, Harm A Tiddens. Changes in Airway Dimensions on 
Computed Tomography Scans of Children with Cystic Fibrosis. Am J Resp Crit Care 
Med 2005; 172 (2): 218-24 
Reprinted with permission from the American Thoracic Society 
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Introduction 
 
Chronic bacterial infection and an excessive neutrophil-mediated inflammatory 
response are important characteristics of pulmonary disease in cystic fibrosis (CF) 1. 
These processes lead to structural damage of the airways, including wall thickening 
and lumen dilatation 2, 3. At birth, airway dimensions are believed to be normal 3, but 
structural abnormalities develop early in life and are progressive 4, 5. Quantitative 
measurement of airway dimensions could be a sensitive and relevant endpoint for 
clinical management and for therapeutic interventions in CF related lung disease. 
Airway abnormalities can be assessed in a reproducible fashion using computed 
tomography (CT) scoring systems 6–9. Previous studies using these scoring systems 
have shown that bronchiectasis together with mucus plugging are the most sensitive 
components of CF lung disease 4, 10. Hence, CT scoring systems have been shown to 
be more sensitive for the detection of airway abnormalities in patients with CF 
between 5 and 28 years old when compared with conventional pulmonary function 
tests (PFTs) 4, 10–13. Similarly, plain chest radiographs were found to be more sensitive 
than PFTs for patients aged between 0.5 months and 43 years 6, 14–18. Furthermore, 
airway wall thickening and mucus plugging, as can be observed on CT scans, was 
found to be reversible with antibiotic therapy in two studies of patients with CF with 
ages ranging from 19 to 43 and 9 to 33 years 19, 20. In diseases like asthma and chronic 
obstructive pulmonary disease, airway wall thickness (AWT) is related to airway 
inflammation 21.  
 
A disadvantage of present scoring systems is that the total scores are a composite of 
various structural abnormalities, including the following: bronchiectasis, airway wall 
thickening, mucus plugging, mosiac perfusion, atelectasis, consolidation, bulla and 
cysts, acinar nodules, alveolar consolidation, emphysema, air trapping, overinflation, 
septal thickening, ground glass opacities, and sacculations or abcesses. The composite 
CT score makes it difficult to discern the most important structural change in 
individual patients. In addition, the sensitivity of scoring systems to detect small 
changes in luminal dilatation and AWT is unknown. Quantitative measurements of 
airway dimensions have been developed and applied in chronic obstructive lung 
disease 22, 23. Therefore, a quantitative measurement of AWT and lumen dilatation 
could be an important addition to the time-consuming and subjective scoring 
systems. Although semiautomated airway measurements are still relatively time 
consuming, software is in development that will allow airways to be measured 
substantially faster in the near future. 
 
We hypothesized that children with CF have thicker airway walls and more dilated 
lumens than control subjects and that airway wall thickening and bronchial dilatation 
would be progressive over 2 years in CF. To test this hypothesis, airway wall and 
lumen dimensions and dimensions of the accompanying pulmonary artery were 
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measured on CT using an image analysis system that can measure airways with lumen 
diameter of 1 mm and above 22, 23. Some of the results of these studies have been 
previously reported in the form of an abstract 24. 
 
 
Methods (The full Methods is a supplement at the end of this chapter) 
 
Study population 
CF. Children with CF who had two biennial routine CT scans (CTcf1 and CTcf2), 
during a clinically stable period, in combination with two PFTs (PFTcf1 and PFTcf2) 
were included in this study.  
Control. Control subjects were patients without a diagnosis of heart or chronic lung 
disease who had a thin-slice thoracic CT scan (CTcontrols) performed for a variety of 
clinical indications (Table 1). The lungs of the control subjects were normal as 
assessed by the radiologists. Additional details of the study population are provided in 
an online supplement. The ethical review boards of Erasmus MC/Sophia 
(Rotterdam, the Netherlands) and Columbus Children’s Hospital (Columbus, OH) 
approved this study. 
 
Table 1 Diagnosis of control subjects 
Clinical diagnosis Reason for CT scan Findings Number Of 
Subjects 
Osteochondrosarcoma (1), 
rhabdomyosarcoma (1), 
hepatoblastoma (1) 
Lung metastasis? No metastasis 3 
Recovered spontaneous 
pneumothorax 
Subpleural blebs? No blebs 3 
Solitary nodule Follow-up scan No nodule 3 
Chest pain (later diagnosed as 
reflux) 
Lung abnormalities? Normal lungs 2 
Chest wall mass: undefined (1) 
and osteochondritis (1)  
Exact localization and 
extension 
Extra pulmonary 
mass 
2 
Recurrent sinusitis Lung involvement? Normal lungs 2 
Mitochondrial disease Lung abnormalities? Normal lungs 1 
Aspiration Foreign body? No foreign body 1 
 Vascular ring? No vascular ring 1 
Lupus like syndrome Lung involvement? Normal lungs 1 
Pneumonia’s in history Bronchiectasis? Normal lungs 1 
Small pulmonary hemorrhage Follow-up scan No hemorrhage 1 
 
CT Scans 
CF. CT scans were acquired using 1-mm-thick images and 10-mm intervals from lung 
apex to base during full-suspended inspiration. CT images were archived and printed 
on film blinded for patient name, age, and date of the scan. 
Control. Volumetric CT scans were obtained from lung apex to base during suspended 
full inspiration and reconstructed at 1.25-mm thick slices. 
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CT Scoring 
CF. All printed scans were scored using scoring systems published by Bhalla and 
coworkers 6, Brody and coworkers 7, Helbich and coworkers 8, and Santamaria and 
coworkers 9 in random order by a single experienced observer. 
 
Inspiration during CT Scanning 
Lung volume during CT scanning was estimated using a previously described method 
25, 26 and expressed as a percentage of predicted total lung capacity (TLC) 27. 
 
Quantitative Analysis of Airways and Arteries 
Airway–artery pairs were measured using a previously described method 22, 23. The 
following dimensions were measured: airway wall area (WA), airway lumen area (LA), 
airway lumen perimeter (Pi), and arterial area (AA; see Figure 1). AWT and WA/AA 
were used as markers of airway wall thickening and LA/AA as a marker of bronchial 
dilatation. Two observers measured 86 randomly selected airway–artery pairs, and 
one observer remeasured the same airway–artery pairs after 3 months to determine 
inter- and intraobserver variability. Two observers matched cross-sectioned airway–
artery pairs on CTcf1 and CTcf2. The matched airway–artery pairs in subjects with CF 
and all visible cross-sectioned airway–artery pairs in control subjects were measured 
by one observer. 
 
Figure 1 Airway-artery dimensions 
 
AA = arterial area 
LA = airway lumen area 
WA = airway wall are 
AWT = airway wall thickness (AWT = 2 * square root ((LA + WA) / pi) - 2 * square root (LA / pi)) 
 
PFTs 
CF. The following lung function parameters were measured and expressed as percent 
predicted: FEV1 28, FVC 28, forced expiratory flow between 25 and 75% of expiratory 
VC (FEF25–75) 29, airway resistance (Raw) 27, residual volume (RV) 27, and TLC 27. Two 
ratios were calculated and expressed as a percentage: RV/TLC% and FEV1/FVC%. 
Two patients were too young to perform spirometry at the time of the first scan. 
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FEF25–75 was measured in 16 and Raw, RV, and TLC were measured in 18 of 23 
children.  
 
Statistical Analysis 
A p value of less than 0.05 was considered significant, and data are presented as mean 
± SD (range). 
 
Comparison with Published Data 
We employed the methods described in this manuscript on infant data which has 
been previously published by Long et al. to enable comparison between children and 
infants 5. 
 
 
Results  
 
Study Population 
The age of the 23 children with CF (12 male) at CTcf1 was 11.1 ± 3.7 (4.0–15.9) years, 
and at CTcf2, 12.9 ± 3.7 (6.2–17.9) years. The age of the 21 (11 male) control subjects 
was 11.6 ± 4.7 (3.6–17.2) years. The height of the 23 children with CF at CTcf1 was 
147 ± 16 (122–174) cm, and at CTcf2, 155 ± 16 (130–180) cm. The height of the 21 
control subjects was 144 ± 25 (99–181) cm. PFTs and CT scores at CTcf1 of children 
with CF are shown in Table 2. 
 
Inspiration during CT 
There was no significant difference between the lung volume measured on CTcf1 
(61.7 ± 11.1% predicted TLC) and CTcf2 (63.6 ± 8.7% predicted TLC, p = 0.6) and 
CTcf1 and CTcontrols (56.2 ± 21.4% predicted TLC, p = 0.2), but it did show a trend 
toward a higher lung volume in CTcf2 compared with CTcontrols (p = 0.08). CT 
estimated gas volume was 2,429 ± 1,211 (506–5,533), 2,327 ± 787 (1,037–3,606), and 
2,823 ± 1,038 (1,111–4,785) ml for CTcontrols, CTcf1, and CTcf2, respectively. 
 
Quantitative Analysis of Airways and Arteries 
In children with CF, 619 airway–artery pairs were matched. Mucus plugs were 
observed in 49 airways on CTcf1 and in 127 airways on CTcf2. Therefore, more airways 
were excluded for analysis on CTcf2 (20.5%) versus CTcf1 (7.9%), and 443 airway– 
artery pairs were measured on CTcf1 as well as on CTcf2. In the control subjects, 397 
airway–artery pairs were measured, and no mucus plugs were observed. 
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Table 2 Lung function test results and thin section CT scores at time of CTcf1 and 
changes over the study period in children with CF 
 PFTcf1 and CTcf1 
 
Mean ± SD (range) 
Difference (CTcf2 to CTcf1) 
Or (PFTcf2 to PFTcf1) 
Mean ± SD (range) 
 
 
P-value
FEV1 (%pred) 71 ± 16 (37 to 110) + 5 ± 15 (-15 to 40) 0.25 
FVC (%pred) 83 ± 16 (48 to 110) + 3 ± 14 (-19 to 32) 0.48 
FEF 25-75 (%pred) 54 ± 29 (22 to 132) - 7 ± 16 (-26 to 80) 0.26 
FEV1/FVC (%) 74 ± 8 (57 to 90) + 3 ± 6 (-6 to 20) 0.06 
Raw (%pred) 137 ± 72 (57 to 355) + 6 ± 57 (-87 to 170) 0.98 
RV (%pred) 129 ± 38 (47 to 189) - 12 ± 29 (-67 to 40) 0.12 
TLC (%pred) 97 ± 13 (75 to 118) + 1 ± 11 (-19 to 24) 0.91 
RV/TLC (%) 32 ± 10 (14 to 60) - 12 ± 22 (-13 to 6) 0.03 
Brody (points) 12 ± 8 (1 to 31) + 4 ± 5 (-5 to 18) 0.002 
Helbich (points) 8 ± 3 (3 to 15) +1 ± 2 (-2 to 4) 0.01 
Santmaria (points) 9 ± 3 (3 to 16) +1 ± 2 (-3 to 4) 0.02 
Bhalla (points) 8 ± 3 (3 to 15) + 1 ± 2 (-1 to 4) 0.005 
Bronchiectasis* 
(points) 
1.1 ± 1.1 (0 to 3) +0.4 ± 0.6 (0 to 2) 0.007 
Airway wall 
thickening* (points) 
1.0 ± 0.2 (0 to 1) +0.04 ± 0.2 (0 to 1) 0.32 
Mucous plugging* 
(points) 
1.8 ± 0.9 (0 to 3) + 0.3 ± 1.0 (-2 to 2) 0.15 
SD is Standard Deviation. P-values are obtained with Wilcoxon Signed Rank test. * Bronchiectasis, 
airway wall thickening and mucous plugging scores given are obtained using the scoring system of 
Brody et al 7 
 
Reproducibility of airway measurements. No systematic intra- or interobserver 
differences in measurements were observed. Intraclass correlation coefficients for 
intra- and interobserver variability for WA and LA were greater than 0.99 and greater 
than 0.97 and greater than 0.99 and greater than 0.98, respectively. The mean 
interobserver difference was 0.78 ± 3.6% (-10 to 15%) for LA and 0.87 ± 3.2% (-10 
to 11%) for WA. The mean intraobserver difference was -0.17 ± 2.2% (-5 to 6%) for 
LA and 1.02 ± 3.9% (-8 to 12%) for WA. Differences expressed as a percentage 
decreased with increasing airway size. 
 
Airway lumen dilatation. Figure 2 shows the relation between airway lumen–artery 
dimensions and age for the children of the present study and the infants of Long and 
coworkers 5. The regression equations for these relations are given in Table 3. 
LogLA/AA showed no significant relationship with age for children with CF (CTcf1, 
CTcf2) and control subjects (p > 0.31). Intercepts for logLA/AA versus age were 
significantly (p < 0.0001) higher for children with CF (CTcf1, CTcf2) relative to control 
subjects. LA/AA was 1.92 times higher in children with CF compared with control 
subjects. There was no difference in intercept between CTcf1 and CTcf2. The data of 
Long and coworkers 5 in infants showed that the mean airway lumen/artery ratio 
between infants with CF and control subjects increased from 0.92 at age 1 month to 
1.60 at age 5 years (p = 0.02). 
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AWT. Figure 2 shows the relation between airway wall–artery dimensions and age for 
the children of the present study and the infants of Long and others 5. The regression 
equations for these relations are given in Table 3. LogWA/AA showed no significant 
relationship with age for the children with CF (CTcf1, CTcf2) and control subjects (p > 
0.31). Intercepts for logWA/AA versus age (p < 0.0001) were significantly higher for 
children with CF (CTcf1, CTcf2) relative to control subjects. WA/AA was 1.45 times 
higher in children with CF compared with control subjects. There was no difference 
in intercept between CTcf1 and CTcf2. The data of Long and coworkers 5 in infants 
showed that the mean airway wall/artery ratio between infants with CF and control 
subjects increased from 1.05 at age 1 month to 1.46 at age 5 years (p = 0.02). Figure 3 
shows the relation between logAWT and logPi (perimeter). The regression equations 
of these correlations are given in Table 3. LogAWT (Figure 3) showed a significant 
correlation with logPi (p = 0.001). The slope was not significantly different for CTcf1 
versus CTcf2 (p = 0.16). The intercept was significantly higher (p = 0.02) for CTcf2 
relative to CTcf1. The difference in intercept was 2%, which corresponds to 0.03 mm. 
 
Table 3 Regression equations of the relationships between airway-artery dimensions 
and age and airway size for children (present study) and infants (Long et al 5) 
 Control subjects CT1 CT2 
 A b A b  A b  
Children 
      
Log LA/AA  
vs age 
0.004793 -0.7275 0.004793 -0.4428 0.004793 -0.4490 
Log WA/AA 
vs age 
0.000475 0.0981 0.000475 0.2623 0.000475 0.2513 
Log AWT  
vs Pi 
  0.2772 -0.877 0.2851 -0.8676 
Infants        
Log LA/AA  
vs age 
-0.00335 -0.6673 0.04206 -0.7111   
Log WA/AA 
vs age 
-0.01114 0.1809 0.01647 0.1987   
Regression lines (logX = A * age + b and logX = A * logPi + b) are calculated with repeated 
measurement analysis of variance (RMANOVA). A represents the slope and b the intercept of the 
regression. Infant data are re-analyzed airway-artery pairs in 34 infants with CF and 20 control infants 
published by Long et al 5.  
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Figure 2 Relationship of airway-artery ratio and age for children with CF and control 
subjects in the present study and for infants studied by Long et al 5 
 
∆ CTcontrols children, □ CTcf1, ○ are CTcf2, ∇ infants with CF, ◊ control infants. Regression lines are -- 
-- -- for control children, -- -- -- for CTcf1 and - - - -  for CTcf2. Regression lines are - - - - for infants 
with CF and -- -- -- for control infants. Regression lines are calculated with repeated measurement 
ANOVA method (see Table 3). Regression lines for LA/AA for CTcf1 and CTcf2 overlap. The 
regression line for LA/AA for children is 1.9 times higher for CF compared to control subjects. 
Regression lines for WA/AA for CTcf1 and CTcf2 overlap. The regression line for WA/AA for 
children is 1.4 times higher for CF compared to control subjects. 
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Figure 3 Relationships of airway wall thickness of children with CF against airway 
lumen perimeter 
 
Open circles (○) are CTcf1 and open squares (□) are CTcf2. Regression lines are for CTcf1 and - - - - for 
CTcf2. Regression lines for CTcf1 and CTcf2 almost overlap. Airway wall thickness (AWT) and airway 
lumen perimeter (Pi) are given in centimeters and displayed on a logarithmic scale. Regression lines 
are calculated with repeated measurement ANOVA method (see Table 3). Airway walls at CTcf2 are 
2% or 0.03 mm thicker than at CTcf1 (p=0.02). The increase in AWT correlated with the decrease in 
FEF25-75 % predicted (p=0.002). 
 
Airway–artery dimensions, CT scores, lung function. LA/AA correlated (p < 
0.01) and WA/AA did not correlate (p > 0.25) with CT scores (Bhalla, Helbich, 
Santamaria, Brody). LA/AA and WA/AA did not correlate significantly (p > 0.12) 
with PFTs (FEV1, FVC, FEF25–75, FEV1/FVC, Raw, RV, TLC, RV/TLC). For all 
comparisons, there were no differences between CTcf1 and CTcf2. 
 
Changes in airway–artery dimensions, CT scores, CT component scores, and 
lung function. The change in AWT (∆AWT) showed a significant negative 
correlation with the change in FEF25–75 (p = 0.002) in the 15 children who were able 
to perform spirometry and for whom we could calculate percent-predicted values for 
the FEF25–75. For each 0.01 mm increase in AWT, the FEF25–75 decreased by 0.45% 
predicted. Changes in the other airway parameters (∆LA/AA and ∆WA/AA) did not 
correlate significantly with changes in lung function tests (∆FEV1, ∆FVC, ∆FEF25–75, 
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∆FEV1/FVC, ∆Raw, ∆RV, ∆TLC, ∆RV/TLC) or changes in CT scores (∆Bhalla, 
∆Helbich, ∆Santamaria, ∆Brody). Changes in bronchiectasis (∆bronchiectasis score) 
and airway wall thickening scores (∆AWT score) did not correlate significantly with 
changes in FEV1 (∆FEV1, p = 0.47) or changes in FEF25–75 (∆FEF25–75, p = 0.11). 
 
All CT scores worsened significantly over time (p < 0.02). Mean changes expressed as 
percentage of the maximal possible scores were 4, 4, 3, and 4% for Brody, Helbich, 
Santamaria, and Bhalla, respectively. Of the CT component scores, only the 
bronchiectasis score worsened significantly (p = 0.007), whereas all other component 
scores remained unchanged (p > 0.15; see also Table 2). Most PFTs (FEV1, FVC, 
FEF25–75, FEV1/FVC, Raw, RV, TLC) remained unchanged with time (p > 0.06). 
Only RV/TLC% improved significantly (p = 0.03) by -12% over the 2-year interval 
(see Table 2). 
 
 
Discussion  
 
This longitudinal study aimed to compare airway wall and lumen dimensions on CT 
scans of children with CF with those of control subjects and to examine changes in 
these measures over a 2-year interval in CF. We hypothesized that children with CF 
would have thicker airway walls and more dilated lumens than control subjects and 
that airway wall thickening and airway dilatation would be progressive over 2 years in 
children with CF. To test the hypothesis, dimensions of airway wall and lumen and 
accompanying pulmonary artery were measured.  
 
The most striking finding of our study was that the mean airway lumen-to-artery ratio 
was almost double in children with CF compared with control subjects. This 
increased ratio can be caused by dilatation of the airway and/or by a reduction in size 
of the accompanying artery. The ratio did not show an increase with age in control 
subjects or children with CF and remained unchanged over 2 years in CF. This result 
contrasts with a recent publication that showed a significant increase with age in the 
airway lumen-to-artery ratio of infants with CF 5. Therefore, we remeasured that 
cohort using our method. The reanalysis showed that the airway lumen–artery ratio in 
infants increased from 0.92 at age 1 month to 1.6 at age 5 years. This suggests 
progressive bronchial and/or arterial disease in the infants. Beyond age 5, there was a 
flattening of the curve in children for which several explanations are possible. First, 
bias could have been introduced by the exclusion of more mucus-plugged airways in 
the older children. Similarly, more mucus-plugged airways were excluded from the 
analysis on CTcf2 than on CTcf1. This, together with different methods of airway 
sampling because of differences in scanning protocols between the groups, could 
have influenced our results. Second, inflation techniques differed between the infants 
and the children, which may have influenced the results. A third explanation could be 
that the differences are caused by a center effect because it is known that important 
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differences exist between centers and patient populations 30. Finally, it could be that 
there was a stabilization of the disease process leading to stable airway lumen 
dimensions after age 5. It might be that treatment is more effective in children of 6 
years and older. Most drugs in CF are only used in children 6 years and older because 
they are able to perform lung function. For example, in our center, most children 6 
years and older are treated with rhDNase, whereas few children younger than 6 years 
are treated with rhDNase.  
Our finding, however, appears at contrast with our observation that the scoring 
systems show a steady significant increase in bronchiectasis in the children with CF. 
There are a number of possible explanations for the discrepancy between changes in 
bronchiectasis score and quantitative LA/AA ratio. First, it is known that peripheral 
airways are important in CF lung pathology 2, 13. The scoring systems include 
assessment of peripheral bronchiectasis even when a visible artery does not 
accompany the airways. Because our quantitative method does not include airways 
not accompanied by arteries, it is possible that it is insensitive to peripheral airway 
pathology/peripheral bronchiectasis. Second, sample size could play a role because 
more airways could be evaluated in the qualitative CT assessment of bronchiectasis 
than in the quantitative analysis.  
It is important to realize that, for the radiologic diagnosis of bronchiectasis in CT 
scoring systems, airway size is often compared with the adjacent artery. This 
comparison assumes that the arterial diameter is not changed in relation to the disease 
process. The increased airway/artery ratio observed in our study and in the study by 
Long and coworkers 5 might be in part the result of hypoxia-induced vasoconstriction 
24, 31. If arterial size is changed in CF, it cannot be used as the reference structure to 
define bronchiectasis or airway wall thickening as is done both in the scoring systems 
and in quantified ratios. If the arterial size is reduced in CF, this would result in an 
overestimation of the degree of dilatation and airway wall thickening. Although we 
believe that this is unlikely to be a full explanation for our finding, it could contribute 
to the difference in airway/arterial ratio. In theory, comparing the mean absolute 
arterial size of all vessels in the infants and children with CF and control infants and 
children could test this assumption. However, because the vessels for analysis were 
selected based on the identification of airways and the identification of airways is 
dependent on them being big enough to be reliably measured on CT, this approach is 
flawed in this study. Future studies may want to compare absolute values for airway 
lumen and airway wall directly at well-defined, specific locations of the airway tree 
without use of the accompanying pulmonary artery.  
 
A second important finding in our study was a 45% higher WA/AA ratio in the 
subjects with CF compared with the control subjects. This ratio did not increase with 
age and remained unchanged from CTcf1 to CTcf2. This could be because of relatively 
low inflation, exclusion of mucus-plugged airways, or differences in airway sampling 
between infants and children and control children and CF children. However, AWT 
as a function of airway size was higher for CTcf2 compared with CTcf1, reflecting a 
mean increase in AWT over the 2-year follow-up period. The reason why this change 
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from CTcf1 to CTcf2 was not reflected in the WA/AA ratio might be because the 
WA/AA ratio is more variable than AWT since the ratio includes variation in the 
measurement of airways and arteries. Long and coworkers found an increase in the 
WA/AA ratio in infants with CF from 1.05 at 1 month to 1.46 at 5 years, which was 
not significant. Therefore, their data correspond well to our data, which showed a 
mean value of 1.45 at the age of 5 years. The increase in AWT from CTcf1 to CTcf2, 
although significant, was only 0.03 mm. A 0.03 mm increase in AWT is modest as is 
its potential effect on airway resistance. Despite this, the change in AWT correlated 
significantly with the change in FEF25–75 predicted, a lung function test believed to be 
sensitive to abnormalities in the peripheral airways 32, 33. This could be because only 
modest changes in CT-measured AWT reflect modest changes in small airway caliber 
34 that could have a striking effect on airflow. Alternatively, or in addition, the modest 
increase in AWT could be a surrogate for other pathologic abnormalities, including, 
for example, obliteration of small airways. It could also be that the 0.03 mm is an 
underestimation of the real difference between CTcf1 and CTcf2 because more mucus 
plugged airways were excluded on CTcf2. The quantitative analysis of AWT was more 
sensitive to change than the semiquantitative scoring of AWT. The semiquantitative 
evaluation of AWT as done in the scoring systems is subjective and not very 
reproducible. The fact that, in this study, AWT in the scoring systems was not 
progressive, but quantitatively assessed AWT increased over 2 years, may suggest an 
added value of quantitative analysis of AWT to scoring in children with CF.  
 
The PFT findings in a larger sample of this cohort have previously been described 4. 
The significant improvement in RV/TLC seen in this study was also observed in the 
larger cohort. This increase could be from a learning effect because this cohort 
includes many young patients. In the larger sample, both bronchiectasis score and 
mucus-plugging score worsened significantly. There are a number of potential 
reasons for dissociation between changes in structure and function: PFTs are a 
measure of global lung function, they depend on patient cooperation, and they are 
expressed as percent predicted using equations derived from a large population 
sample. In contrast, CT can detect (small) localized areas of bronchiectasis and 
individual mucus plugs, which may, over the short term, have little influence on lung 
function 4. 
 
There are several limitations of our study. First, for ethical reasons, we used control 
scans that were performed for a clinical indication. However, none of the clinical 
indications would be expected to cause changes in airway wall or vascular dimensions. 
In addition, the airway/arterial ratio in the control subjects was very comparable to 
the published normal values in adults 35–37. However, even if our control scans were 
not completely normal, any bias would likely result in an underestimation of true 
difference between patients with CF and control subjects. 
A second limitation is that children with CF and control subjects were scanned using 
different CT scanners and protocols. However, the CT scanners were made by the 
same manufacturer and a high-enough beam current was used to provide good 
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quality images. Although differences in scanners and scanning technique might affect 
quantitative measurements of airway dimensions, such as AWT, it is unlikely that it 
will affect the ratio between dimensions. Therefore, we restricted our between group 
analyses to comparisons of ratios rather than absolute airway dimensions versus age. 
Differences in protocols also meant that airways were sampled differently in the 
various groups. Infants were scanned at only four levels, older children with CF were 
scanned at approximately 25 levels, and for older control subjects, full-lung scans 
were analyzed. Although we sampled a similar number of airways per CT in the older 
children with CF and control children, there were fewer airways per subject for 
infants with CF and control infants. Despite these sampling differences, there was no 
offset of the regression lines for age versus LA/AA and WA/AA between the infants 
and children for both control subjects and patients with CF. Another important 
difference between this study and that of Long and coworkers 5 is that we did not 
control for lung volume during scanning. Lung volume is an important determinant 
of airway lumen 38 and arterial dimensions. The differences in the slopes of the 
relationships between age and LA/AA and WA/AA between our children and the 
infants of Long and coworkers could be explained by differences in inflation level 
between the studies. To overcome the potential for such differences, future studies 
should be done using CT scanning with spirometer gating 39, 40. 
A third limitation is that we could have introduced a selection bias because a higher 
percentage of airways on CTcf2 were excluded from the analysis because of mucus 
plugging. The exclusion of these occluded (possibly more severely affected) airways 
might have led to an underestimation of the progression of AWT as a function of 
airway size and an underestimation of the changes in the LA/AA and WA/AA ratios 
of CTcf2 relative to CTcf1. In addition, it may be that fewer airways were excluded in 
the infants with CF compared with the children with CF, which might have led to an 
underestimation of the difference in the slopes of age versus WA/AA and LA/AA 
ratios in children with CF relative to infants with CF. 
A fourth limitation is that some of the patients were too young to perform PFTs or 
were excluded from comparisons because their age was younger than the specified 
age for Wang and coworkers’ 29 predicted equations for FEF25–75 results, and 
therefore some comparisons were made with a smaller number of subjects, which 
reduced the power of our statistical analysis. 
 
To conclude, quantitative measurements of airways are highly reproducible. In 
children with CF, the ratio between airway LA and AA and between airway WA and 
AA is increased and the airway walls are thickened. AWT, but not the ratio between 
airway WA and airway LA and AA, increased over 2 years of follow-up. Although 
lung function did not change significantly over the 2-year follow-up period, there 
were significant changes in quantitative airway wall thickening and qualitative CT 
scores as estimates of airway structure. Some of our findings are potentially 
influenced by differences in airway sampling between the groups, by differences in 
lung inflation during the CT procedure, and by the possibility of changes in arterial 
size in patients with CF. Future quantitative studies should address these issues by 
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measuring absolute values for airway wall, airway lumen, and artery at specified 
locations of the airway tree using volumetric CT scanning at a standardized well-
inflated lung volume. Our data extend previous findings regarding CT imaging and 
quantitative assessment of CT findings in CF 5, 11, 41, and further indicate that CT 
scanning and quantitative CT measures may provide valuable information on the 
presence and progression of lung disease in CF. 
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Supplement (full methods) 
 
Study population 
Children with cystic fibrosis (CF): The Cystic Fibrosis Team Rotterdam (CFTR) in 
Sophia Children’s Hospital (Rotterdam, the Netherlands) adapted in 1996 a clinical 
protocol of biennial computed tomography (CT) scans in combination with 
pulmonary function tests (PFTs). CT scans and PFTs evaluations were done during a 
clinically stable period. Clinical stability was determined by clinical evaluation; patients 
who were on treatment for an exacerbation with intravenous antibiotics were 
considered unstable and the CT scan was postponed. Children with CF who had two 
biennial CT scans (CTcf1 and CTcf2) in combination with two PFTs (PFTcf1 and 
PFTcf2) within one month from the CT scan were included in this study. CF was 
diagnosed by a positive sweat test and/or genotyping for known CF mutations 
and/or an abnormal potential difference measured across the rectal mucosa.  
 
Control subjects: Control subjects were all patients who had a thin-slice thoracic CT 
scan (CTcontrols) between 1999 and 2003 at Columbus Children’s Hospital performed 
for various clinical indications as shown in Table 1. Scans that were reported by the 
radiologist as normal were re-evaluated by a second radiologist. Children diagnosed 
with heart or chronic lung disease such as asthma and children with abnormal CT 
scans reported in the radiologist report were excluded for further analysis. Scans that 
were considered normal at the second evaluation were included. The ethical review 
boards of Erasmus MC-Sophia (Rotterdam, Netherlands) and Columbus Children’s 
Hospital (Ohio, USA) approved this study. 
 
Table 1 Diagnosis of control subjects 
Clinical diagnosis Question of CT Findings Number
Osteochondrosarcoma (1), 
rhabdomyosarcoma (1), 
hepatoblastoma (1) 
Lung metastasis? No metastasis 3 
Recovered spontaneous 
pneumothorax 
Subpleural blebs? No blebs 3 
Solitary nodule Follow-up scan No nodule 3 
Chest pain (later diagnosed as reflux) Lung abnormalities? Normal lungs 2 
Chest wall mass: undefined (1) and 
osteochondritis (1)  
Exact localization and 
extension 
Extra pulmonary 
mass 
2 
Recurrent sinusitis Lung involvement? Normal lungs 2 
Mitochondrial disease Lung abnormalities? Normal lungs 1 
Aspiration Foreign body? No foreign body 1 
 Vascular ring? No vascular ring 1 
Lupus like syndrome Lung involvement? Normal lungs 1 
Pneumonia’s in history Bronchiectasis? Normal lungs 1 
Small pulmonary hemorrhage Follow-up scan No hemorrhage 1 
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CT scans 
Children with CF: CT scanning was done from lung apex to lung base in the supine 
position after a breath hold instruction using a GE Prospeed SX scanner (General 
Electric Medical Systems, Milwaukee, WI). One-mm thick slices were obtained at 10-
mm intervals using a potential of 120 kV and a beam current of 160 mAs (under nine 
years of age 120 mAs). Scans were reconstructed with a high-resolution algorithm 
(detail) and a standard reconstruction algorithm. Scans were archived in DICOM 
format and printed on film blinded for patient name, age and date of the scan 
(window level –600 HU, window width 1500 HU). 
 
Control subjects: Volumetric scanning was done from lung apex to base after a 
breath hold instruction using a GE light speed 8-slice CT scanner (General Electric 
Medical Systems, Milwaukee, WI) using a potential of 120 kV and a beam current 
ranging from 30 to 120 mAs. Scans were reconstructed with a high-resolution 
algorithm (bone) and a standard algorithm at 1.25-mm thick slices. 
 
CT scoring 
Children with CF: All printed scans were scored using scoring systems published by 
Bhalla et al 1, Brody et al 2, Helbich et al 3 and Santamaria et al 4 in random order by a 
single experienced observer (PAdJ) 5. The observer was blinded to the date of the 
scan, patient identification, and the PFTs. The results of these scoring systems in a 
larger group of patients were previously published 6. 
 
Inspiration during CT scanning 
Children with CF and control subjects: Lung volume during CT scanning was 
estimated from the standard-reconstructed images using a previously described 
method 7, 8 and expressed as percentage of predicted total lung capacity using the 
equations of Zapletal et al 9.  
 
Quantitative analysis of airways and arteries 
Airways and the accompanying pulmonary artery are measured on high-resolution 
reconstructed scans as follows 10, 11. First a cross-sectional cut airway or artery is 
identified and enlarged. Next, the computer requests the observer to point with the 
mouse in the center of the airway or arterial lumen. From this point 64 rays are 
automatically cast from the lumen into the parenchyma. The computer allows the 
observer to delete rays that are evidently too long or too short. The borders of inner 
and outer airway wall or outer arterial wall are then determined using the full-with at 
half maximum principle 12. The following dimensions are automatically computed 
from the selected rays: airway wall area (WA), airway lumen area (LA), airway lumen 
perimeter (Pi) and arterial area (AA) (see Figure 1). From these measurements airway 
wall thickness (AWT) and WA/AA as markers of airway wall thickening and LA/AA 
as a marker of bronchial dilatation can be calculated. AWT was calculated under the 
assumption that the airways were a perfect circle (AWT = 2 * square root ((LA + 
WA) / pi) - 2 * square root (LA / Pi)). Two observers (PAdJ and YN) measured 86 
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randomly selected airways and one observer (PAdJ) remeasured those 86 randomly 
selected airways after three months in order to determine intra- and interobserver 
variability. Those 86 airways were not included in the matched airways. 
 
Children with CF and control subjects: Two observers (PAdJ and YN) matched 
identical looking cross-sectioned airway-artery pairs on CTcf1 and CTcf2. 
Intrapulmonary markers, like small vessels, airway branching points and fissures were 
used to confirm that the same airway-artery pairs were being measured. Matched 
airways that contained mucus plugs on one of the scans were recorded but excluded 
for further measurements. The selected matched airway-artery pairs in children with 
CF and all visible cross-sectioned airway-artery pairs in control subjects were 
measured by one observer (PAdJ) using the described semi-automated method. 
 
 
Figure 1 Airway-artery dimensions 
 
AA = arterial area 
LA = airway lumen area 
WA = airway wall are 
AWT = airway wall thickness (AWT = 2 * square root ((LA + WA) / pi) - 2 * square root (LA / pi)) 
 
Pulmonary function tests 
Children with CF: PFTs were done using a Jäeger diagnostic system (MasterLab, 
Jäeger, Germany). The following lung function parameters were measured: forced 
expiratory volume in one second (FEV1), forced vital capacity (FVC), forced 
expiratory flow between 25% and 75% of expiratory vital capacity (FEF25-75), airway 
resistance (Raw), residual volume (RV) and total lung capacity (TLC). The parameters 
were expressed as percentage of predicted using the equations of Quanjer and 
coworkers (FEV1, FVC) 13, Wang and coworkers (FEF25-75) 14 and Zapletal and 
coworkers (Raw, RV, TLC) 9. Two ratios were calculated and expressed as a 
percentage: RV/TLC% and FEV1/FVC%. Two patients were too young for 
spirometry at the time of the first scan. In addition the reference equations of Wang 
and coworkers can only be used for children older than seven years of age and 
therefore 6 additional patients had to be excluded for the FEF25-75 measurement. 
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Finally, Raw, RV and TLC were measured in 18 out of 23 children. Therefore, for the 
statistical analysis of FEF25-75 15 patients could be included, for FEV1, FVC and 
FEV1/FVC 21 patients, and for Raw, RV, TLC and RV/TLC 18 patients.  
 
Statistical analysis 
Lung volume during CT scanning was compared between CTcf1, CTcf2 and CTcontrols 
with the Mann Whitney U test.  
 
Intra- and interobserver variability of automated airway measurements was calculated 
by expressing the difference of the first and second measurement as a percentage of 
the average of both measurements. This percentage was plotted against Pi to detect 
systematic errors depending on airway size 15. In addition we calculated the intraclass 
correlation coefficients as a determinant of the intra- and interobserver variation.  
 
Repeated Measurements analysis of variance (RMANOVA) is a statistical method 
that allows for differences between and within patients and for multiple observations 
per patient. Linear relationships were obtained for WA/AA, LA/AA, AWT and Pi by 
transformation to a 10-logaritmic scale. Next, RMANOVA was used to assess the 
relationships between airway-artery ratio’s (logWA/AA and logLA/AA) and age for 
CTcf1, CTcf2 and CTcontrols and between logAWT and logPi for CTcf1 and CTcf2.  
 
The differences between the groups for WA/AA, LA/AA and AWT were expressed 
as a ratio. For children with CF changes over time were calculated by subtracting 
CTcf1 from CTcf2 (∆logWA/AA, ∆logLA/AA, ∆logAWT, ∆Bhalla-score, ∆Brody-
score, ∆Helbich-score, ∆Santamaria-score, ∆Bronchiectasis-score and ∆Airway wall 
thickness-score) and PFTcf1 from PFTcf2 (∆FEV1, ∆FVC, ∆FEF25-75, ∆Raw, ∆RV, 
∆TLC, ∆FEV1/FVC, ∆RV/TLC).  
 
Relationships between log (airway-artery dimensions) and PFTs and CT-scores and 
between ∆log (airway-artery dimensions), ∆PFTs and ∆CT-scores were assessed with 
RMANOVA. In addition, the Spearman correlation coefficients between 
∆Bronchiectasis-score or ∆Airway wall thickness-score and ∆FEF25-75 or ∆FEV1 was 
calculated. 
 
Changes over time (∆PFTs and ∆CT-scores and ∆component scores) were analyzed 
using Wilcoxon Signed Rank tests.  
 
SPSS 11.0 statistical package (SPSS Inc. Chicago, Il, USA) and SAS statistical package 
(SAS Institute Inc. Cary, NC, USA) were used for statistical analysis. Statistical 
significance was considered at a P-value < 0.05 and data are presented as mean ± SD 
(range) unless indicated otherwise. 
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Comparison with published data 
In order to compare our result with published infant data by Long et al 16, we re-
measured their data using our method. The details of their cohort have previously 
been described. Basically the cohort includes 34 infants with CF and 20 control 
infants who were scanned for a variety of indications and received 4 additional slices 
through the lung following an ethical approved protocol. RMANOVA statistics were 
done for the ratios of airway lumen to artery and airway wall to artery against age as 
described above. 
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Chapter 5 
 
Radiation risks associated with computed 
tomography scanning in cystic fibrosis 
 
 
 
 
 
 
     
5.1  Estimation of cancer risks associated with repetitive computed 
tomography scanning    
5.2  Dose reduction of computed tomography in children with cystic 
fibrosis: Is it feasible to reduce the number of images per scan? 
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Chapter 5.1 Estimation of cancer risks associated 
with repetitive computed tomography scanning 
 
 
 
 
 
 
 
Low-dose radiation from computerized tomography (CT) may increase the risk of 
certain cancers, especially in children. We sought to estimate the excess all-cause and 
cancer-specific mortality, which may be associated with CT scanning of cystic 
fibrosis (CF) patients. The radiation dose was calculated for a published CF 
surveillance CT scanning protocol of biennial CT scans and the risk per scan was 
estimated using atom-bomb survivor data. A computational model was developed to 
calculate the excess mortality in a CF cohort associated with radiation from the CT 
scan and to evaluate the effects of background survival, scanning interval and level 
of CT radiation used. The average radiation dose for the published surveillance CT 
scanning protocol was 1 milli-Sievert. Survival reduction associated with annual 
scans from age 2 years until death using this protocol was approximately 1 month 
and 1 year for CF cohorts with a median survival of 26 years and 50 years, 
respectively. Corresponding cumulative cancer mortality was approximately 1% and 
6% at age 40 and 65, respectively. Biennial CT scanning reduced the survival 
reduction and cumulative cancer mortality by half. In conclusion, routine lifelong 
annual CT scans carry a low risk of radiation-induced mortality in CF. However, as 
the overall survival increases for CF patients, the risk of radiation-induced mortality 
becomes greater. These data indicate that radiation dose must be considered in 
routine CT imaging strategies for CF patients, to ensure that benefits outweigh the 
risks.  
 
 
 
 
 
 
 
Based on: 
 
Pim A. de Jong, John R. Mayo, Kamran Golmohammadi, Yasutaka Nakano, Maarten 
H. Lequin, Harm A.W.M. Tiddens, John Aldrich, Harvey O. Coxson, Don D. Sin. 
Estimation of Cancer Mortality Associated with Repetitive Computed Tomography 
Scanning. 
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Introduction 
 
For the justification of clinical protocols and research proposals that include 
computed tomography (CT) the absolute risk associated with radiation from CT 
scans has to be weighed against potential or proven benefits. The risk associated with 
the low dose radiation delivered during chest CT scanning is chromosomal damage 
that can cause haematological cancers within 5 years 1, 2 and solid cancers more than 
30 years 3 after the exposure. Firm data determining the absolute cancer mortality risk 
of CT radiation dose do not exist 1, 4, however, recent data derived from atom-bomb 
survivors enables an estimate of cancer mortality after exposure to low-dose radiation 
2, 3, 5, 6. Because of the substantial impact of CT imaging on patient management, CT 
utilization is increasing 4, 7, even in children and infants who have been shown to be 
more sensitive to radiation compared with adults 1-3, 7. Therefore, concerns have been 
raised regarding the routine use of surveillance CT scans to document disease 
progression in children with cystic fibrosis (CF) 8-12.  
 
Briefly, CF patients develop progressive irreversible structural lung damage early after 
birth leading to a reduced life expectancy 13-20. Traditionally, chest radiographs, along 
with spirometric measurements and clinical assessment have been used to monitor 
disease progression and interventions in CF patients. More recently, studies have 
shown that the structural lung damage in these patients could be detected earlier 
using chest CT compared to chest radiographs 21, 22. Therefore some CF centres have 
replaced the routine annual chest radiograph for a CT scan every second or third year 
8-10. Those centers have reported that CT is more sensitive than the current gold 
standard examination, pulmonary function parameters such as forced expiratory 
volume in 1 second (FEV1), to monitor CF lung disease 9, 23. This finding may 
stimulate the use of routine chest CT examinations in CF. The argument in favour of 
routine CT scanning in CF is that earlier and more sensitive disease detection would 
lead to more aggressive treatment 15, 24-26 and to prolonged longevity. Premised on 
this logic, together with the idea that CF patients have a reduced life expectancy, and 
therefore less time to develop cancers associated with the radiation exposure of CT 
scanning, it was assumed that increases in longevity would outweigh the radiation risk 
of routine CT scans when obtained biennially instead of annually. 
 
However, with rapid medical progress over the past half century, the median survival 
of CF patients has increased linearly from one year in 1940 to 35 years in 2004. 
Further improvements in life expectancy are expected over the next three decades 15, 
27. Since the risk of radiation-associated cancers increases with increased longevity, 
the potential harm from routine CT scanning is likely to be amplified in the future for 
CF patients. To date, however, there are no studies that have determined the risk 
associated with routine CT scanning in CF.  
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The aim of our study was to develop a computational model to estimate the excess 
risk for all-cause mortality and cancer-specific cause of mortality associated with 
lifelong protocol based routine chest CT scanning in CF. We hypothesised that the 
risk associated with lifelong routine CT scanning in CF would be low, but that with 
continued improvements in survival in CF patients over the coming decades, the risk 
associated with routine CT scanning would increase. 
 
 
Methods 
 
CT dose calculation 
The radiation dose per CT scan was calculated using parameters from a published CF 
protocol 9, 10. Briefly, high-resolution CT scans were obtained on a GE Prospeed SX 
scanner (General Electric Medical Systems, Milwaukee, WI, USA) from lung apex to 
lung base as 1.0-mm thick images at 10-mm intervals using 120 kV and 160 mAs 
(children below nine years of age 120 mAs). The radiation dose per scan was 
calculated in milli Sievert (mSv) using imPACT CT Dosimetry Calculator 28 and 
corrected to paediatric values 29. 
 
Computational model 
We designed a simulation model to estimate the risk of exposure to CT scans in 
terms of survival reduction and cumulative cancer mortality in CF patients (Figure 1). 
Each model included two female and two male cohorts of CF patients. In each model 
one male and one female cohort was exposed to routine CT scans (intervention) and 
the other male and female cohort was not exposed to CT scans (control). The 
mortality in the control cohort was all-cause CF mortality obtained from published 
data 15, 30, 31. The mortality in the intervention cohort was broken down to all-cause 
CF mortality and mortality due to radiation associated hematological cancers 2, and 
solid cancers 3. We developed seven variations of the model. The first five models 
used a 38-year time horizon (cohorts followed from age 2 to 40) and the next two 
models used a 63-year time horizon (cohorts followed from age 2 to 65). In the first 
model we assumed that all patients in the intervention group received annual CT 
scans for the whole follow-up period. In the second model the interval between CT 
scans was increased to two years. In the third model we assumed that the estimated 
dose per CT scan was 5 times higher than the first model. In the fourth model we 
assumed that the dose per CT scan was five times lower than the first model. In these 
first four models we used survival CF data from 1990, when the median survival was 
approximately 26 years 31. Model 5 was the same as model 1 except different CF 
survival data were used from 1999 when the median survival was approximately 32 
years 30. In the sixth model we followed patients up to the age of 65 and exposed 
them to annual CT scans for their whole life. In addition we extrapolated the linear 
increase in CF survival to 2030 when the median survival is expected to reach 50 
years 15, 32. The seventh model was the same as the sixth, except we used CT scans 
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only for early detection and stopped CT scanning at the age of 18. An overview of 
the models is provided in Table 1. 
 
We used 6-month increments or cycle lengths to establish accurate transitional state 
probabilities. For each 6-month period, new probabilities of death were imputed into 
the models. Patients who died during each 6-month cycle were censored from further 
analysis. Survivors of each cycle were passed through another 6-month cycle wherein 
a new set of probabilities of death were applied. To determine the robustness of our 
data, multivariate sensitivity analyses were performed in which simultaneous clinically 
plausible adjustments for the relevant covariates for each of the strategies was made. 
We subjected all probabilities to a 10 percent variation around the probabilities of 
death using a triangular distribution. We sampled all variables based on their 
distribution and produced 100,000 sample sets in a Monte Carlo simulation. All 
modeled simulations were conducted using Data Pro (TREEAGE software Inc; 
Williamstown, MA). 
 
Table 1 Computational models to estimate radiation associated cancer mortality 
Model Dose per 
CT scan  
 
(mSv) 
CT scan 
interval  
 
(years) 
Median 
male CF 
survival 
(years) 
Median 
female CF 
survival 
(years) 
Time 
horizon 
 
(years) 
Consideration 
1 1 1 ±27.5 ±24 2-40 Annual CT 
2 1 2 ±27.5 ±24 2-40 Biennial CT 
3 5 1 ±27.5 ±24 2-40 5-times higher dose 
4 0.2 1 ±27.5 ±24 2-40 5-times lower dose 
5 1 1 ±34.5 ±29.5 2-40 Current CF survival 30 
6 1 1 ±52 ±46 2-65 Future CF survival 
7 1 1, stop at 
age 18 
±52 ±46 2-65 Future CF survival, early 
detection CT 
Model one was based on survival data of 1990 31 when the median cystic fibrosis (CF) survival was 
about 26 years. The model was based on annual computed tomography (CT) scans from the age of 2 
till the age of 40. In model 5 survival data from 1999 were used 30 when the median CF survival was 
about 32 years. In model 6 and 7 CF survival was extrapolated to a median survival of 50 years that is 
assumed to occur in 2030 15. Since the main purpose in CF is early disease detection CT scans were 
done from age two till age 18, thereafter no CT scans were done. The assumption of the models was 
that there is no benefit from CT scanning. 
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Figure 1 Computational model to study the potential lethal cancer risk associated 
with radiation from computed tomography in cystic fibrosis patients  
 
In this model the effect on lethal cancer development potentially associated with computed 
tomography (CT) radiation in cystic fibrosis (CF) was studied by changing the dose per scan, the 
interval between scans, the number of scans per patient and the life expectancy (annual mortality 
rate) in CF males and females. 
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Results 
 
Dose calculation 
CT dose was calculated for 58 CF-children aged 9.9±3.9 (3.5-17.3) years 9. Their 
height and weight was 1.4±0.2 (1.0-1.8) meter and 32.1±12.3 (14.8-61.9) kilogram, 
respectively. The number of images per CT scan was 24±4 (16-34). The calculated 
dose per CT scan was 1.0±0.3 (0.5-1.9) mSv. For model one, we therefore used 1 
mSv per CT scan.  
 
Survival and cancer mortality after repetitive CT scanning  
The reduction in median survival was less than one month in CF patients who had a 
median survival of 26 years and received annual CT scans (1 mSv) from age 2 and on. 
An increased median survival to 32 years resulted in a survival reduction of less than 
1.5 months. However, when the median CF survival increased to 50 years the survival 
reduction increased to over a year for both males and females. If CT scans in these 
patients were used only for early disease detection until the age of 18 years, the 
survival reduction was more than half a year (Figure 2). When the time interval 
between the CT scans was increased to two years, the risk decreased by a factor of 2. 
A five-fold decrease and increase in the dose per CT scan (0.2 mSv and 5 mSv) 
resulted in approximately a five-fold decrease and increase in the survival reduction, 
respectively. For all situations modelled, males had a larger reduction in survival than 
females (Table 2). 
 
The survival reduction was driven by excess number of deaths from haematological 
and solid cancers (Table 3). When the median CF survival was relatively low (model 
1-5), most of the excess deaths in males were from haematological cancers while in 
females solid cancers predominated. The sum of all cancer deaths, however, remained 
below 1% at age 40 for both sexes at 1 mSv. However, when CF survival increased to 
a median of 50 years (models 6 & 7), the combined cumulative mortality from 
haematological and solid cancers was >6% for males and <6% for females when 
annual CT scans were used from the age of 2 and on. The risk decreased to 3.5% for 
males and 3.3% for females when CT scans were discontinued at age 18 years of age.  
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Table 2 Survival reduction of cystic fibrosis patients exposed to computed 
tomography radiation  
  Male Female 
 
Model 
Median 
(months) 
SD Median 
(months) 
SD 
1 Annual CT 1.09 0.017 0.542 0.011 
2 Biennial CT 0.56 0.009 0.276 0.005 
3 5-times higher dose 5.36 0.080 2.672 0.051 
4 5-times lower dose 0.22 0.003 0.109 0.002 
5 Current CF survival 1.38 0.015 0.715 0.011 
6 Future CF survival 15.02 0.208 12.41 0.188 
7 Future CF survival, early 
detection CT  
8.13 0.117 6.65 0.108 
Data given are months based on haematological and solid cancers together 
SD is standard deviation, which was based on a 10% variation 
The assumption was no benefit from computed tomography (CT) scans and therefore these numbers 
represent the estimated risks associated with CT scanning and not a survival reduction in the real 
situation where there will be a benefit from the CT scans  
 
Table 3 Cumulative mortality from cystic fibrosis (controls) and haematological and 
solid cancers after repeated computed tomography scanning 
Solid cancer Haematological 
cancer 
All other causes 
mortality 
including CF 
Male and 
female 
Male Female Male Female 
 
 
 
 
 
Model 
Follow-up 
period in the 
modelled 
cohort 
 
Years % % % % % 
1 Annual CT Age 2 to 40 0.30 0.51 0.22 74 79 
2 Biennial CT Age 2 to 40 0.15 0.26 0.11 74 79 
3 5-times higher dose Age 2 to 40 1.43 2.52 1.10 74 79 
4 5-times lower dose Age 2 to 40 0.06 0.10 0.05 74 79 
5 Current CF survival Age 2 to 40 0.42 0.57 0.25 57 66 
6 Future CF survival Age 2 to 65 5.29 1.00 0.49 60 64 
7 Future CF survival, 
early detection CT 
Age 2 to 65 3.11 0.42 0.20 60 64 
CT is computed tomography, CF is cystic fibrosis, % is percentage of cohort 
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Figure 2 Survival curves for cystic fibrosis patients exposed to radiation from 
computed tomography  
 
Assumed was no survival benefits from the computed tomography (CT) scans and these data are 
only demonstrating and estimated magnitude of risk. The light gray line represents the controls, the 
dark gray line represents the early detection group and the black dotted line represents the annual CT 
group. The median cystic fibrosis background survival in these models was 50 years, which is 
expected to be in 2030.  
The dose per scan was 1 mSv. Scans were acquired annually from age 2 till death (annual) or till age 
18 (early detection). In the annual lifelong group the median survival reduction was 15 and 12 
months for males and females, respectively. In the early detection group the median survival 
reduction was 8 and 7 months for males and females respectively. The cumulative prevalence of solid 
cancers at age 65 was more than 5% and 3% in the annual and early detection group, respectively. 
The cumulative prevalence of haematological cancers ranged from 0.5-1% and 0.2-0.4% in the 
annual and early detection group, respectively. Data are given for males. 
 
 
Discussion 
 
In this study we estimated the excess mortality associated with low-dose radiation 
from routine lifelong chest CT scanning in CF patients. We used a cohort of CF 
patients and varied the radiation dose per scan, scanning interval and background CF 
survival to determine the effects of using different strategies for CT scanning. An 
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important assumption in our model was that CT scans would not provide clinical 
benefits that would improve survival in CF patients. We made this assumption for 
two reasons. First, there is a paucity of studies with estimates of survival benefits 
related to routine CT scanning in CF. Second, the major objective of our study was to 
estimate the risk posed by low-dose radiation related to CT scanning, which has not 
been previously studied in the CF population. This question has both clinical and 
public health policy importance as a growing number of CF centres 8,9 have adopted a 
strategy to use routine CT scans every second or third year at least in managing CF 
patients during childhood. 
 
We found that in the models in which the radiation per CT dose was low (1 mSv) and 
in which the overall expected median CF survival was 32 years or less, the risks 
imposed by low-dose radiation from routine CT scanning were low. However when 
the expected survival of the non-scanned (control) population increased to a median 
of 50 years the risk associated with lifelong routine CT scans became substantial. For 
instance, in model 6, the difference in median survival between those scanned and 
non-scanned was more than 1 year. This reduction was driven largely by a 5% excess 
mortality from solid cancers. When CT scanning was used only for early disease 
detection (model 7) the excess mortality from solid cancers was more than 3%. 
According to the latest projections based on data from USA 15, 32 the median CF 
survival is expected to improve to 50 years by 2030. Under this scenario, CF patients 
born today may be expected to live to age 50 years and beyond, which makes the 
current study highly relevant. Given the potential reduction in survival associated 
with radiation exposure from routine CT scans, it would be important to further 
demonstrate the clinical benefits related to this approach in order to justify the use of 
routine lifelong CT scanning in CF patients. Our data may also be germane and 
applicable to other clinical settings in which routine CT scanning is used. In our 
models the minimum number of CT scans per patients was 17 (model 7) and at age 
65 the cumulative cancer mortality was about 3% in that model. 
 
Notably, in the present study, we showed that biennial CT scanning could reduce the 
risk by half compared to annual CT scans. Moreover, by reducing the radiation dose 
five-fold, the risks can also be reduced five-fold. This shows that it is important to 
consider the dose and frequency of CT scanning for routine clinical purposes. A full-
lung volumetric CT scan of the chest would expose the subject to approximately 5 
mSv (model 4). Three inspiratory and 3 expiratory images would expose the subject 
to 0.2 mSv (model 3). A five-fold reduction in the milli Amperes per second (mAs) 
would be another option to reduce the radiation dose to approximately 0.2 mSv. 
Clearly, the model results stress the importance that lifelong routine imaging 
strategies can only be used when imaging strategies can be developed that will reduce 
lifelong radiation exposure below acceptable risk levels that are outweighed by the 
benefits. 
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There are several limitations to our study. Firstly, our data may have overestimated 
the mortality risks related to low-dose radiation since the atom-bomb survivor data, 
which we used to model the risks, were obtained before the advent of newer 
therapies to treat haematological cancers and improve survival of such patients 33. 
Secondly, for largely unexplained reasons the atom-bomb survivor data showed a 
larger risk for haematological cancer in men than in women 2. The data on solid 
cancers was not sex-specific, but it may be that the effect on mortality reduction of 
solid cancer is greater in women because of the development of breast cancer which 
could not be included in our model 3. Thirdly, we did not consider the negative 
effects of radiation on non-cancer mortality like heart and blood vessel disease since 
there is no evidence of an increased risk for such diseases at the doses employed with 
CT scanning 3. Fourthly, we did not take costs or potential benefits of CT into 
account since we aimed to model only the potential mortality risks associated with 
low-dose radiation exposure from routine CT scanning. Consideration of costs, in 
addition to safety issues, will be important in formulating a coherent public health 
policy in the use of routine CT scans in CF. Fifthly, the data we used to model cancer 
risks were obtained from the general population, not from the CF population. It is 
however re-assuring that several studies have shown that the cancer risks in CF are 
comparable to the normal population 34, 35. Sixthly, our data should be interpreted in 
the context of other sources of radiation. In a Swiss survey the dose of a lateral plus 
antero-posterior chest radiograph was about 0.17 mSv and of a volumetric chest CT 
scan 9.0 mSv 36. The dose for this scan is 10 times the dose of a high-resolution CT 
scan (HRCT) 7. Therefore the dose for a HRCT would be 5 times the dose of chest 
radiographs. Interestingly, 140-350 transatlantic flying hours with a subsonic aircraft 
or 60-150 transatlantic flying hours with a Concorde results in a radiation exposure of 
1 mSv 37. Finally, natural background radiation in the USA due to cosmic radiation, 
natural radioactivity and domestic radon results in an average exposure of ~3 mSv / 
year. 
 
In conclusion, our model indicated that the risk of routine lifelong annual CT 
scanning in CF is low but will increase when survival further improves. Our data urge 
caution in using CT scans for lifelong surveillance purposes in any disease unless 
there is a clear understanding of the benefits. Ways to reduce the dose per CT scan 
are available and more investigation in dose reduction as well as the optimal timing of 
routine CT scans is needed. The radiation dose related to routine CT scanning is 
likely to be reduced in the near future due to technical improvements. Our 
computational model can help to determine whether protocol improvements are 
sufficient to keep life-time exposure within acceptable limits. 
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5.2 Dose reduction of computed tomography in 
children with cystic fibrosis: Is it feasible to reduce 
the number of images per scan? 
 
 
 
 
 
 
 
 
 
 
 
We aimed to determine whether it would be feasible to reduce the number of 
computed tomography (CT) images in children with cystic fibrosis (CF). One-mm 
thick CT images at 10-mm intervals were obtained biennially in CF-children. CT 
scans (20 baseline, 10 follow-up) were scored as sets including all, every second, 
every third, three selected, or five selected images. CT score (mean±SD) of every 
second image (15±2.6) was lower than that of all images (18±2.3, p=0.002). CT 
score worsened only when all or every second image was included (p=0.02). 
Significant information is lost when the interval between CT images is extended to 
>10-mm. 
 
 
 
 
 
 
 
 
 
 
 
Based on: 
 
P.A. de Jong, Y. Nakano, M.H. Lequin, H.A.W.M. Tiddens. Dose reduction of 
computed tomography in children with cystic fibrosis: Is it feasible to reduce the 
number of images per scan? 
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Introduction 
 
In children with cystic fibrosis (CF) thin-section computed tomography (CT) 
scanning was shown to be useful to detect onset and progression of CF related lung 
disease 1-6. CT scanning can detect CF related lung disease even before chest 
radiography 7-9 and pulmonary function testing 1, 3-5. In addition, repeated CT 
scanning is more sensitive than pulmonary function testing to monitor progression of 
CF related lung disease 3. A disadvantage of repeated CT scanning is the higher 
cumulative radiation exposure for the patients 10-12. This, together with the prolonged 
survival of CF patients 13-15, increases the risk of radiation associated cancers 16, 17.  
 
Reducing the dose per CT scan to the absolute minimum with acceptable diagnostic 
quality is a general and important radiologic principle. Several strategies for dose 
reduction of thin-section CT are available 12, 18-22. One option is reducing the number 
of images per CT scan. Adequate sampling of the lung may be feasible using fewer 
images than commonly used in high-resolution CT protocols with 1-mm thick images 
at 10-mm intervals 3, 4. However, CF related lung disease being heterogeneous in its 
presentation and therefore such reduction carries the risk that relevant abnormalities 
remain undetected. The relation between number of images and sensitivity to detect 
lung abnormalities has not been studied in CF to date. 
 
The aim of this study was to investigate the relation between number of images per 
CT scan and severity of lung abnormalities as determined by an established CT 
scoring system 23.  
 
 
Methods 
 
Subjects 
Twenty subjects were randomly selected from a published cohort of children 
diagnosed with CF 3. All children underwent routine biennial CT scanning as part of 
their annual check-up during a clinically stable period. Clinical stability was 
determined by clinical evaluation; patients treated with intravenous antibiotics for an 
exacerbation were considered unstable, in which case scanning was postponed. CF 
was diagnosed by a positive sweat test and/or genotyping for known CF mutations 
and/or an abnormal potential difference measured across the rectal mucosa.  
 
CT scanning protocol 
CT scans were obtained using a single slice CT scanner (Prospeed SX; GE Medical 
Systems, Milwaukee, Wisconsin) in the supine position. The children were instructed 
to take a deep breath and hold it for at least 5 seconds. During each breath holding, 
two 1-mm thick images were obtained at 10-mm intervals from the lung apex to the 
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lung base. Scanning parameters were as follows: 120 kV, 160 mA (120 mA in children 
younger than 9 years), 1-second scanning time, and field of view 350 mm (250 mm in 
children younger than 9 years). Scans were reconstructed using a high-spatial 
frequency reconstruction algorithm (Detail; GE Medical Systems, Milwaukee, 
Wisconsin).  
 
Evaluation of CT scans 
The first CT scans from all 20 children (CT1) and the second CT scans (CT2) from 10 
randomly selected children were used to compose five different sets of images 
(Figure 1). Set 1 contained all images for each scan (interval between images 10 mm), 
Set 2 contained every second image (interval 20 mm), Set 3 contained every third 
image (interval 30 mm), Set 4 contained a selection of five images and Set 5 contained 
a selection of only three images. The selected images were taken at the following 
anatomical positions: between the lung apex and the top of the aortic arch (Set 4 and 
Set 5); at the top of the aortic arch (Set 4); below the carina (Set 4 and Set 5); between 
the carina and the top of the diaphragm (Set 4) and at the top of the diaphragm (Set 4 
and Set 5). The resulting 150 sets were blinded for patient characteristics, assigned a 
random number and scored 23 in random order by an experienced observer known to 
be able to score with low intra- and interobserver variability 4. The scoring system 
used evaluates the 5 lobes and the lingula as a sixth lobe for the severity and/or 
extent of bronchiectasis, airway wall thickening, mucous plugging, alveolar 
consolidations, collapse and bulla or cysts 23. 
 
Statistical analysis  
For each set of images a score on a scale from 0 (no abnormalities) to 100 (worst 
possible) was calculated. CT scores from CT1 (n=20) were compared between the five 
different sets using unpaired sample T-tests. Changes in CT scores from CT1 to CT2 
(n=10) were calculated using paired sample T tests for each of the five sets. 
Significance level was set at p<0.05. Data are presented as mean ± standard deviation 
(range) unless indicated otherwise. 
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Figure 1 Study protocol 
   
 
  
These scout films show the levels of the computed tomography (CT) images used (white lines) in the 
five sets of this study. Set 1 contained all images for each scan (interval between images 10 mm), Set 
2 contained every second image (interval 20 mm), Set 3 contained every third image (interval 30 mm), 
Set 4 contained a selection of five images and Set 5 contained a selection of only three images. 
 
 
Results 
 
Subjects 
Subjects (6 girls, 14 boys) were 10.0 ± 4.1 (3.7-17.6) years of age and had body height 
1.4 ± 0.2 (1.0-1.8) meters and body weight 32.2 ± 15.1 (16.7-70.1) kilograms. The 
number of CT images in Set 1 for CT1 was 25 ± 5 (18-34).  
 
CT findings at baseline 
The CT score in Set 1 for CT1 was significantly higher than that in the other sets with 
larger intervals (Table 1). The incidence of CT abnormalities decreased for each set 
relative to Set 1. For example, the decrease from Set 1 to Set 2 was for bronchiectasis 
85% to 65%, airway wall thickening 100% to 95%, alveolar consolidations 70% to 
50%, collapse 55% to 40%, mucous plugging 90% to 75% and bulla and cysts 10% to 
5%, respectively.  
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CT changes over two years 
CT2 worsened relative to CT1 only for Set 1 and Set 2 (p=0.02). No significant 
changes were detected for the other sets with larger intervals (p>0.31) (Table 2). 
 
Table 1 CT score at different intervals between CT images in children with cystic 
fibrosis 
CT score  
 
Set number 
 
 
Set description 
Mean Standard 
deviation 
Range 
1 All images (every 10 mm) 18 2.3 6 – 38 
2 Every second image 15* 2.6 0 – 42 
3 Every third image 15* 2.1 1 – 34 
4 Five selected images 11* 2.4 0 – 38 
5 Three selected images 12* 2.1 1 – 30 
Results are based on 20 CT scans obtained from 20 subjects 
CT scores were obtained using a validated scoring system 23  
CT scores are lower in Set 2, 3, 4 and 5 compared to Set 1 (p<0.002, unpaired sample T test) 
 
Table 2 Change in CT score over two years at different intervals between CT images 
 
Mean 
change 
95% confidence 
interval 
P-value 
All slices 6.8 1.4 – 12.1 0.02 
Every second image 5.5 1.1 – 9.8 0.02 
Every third image 1.4 -1.5 – 4.3 0.31 
Five selected images 1.6 -2.2 – 5.5 0.37 
Three selected images 0.4 -4.7 – 3.8 0.83 
Results are based on 10 baseline and 10 follow-up CT scans obtained from 10 subjects 
CT scores were obtained using a validated scoring system 23  
Results were obtained using paired sample T tests 
 
 
Discussion 
 
Repeated CT scanning in CF is gaining importance as a clinical and research outcome 
measure. However, CT scanning involves radiation and therefore a risk to the patient, 
especially when repeated CT scanning is started in childhood. In this study we 
investigated whether radiation dose in children with CF could be reduced by reducing 
the number of images per CT examination. 
Our results clearly show that CT scores and numbers of cases with CT abnormalities 
decreased with reduction of number of images per CT scan. In addition, over a time 
interval of two years we were able to detect significant worsening on images taken 
every 10-mm or every 20-mm, but not at greater intervals. Reducing the number of 
images per CT scan to less than 1 image every 10-mm does not seem to be a valid 
option for dose reduction in CF. Our results can be explained by the heterogeneous 
nature of CF related lung disease. For this reason, the fewer the number of images in 
 
RADIATION RISKS ASSOCIATED WITH CT SCANNING IN CYSTIC FIBROSIS 
 
 
  
 
104
 
children with CF, the higher the risk that localized structural abnormalities remain 
undetected. Our results also suggest that full-lung volumetric CT scans would be an 
even more sensitive method than the thin-section sequential CT protocol used in this 
study and other studies. However, this needs to be investigated in further studies. 
Whether our results are applicable to more advanced CF in adults or other chest 
diseases is unknown and will depend on the heterogeneity of the abnormalities in 
those situations. 
 
It is unfortunate that reducing the number of images per CT scan in CF children does 
not seem to be a valid strategy to reduce radiation dose. Fortunately, there are other 
options for dose reduction in this disease. For example, at the time of our study our 
CT scanning protocol was a relatively high-dose protocol, which dose, however, 
could be substantially reduced over the last years. Suggestions for dose reduction by 
lowering the milli Amperes per second based on patients’ body weight have been 
published 21.  
 
At the time of the study we did not include expiratory CT scans. Gas trapping in CF 
has recently gained much attention 24-27. A similar approach as used in our study 
could be used to determine the optimal number of expiratory images needed to 
adequately estimate the severity of gas trapping.  
 
A limitation of our study is that all images were scored by a single observer. However, 
this observer is known to be able to score with a low intra- and interobserver 
variability using the scoring system applied in the present study 4. In addition all 
images were scored in random order. Another limitation is that the follow up scan 
was done in only 10 of the 20 patients in order to reduce the work load from the time 
consuming CT scoring. For the present study design 150 sets had to be scored at 
approximately 10 to 15 minutes per set. It is unlikely that a larger number of follow 
up scans would change the conclusions of our study.  
 
In conclusion, the sensitivity of inspiratory CT scans to determine the severity of CF 
related lung disease is higher when images are taken at 10-mm intervals rather than at 
larger intervals. Therefore, reducing the radiation dose in CF by reducing the number 
of inspiratory images per CT scan is not an attractive strategy. Other methods to 
further reduce the radiation dose should be investigated.  
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Chapter 6 
 
Monitoring of lung growth using computed 
tomography 
 
 
 
 
 
 
 
6.1  Estimation of lung growth using computed tomography 
6.2  Estimation of lung dimensions throughout the growth period 
using computed tomography 
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6.1 Estimation of lung growth using computed 
tomography 
 
 
 
 
 
 
 
 
 
Anatomical studies suggest that normal lungs grow by rapid alveolar addition until 
about 2 yrs of age followed by a gradual increase in alveolar dimensions. The aim of 
this study was to examine the hypothesis that normal lung growth can be monitored 
by computed tomography (CT). Therefore, the gas volume per gram of lung tissue 
was estimated from measurements of lung density obtained from CT scans 
performed on children throughout the growth period. CT scans were performed on 
17 males and 18 females, ranging in age from 15 days–17.6 yrs. CT-measured lung 
weight was correlated with predicted post mortem values and CT measured gas 
volume with predicted values of functional residual capacity. The median value for 
lung expansion was 1.86 mL*g-1 at 15 days, decreased to 0.79 mL*g-1 by 2 yrs and 
then increased steadily to 5.07 mL*g-1 at 17 yrs. Computed tomography scans can 
be used to estimate lung weight, gas volume and expansion of normal lungs during 
the growth period. The increase in the lung expansion after the age of 2 yrs suggests 
progressive alveolar expansion with increasing lung volume. 
 
 
 
 
 
 
 
 
 
 
Based on: 
 
P.A. de Jong, Y. Nakano, M.H. Lequin, J.R. Mayo, R. Woods, P.D. Paré, and H.A. 
Tiddens. 2004. Progressive damage on high resolution computed tomography despite 
stable lung function in cystic fibrosis. Eur Respir J 23(1):93-7. 
 
Reprinted with permission of the European Respiratory Society 
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Introduction 
 
Several reports have shown that only between one-third and one-half of the number 
of alveoli in the human lung are present at birth 1–3. This number increases rapidly 
after birth by a process of septation of the primary saccules and reaches adult values 
between 1.5–2 yrs of age, and is certainly finished by 8 yrs 1–3. After this process is 
completed, the number of alveoli remains constant and the lung continues to grow by 
increasing the dimensions of all of the lung structures. The small conducting airways 
that are completely surrounded by alveoli increase their dimensions in a similar 
fashion, resulting in a substantial increase in peripheral airway conductance around 2 
yrs because flow increases in proportion to the fourth power of the change in their 
radius 4. Direct measurement of airway conductance suggests a rapid increase in 
peripheral airway conductance at ~5 yrs of age when alveolar addition slows down 
and linear dimensions of the lung begin to increase. Lung distension after the period 
of rapid alveolar addition also increases due to changes in the mechanical properties 
of the chest wall. These changes result in a relative underdistension of the lung at <8 
yrs of age and a relative overdistension thereafter 5, 6.  
 
The present study was designed to determine if quantitative measurements of 
computed tomography (CT) scans could measure normal lung development. 
Furthermore, if CT scans can be used to monitor normal lung growth they may be 
useful in assessing the effect of chronic lung disease on lung growth. 
 
 
Methods 
 
Subjects 
All thoracic CT scans performed at Sophia Children’s Hospital (Rotterdam, the 
Netherlands) between 1998–2001 that were reported as normal by radiologists were 
included in the study. The study was approved by the ethical committee of Sophia 
Children’s Hospital (Rotterdam, the Netherlands). 
 
Computed tomography scans 
The examinations were all performed on a GE Prospeed SX CT scanner (General 
Electric Medical Systems, Milwaukee, WI, USA) and the images were archived in 
DICOM (Digital Imaging and Communications in Medicine) format. The CT scans 
were performed in the supine position at full-suspended inspiration from age 6 yrs 
and during quiet breathing for the younger children. Three subjects had axial CT 
scans with 1-mm thick slices at 10-mm intervals (ages of 11, 12 and 17 yrs). The other 
subjects had spiral CT scans with slice thicknesses ranging 3–10 mm. Field of view 
ranged 25–35 cm, and beam current and potential 130–250 mA and 120–140 kV. The 
images were reconstructed with a standard reconstruction algorithm. 
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Computed tomography analysis 
The CT scans were transferred to the iCAPTURE Centre/McDonald Research 
Laboratory (Vancouver, BC, Canada) and analysed using a method described 
previously 6, 7. Briefly, this program uses the voxel dimensions to calculate lung 
volume and the x-ray attenuation values of the lung to estimate lung density. Lung 
weight, in grams, is calculated by multiplying the lung density by the volume. Lung 
expansion, in millilitres of gas per gram of tissue, is calculated by sub-tracting the 
inverse of the density of tissue (assumed to be 1.065 g*mL-1 ) from the inverse of the 
CT-measured lung density 7, 8. CT-estimated lung weight was compared to previously 
reported post mortem values from children with normal lungs 9. CT-determined gas 
volume was compared to predicted normal values for functional residual capacity 
(FRC) using equations for children of various body lengths. FRC was measured in the 
supine position in children aged 0–6 yrs 10 and in the sitting position in the children 
aged 6 yrs 11. CT-determined gas volume was also compared to published values of 
total lung capacity (TLC) for children with a body length <115 cm 3 and to predicted 
values for children with a body length >115 cm 11. The values for alveolar number at 
each body length, calculated separately for both males and females using data from 
Thurlbeck 3, were compared to the CT-determined lung expansion in mL gas*g-1 
tissue at the same body length. 
 
Statistics 
Spearman’s correlation was used to compare CT-measured lung weight to predicted 
lung weight and CT-measured gas volume to predicted FRC and TLC. 
 
 
Results 
 
The CT scans from 17 male and 18 female children, ranging in age from 15 days–17.6 
yrs were examined in this study. Twenty-three had primary tumours outside the lung 
(lymphoma (n=9), Wilms tumour (n=3), osteosarcoma (n=4), rabdomyosarcoma 
(n=3), hepatoblastoma (n=2), Ewing sarcoma (n=1), melanoma (n=1)), where the 
scans were performed to rule out lung metastasis. The remaining scans were 
performed for suspected malignancies (n=2), dysphagia (n=1), haemoptysis (n=2), to 
assess lung damage following infections (n=3) and for a variety of other reasons 
(n=4). Sex, age, height, weight of the subjects and the CT estimates of gas volume, 
weight, mean volume of gas*g-1 tissue and predicted alveolar numbers of the subjects’ 
lungs are shown in Table 1.  
 
The CT-measured lung weight compares favourably to published post mortem values 
for children with a body length of ≤140 cm, which corresponds to 12 yrs of age 9; 
both are shown as a function of body length in Figure 1. There was a positive 
correlation (Spearman’s correlation coeficient=0.91, p<0.0001) between the CT-
measured lung weight and published post mortem values. CT-measured gas volume 
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compared favourably to predicted values for FRC, especially for children <10 yrs 
(body length of 135 cm). The gas volume of the older children tended to be above 
FRC during the scanning procedure (Figure 2). The Spearman’s correlation 
coefficient for the relationship between CT-measured gas volume and predicted 
values for FRC over the total age range was 0.90 (p<0.0001). A comparison of 
published values for the total number of alveoli to the mean values of lung 
expansion*g-1 lung at the same body length, for both males and females, is shown in 
Figure 3. These data show an initial decrease of the lung volume*g-1 tissue between 
birth and the first year (body lengths <85cm), followed by a plateau and then a 
progressive increase. The gas volumes of the two youngest cases (both female) were 
47 and 59% of TLC, respectively. 
 
Table 1 Patient characteristics 
 Subjects n Min Max Mean±SD 
Patient characteristics:     
Age (years) 35 0.04 17.6 8.9±5.7 
Height (cm) 35 54 179 132.7±37.5 
Weight (kg) 35 2.7 91.5 35.2±22.7 
CT estimates:     
Gas volume (mL) 35 86 5061 1489±1289 
Lung expansion (mL*gram-1) 35 0.79 5.07 2.65±1.23 
Lung weight (g) 35 45 1001 452±272 
Alveolar number male (*106)# 17 112.15 491.29 419.19±86.22 
Alveolar number female (*106)# 18 93.49 428.55 364.83±76.20 
Min.: minimum; Max.: maximum; CT: computed tomography. n=35, 17 males and 18 females.  
# : alveolar numbers shown are predicted post mortem data from ref 3. 
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Figure 1 Computed tomography estimated normal lung weight (●, ----) compared 
with published post mortem normal lung weight (○, ––). 
 
 
Figure 2 Computed tomography estimated gas volume of the lung (●) compared 
with predicted functional residual volume (––) and predicted total lung capacity (----). 
 
 
MONITORING OF LUNG GROWTH USING COMPUTED TOMOGRAPHY  
 
 
  
 
114
 
 
Figure 3 Computed tomography estimated lung expansion (●) and published post 
mortem alveolar numbers (○). R2=0.43, p=0.01. 
 
 
 
Discussion 
 
Previous studies have shown that quantitative measurements of CT scans can 
quantify the changes in lung tissue associated with chronic lung disease. The present 
study shows that the CT scan can be used to estimate the lung weight and gas volume 
in children with normal lungs.  
 
The CT measurements of total lung weight, volume and expansion reported here 
compare favourably to published values of post mortem lung weight 9 and predicted gas 
volume at FRC in children. Previous anatomical studies have shown that the number 
of alveoli increase rapidly following birth. As the added alveoli are a uniform size the 
current authors postulated that the divisions of existing airspace into smaller units 
would cause the gas volume*g-1 of tissue to fall. This hypothesis is supported by the 
data showing a decline in gas volume*g-1 tissue from birth to 2 yrs of age. This 
decrease in lung expansion between birth and 2 yrs of age is consistent with the rapid 
addition of alveolar tissue by septation of growing alveoli and larger structures 
(possibly primary saccules) to form mature respiratory bronchioles, alveolar ducts and 
sacs 3. In the current study, since there is only data on two very young patients, the 
 
MONITORING OF LUNG GROWTH USING COMPUTED TOMOGRAPHY  
 
 
  
 
115
 
initial decline could be due to other reasons such as relatively large airspaces in these 
subjects or chance. However, since there is no pathological verification of the lung 
structure and since the data is consistent with published results, the current authors 
think that this initial decline in lung expansion is due to the septation process. The 
subsequent increase in gas volume*g-1 of tissue from age 2–8 yrs probably results 
from a combination of increased alveolar size and increased outward recoil of the 
chest wall, which leads to an increased FRC 5, 6. While it has been shown that young 
males have more alveoli than young females (Figure 3) 3, the increase in alveolar 
number with age follows the same trend in both sexes and, therefore, it is unlikely 
that sex differences are responsible for the initial decline in lung expansion.  
 
In this study, the CT measurements of lung weight for the subjects were compared to 
predicted values derived from the autopsy studies of Coppoletta and Wolbach 9. 
These investigators measured the weight of the vital organs of children between birth 
and 12 yrs of age in relation to body length using >1,000 autopsy records. 
Comparison of the CT measurements of lung weight for the present subjects to the 
values predicted for their body length show excellent agreement, indicating that lung 
weight can be accurately measured using a CT scan performed during the growth 
period. Although it can be argued that it is hard to compare the results of data on 
children obtained in the 1930s with children of today, these are the only values that 
are available for analysis.  
 
The results presented here also show that CT scans performed on children ≤10 yrs 
are obtained at gas volumes that are close to FRC. Older children appear to have 
inflation levels somewhere between FRC and TLC, indicating that their CT scans 
were performed after a breath of variable size. The fact that the CT scans were 
consistently performed close to FRC ≤10 yrs indicates that the observed decline in 
lung expansion between birth and 2 yrs of age can be attributed to an addition of new 
alveoli. After the period of rapid alveolar addition is complete the gradual expansion 
in gas volume*g–1 lung is consistent with expansion in the size of alveoli in 
combination with a gradual increase in FRC due to changes in the mechanical 
properties of the lung and chest wall 5, 6.  
 
This study has some limitations. As mentioned above, the authors do not have any 
direct pathological validation of the measurements in these subjects. They have, 
therefore, had to rely on published data to compare results. However, the current 
data did correlate well with the other previously published data and the authors 
propose that while this may weaken the study it does not invalidate it. The 
measurement of lung expansion from CT is critically dependent on the lung volume 
at which the scan is performed. Therefore, in this study, lung volume was measured 
on the scans and this volume was related to the predicted values for FRC. The 
technique used to make the prediction equations is different for the children aged <6 
yrs 10 compared to the older children 11. Bar-Yishay et al. 10 measured FRC in the 
supine position, Zapletal et al. 11 measured FRC in the sitting position. This results in 
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higher values for FRC in the older children. In addition, the CT scanning technique 
was different for the children aged <6 yrs compared to the older children and the big 
breath method in the older children results in higher long volumes during the 
scanning procedure compared to the quiet breathing of the younger children. The 
exact effect of these errors are not known, however, the observed decline in lung 
expansion before the 2 yrs cannot be contributed to these errors since the scanning 
technique and FRC prediction is similar for children aged <6 yrs.  
 
In conclusion, it has been shown that quantitative measurements of normal lung 
development can be made using computed tomography scans. The authors propose 
that the computed tomography scan can be used as a relatively non-invasive tool to 
provide valuable information about normal lung growth and the pathogenesis of lung 
disease.  
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6.2 Estimation of lung dimensions throughout the 
growth period using computed tomography 
 
 
 
 
 
 
 
 
 
We aimed to use computed tomography (CT) to estimate airway wall and lumen, 
arterial and parenchyma dimensions in children throughout the growth period and 
to provide normative data to study alterations caused by pulmonary disease. Clinical 
CT scans reported as normal that were performed in children for non-pulmonary 
and non-cardiac reasons were analyzed for lung weight; gas volume; lung expansion; 
lung surface to volume ratio; airway wall area; airway lumen area; airway lumen 
perimeter; arterial area and airway surface to volume ratio. Ages of the 85 subjects 
ranged from 0 to 17.6 years. The data show only little increase in lung expansion 
throughout childhood. There was substantial variability in lung expansion between 
subjects (R2 = 0.51 and 0.45 for males and females, respectively). Airway wall and 
lumen and arterial area were exponentially associated with subjects’ height. Airway 
surface to volume ratio (cm-1) was linearly associated to lung surface to volume ratio 
(cm-1, R2=0.46-0.66, p<0.001). Our data provide normative CT estimates of airway 
wall and lumen, arterial and parenchyma dimensions throughout the growth period 
that may be useful to study alterations in disease. 
 
 
 
 
 
 
 
 
 
 
Based on: 
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Introduction 
 
Between one-third and one-half of the adult number of alveoli are present in the 
human lung at birth 1. This number increases rapidly by a process of septation of the 
primary saccules and probably reaches adult values between 1.5–2 years of age and 
certainly by 8 years 1-5. After the phase of rapid alveolar addition is completed, the 
number of alveoli remains constant and the lung continues to grow by increasing the 
dimensions of all of the lung structures 1, 4, 5. In contrast to alveoli, the number of 
conducting airways and pulmonary arteries is complete at birth and they increase only 
in size during postnatal growth 6, 7. Whether airway sizes and airway growth patterns 
differ between sexes in infancy 8-17 or later in childhood 18-25 remains controversial.  
 
Alterations in the growth of lung structures occurs secondary to a wide variety of 
congenital 26 and developmental insults 27-29 yet little normative data exists regarding 
how lung structure changes with age or height. Therefore, a better understanding of 
lung growth in health and disease in needed. Computed tomography (CT) scanning 
has made it possible to study lung structure in vivo 21, 30-34 and provides a useful tool 
for evaluation of both lung disease 28, 29, 35, 36 and normal lung parenchyma (lung 
weight, gas volume and expansion) 37. 
 
Previously we estimated lung parenchyma dimensions in a cohort of children ranging 
from birth through adolescence 37. In the present study we estimated airway wall and 
lumen dimensions of the conducting airways and dimensions of the accompanying 
pulmonary artery in addition to the lung parenchyma in a different cohort of children 
and compare our findings to the previous study. The aim of this study was to use CT 
to estimate airway wall and lumen, arterial and parenchyma dimensions in children 
throughout the growth period and to provide normative data to study alterations 
caused by pulmonary disease. 
 
 
Methods  
Subjects 
Only CT scans initially reported as normal with confirmation of this opinion by a 
second radiologist were included in the study. The questions of the CT scan, the 
clinical diagnoses or the findings were the following: Pulmonary haemorrhage 
(minimal bleeding, n=2); cystic fibrosis (n=6, all stable <1 yrs of age); 
cystadenomatous malformation of the lung (n=1); tumours with no metastasis 
including brain tumour not specified (n=1), lymphoma (n=9), Ewing sarcoma (n=1), 
ovarian teratoma (n=1), unknown (n=3), wilms tumour (n=5), hepatoblastoma 
(n=4), rhabdomyosarcoma (n=4), neuroblastoma (n=2), osteochondrosarcoma 
(n=4), testis tumour (n=1) and melanoma (n=1); vascular ring excluded (n=3); 
haemangioma (n=1); foreign body excluded (n=2); sternal cleft (n=1); 
 
MONITORING OF LUNG GROWTH USING COMPUTED TOMOGRAPHY  
 
 
  
 
119
 
laryngotracheomalacia (mild, n=1); aspiration or reflux (n=4); respiratory distress 
(n=2); meckel diverticulum (n=1); langerhans cell histiocytosis (n=1); mitochondrial 
disease (n=2); follow-up small cyst (n=1); recurrent infections (n=4); seroma (n=1); 
recovered pneumothorax (n=3); solitary nodule follow up (n=3); chest wall mass 
(n=2); recurrent sinusitis (n=2); haemoptysis (n=2); lupus like syndrome (n=1); chest 
pain (n=1); uveitis (n=1); and dysphagia (n=1).  
 
We included 35 subjects from Rotterdam and 50 subjects from Columbus. All 35 of 
the CT scans performed at Erasmus MC-Sophia (Rotterdam, The Netherlands) were 
included in a previous report 37. Nineteen of the 50 CT scans obtained at Columbus 
Children’s Hospital (Columbus, Ohio, USA) have been previously reported 28. In that 
report airway wall and lumen and arterial dimensions were measured using a different 
measurement program and in that study the normal dimensions were compared with 
cystic fibrosis patients. The ethical review boards of Erasmus MC-Sophia and 
Columbus Children’s Hospital approved the study.  
 
Computed tomography scans 
The CT examinations performed in Columbus were obtained on a GE lightspeed 
Ultra 8-slice CT scanner (General Electric Healthcare, Milwaukee, WI) using a 
potential of 120 kV and a beam current ranging from 30 to 120 mAs. Volumetric 
inspiratory scanning was performed from lung apex to base after a breath-hold 
instruction in the children from 5 years and on. A previously described method of 
volume controlled CT was used in children younger than five years of age 38-40. 
Briefly, the infants were sedated and an apnoea was briefly induced to allow lungs to 
be inflated to an airway pressure of 25-cm H2O using a facemask during the CT 
scanning. The 19 infants previously reported were scanned on the same scanner using 
the same scanning technique but only at 4 selected levels 28. Those 19 CT scans could 
therefore only be used to estimate airway wall and lumen and arterial dimensions and 
not to estimate lung parenchyma. The other 31 CT scans from Columbus could be 
used to measure airway wall and lumen, arterial and parenchyma dimensions. All 
scans were reconstructed using both a high-resolution (“Bone”) and an intermediate 
(“Standard”) reconstruction algorithm at 1.25-mm slice thickness. No contrast was 
used for the CT scanning. 
 
The scanning protocol of the Rotterdam subjects has previously been described 37. 
Volumetric CT scans (3-10 mm collimation) were performed after a breath-hold 
instruction or while quiet breathing on a GE single slice scanner and reconstructed 
using an intermediate (“Standard”) algorithm. Because of the thick slices only lung 
parenchyma and not airway and arterial dimensions could be estimated and therefore 
no additional measurements were done on those CT scans. Only the data were re-
analysed as described later. The reason to show these 35 subjects again is to 
demonstrate the differences of parenchyma dimensions between Rotterdam and 
Columbus subjects and to explain these differences 37. 
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Computed tomography parenchyma analyses 
The CT scans were transferred to the James Hogg iCAPTURE Centre for 
Cardiovascular and Pulmonary Research (Vancouver, BC, Canada). The lung 
parenchyma was analysed using the “Standard” reconstruction algorithm as 
previously described 33, 34. Briefly, the lung was segmented from the chest wall and 
surrounding structures. The gas volume is calculated by summing the voxels within 
the lung and density is calculated from the x-ray attenuation values. Lung weight, in 
grams, is calculated by multiplying the lung density by volume. Lung expansion, in 
millilitres of gas per gram of tissue, is calculated by subtracting the inverse of the 
density of tissue (assumed to be 1.065 g*mL-1) from the inverse of the CT-measured 
lung density 33, 34. Lung surface area to volume ratio (S/V) is calculated using the lung 
expansion values at TLC as previously described; S/V lung = e 6.84-(0.32*lung expansion at 
TLC) Ref 34. 
 
CT-estimated lung weight was compared to previously reported post mortem values 
from children with normal lungs 41. The CT-determined gas volume was compared to 
predicted normal values for functional residual capacity (FRC) and total lung capacity 
(TLC) using standard prediction equations based on body length 1, 4, 42-44. CT-
estimated lung expansion was compared between Columbus and Rotterdam subjects 
and between males and females. To overcome the problem of different inflation 
levels between subjects during the CT procedure, lung expansion at full lung inflation 
was calculated by dividing the predicted TLC by the CT-estimated lung weight 
(hereafter: lung expansion at TLC).  
 
Computed tomography airway and artery analysis 
Airway wall and lumen and arterial dimensions were estimated using the 50 
Columbus subjects at specified locations of the bronchial tree (Figure 1) as previously 
described 31, 32. If in the 19 Columbus subjects with 4 slices a given airway branch 
could not be found this branch was excluded. The measurement locations were: 
trachea (T), right bronchus intermedius (RBI), right apical bronchus (RAB) and the 
first, second and third branch after the right apical bronchus (RAB1, RAB2 and 
RAB3 respectively). Airway lumen area (LA) and perimeter (Pi) and airway wall area 
(WA) were measured from T through RAB2, since RAB3 was too small to be 
measured. Arterial area (AA) was measured from RAB through RAB3, since T and 
RBI do not have a measurable pulmonary artery. A seed point is manually placed in 
the lumen of the airway or artery and 64 rays are cast from this point into the 
parenchyma. The borders of inner and outer airway wall or outer arterial wall are 
determined using the full-width at half maximum principle 45. Rays that are too long 
or too short are manually edited and the dimensions calculated by connecting the 
ends of the rays using a spline function. Lumen area (LA) is defined as the area 
internal to the inner wall in airways and the internal perimeter (Pi) is the length of the 
inner boundary of the rays. Airway wall area (WA) is the area between the inner and 
outer boundaries. Arterial area (AA) is the area internal to the outer wall of the artery. 
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Trachea lumen area was compared to previously published values of CT estimated 
trachea lumen area 46, 47. Airway lumen perimeter was divided by airway lumen area to 
estimate airway surface to volume ratio (airway S/V-ration = Pi/LA). The airway 
surface to volume ratio was compared to the lung surface to volume ratio. 
 
Figure 1 sites at the bronchial tree of airway-artery measurements 
 
Figure shows a bronchogram that clearly demonstrates the divisions of the airway tree where the 
measurements were performed on CT for the present study. 
A: trachea (T):     lumen area and wall area 
B: right bronchus intermedius (RBI): lumen and wall area 
C: right apical bronchus (RAB):   lumen and wall area and arterial area 
D: first branch after RAB:   lumen and wall area and arterial area 
E: second branch after RAB:   lumen and wall area and arterial area 
F: third branch after RAB:   arterial area 
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Statistical analysis 
Parenchyma dimensions were estimated in 66 subjects (35 Rotterdam, 31 Columbus. 
Airway wall and lumen and arterial dimensions were estimated in 50 subjects (all 
Columbus). Comparison between airway and arterial dimensions and parenchyma 
dimensions was possible in 31 subjects (all Columbus). Those data were analysed 
using a software package (SPSS version 10.0; SPSS, Chicago, Ill). Significance level 
was set as p<0.05. For all variables mean ± SD (range) were calculated. Exponential, 
power, linear and logistic curve fitting with 95% confidence intervals was performed 
to correlate airway wall and lumen area, arterial area, lung weight, lung expansion at 
TLC with subject height. The best fitting curve is reported. Spearman correlation was 
used to determine the relationships between LA of the trachea and the other 
measured airways, between the AA of the right apical bronchus and the other 
measured arteries and between the lung S/V-ratio and the airway S/V ratio (Pi/LA). 
 
 
Results 
 
Study population 
Table 1 shows the subjects’ age, sex and height and results from CT parenchyma 
analysis. The calculated mean (SD) lung expansion at TLC was 6.53 (1.37) (female) 
and 6.18 (1.94) (male) ml gas/g tissue.  
 
Parenchyma  
Lung weight (CT measured and predicted published values) was compared to 
subjects’ height (Figure 2) and the regression equation for the line of best fit is shown 
in Table 2. CT measured gas volume was compared to predicted TLC and predicted 
FRC in Figure 3. CT measured lung expansion is shown in Figure 4a for Rotterdam 
and Columbus subjects and lung expansion at TLC is shown in Figure 4b for males 
and females. The corresponding regression equations of lung expansion at TLC for 
males and females are shown in Table 2.  
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Figure 2 CT measured lung weight and predicted lung weight (line) against subjects’ 
height 
 
Closed diamonds represent Rotterdam data and open squares represent Columbus data. Solid line 
represents predicted lung weight from published data on autopsy specimens 41. CT measured lung 
weight = 29.167 * EXP subject height * 0.0192 (R2=0.94, p<0.0001). 
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Table 1 Patient characteristics and CT estimates given per age 
Age 
(yrs) 
N 
(male) 
Subject height 
(cm) 
CT weight 
(g) 
CT gas 
volume (ml) 
Predicted TLC 
(ml) 
Pred TLC / 
CT weight 
(ml/g) 
  mean SD mean SD Mean SD mean SD mean SD
0 17 (11) 65.1 9.8 99 27 225 128 423 173 4.4 1.4
1 12 (9) 79.4 3.9 146 26 472 241 729 106 5.3 1.1
2 6 (3) 88.7 3.4 200 47 674 414 998 108 5.2 1.8
3 5 (4) 101.6 1.8 213 18 565 244 1345 47 6.2 0.3
4 2 (2) 114.5 0.7 277 0 433 0 1837 184 6.2 0.0
5 4 (3) 116.0 7.7 258 23 445 36 1825 485 7.5 2.7
6 2 (1) 123.0 5.7 329 55 758 52 2292 349 7.0 0.1
7 2 (1) 120.5 6.4 335 141 1125 875 2170 378 6.9 1.8
8 1 (1) 133.0 0.0 324 0 680 0 2842 0 8.8 0.0
9 2 (2) 132.5 2.1 319 66 1060 942 2832 117 9.1 2.3
10 1 (0) 144.0 0.0 449 0 1818 0 3320 0 7.4 0.0
11 2 (0) 146.5 10.6 548 23 2750 768 3489 648 6.4 1.4
12 7 (4) 153.0 6.8 619 82 2490 715 4010 399 6.6 0.9
13 4 (0) 160.3 2.6 616 141 1887 672 4373 188 7.4 1.7
14 6 (2) 168.3 12.5 727 159 2557 489 5114 1057 7.2 1.7
15 5 (2) 171.8 3.9 795 147 3247 1611 5352 376 6.8 0.8
16 3 (0) 165.0 10.6 740 228 3489 1382 4731 804 6.6 0.9
17 4 (2) 166.5 5.9 711 163 2649 875 4976 594 7.2 1.1
N is number. SD is standard deviation. CT weight, CT gas volume and predicted total lung capacity 
divided by CT weight were obtained in 66 out of 85 subjects. 
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Figure 3 CT measured gas volume and predicted TLC and FRC against subjects’ 
height  
 
Closed diamonds represent Rotterdam data and open squares represent Columbus data. 
Dashed line represents predicted total lung capacity (TLC) and solid line represents predicted 
functional residual capacity (FRC). Subjects’ height for approximately 2 years and 8 years of age is 
given. 
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Figure 4 A. CT measured lung expansion for Rotterdam and Columbus subjects 
against subjects’ height. B. Lung expansion at total lung capacity (Predicted TLC 
(ml)/ CT measured lung weight (g)) for males and females against subjects’ height 
 
A: Closed diamonds represent Rotterdam data, open squares represent Columbus data. Dashed line 
represents best fit through Columbus data and solid line represents best fit through Rotterdam data. 
Subjects’ height for approximately 2 years and 8 years of age is given. Note the marked differences in 
lung expansion between Rotterdam and Columbus infants caused by differences in lung inflation 
during the CT scanning procedure. B: Closed triangles represent females and open circles represent 
males. Lines represent 95% confidence interval through data for males and females together. Data 
were grouped for males and females due to small sample size.  
 
Figure 5 The relationship between airway lumen area (cm2) and subject height (cm) 
 
A. The left panel shows data for trachea and right bronchus intermedius. Solid squared represent 
trachea, open diamonds represent right bronchus intermedius. B. The right panel shows data for 
right apical bronchus (RAB), first branch after RAB (RAB1) and second branch after RAB (RAB2). 
Solid circles represent RAB, open squares represent RAB1, closed triangles represent RAB2. 
Regression lines are provided for each generation and corresponding equations are given in Table 2. 
95% confidence intervals are not shown. Data were grouped for males and females due to small 
sample size. 
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Table 2 Regression equations for CT estimated lung structures versus subject height 
Y Number Sex A B Correlation 
(R2) 
P-
value 
Lung weight (g) 66 Both 29.167 0.0192 0.94 <0.001
Lung expansion (ml/g) 31 Female 0.652 0.466 0.45 <0.001
Lung expansion (ml/g) 35 Male 0.2374 0.6867 0.51 <0.001
Lumen area (cm2)       
Trachea 48 Both 0.0003 1.6426 0.90 <0.001
Right bronchus intermedius 34 Both 0.0003 1.4572 0.85 <0.001
Right apical bronchus (rab) 29 Both 2*10-6 2.0165 0.80 <0.001
First branch after rab 29 Both 3*10-6 1.6847 0.75 <0.001
Second branch after rab 25 Both 5*10-7 1.9444 0.77 <0.001
Wall area (cm2)       
Trachea 48 Both 0.0016 1.2724 0.87 <0.001
Right bronchus intermedius 34 Both 0.0024 1.1099 0.86 <0.001
Right apical bronchus  29 Both 0.0004 1.3027 0.80 <0.001
First branch after rab 29 Both 0.0005 1.1278 0.83 <0.001
Second branch after rab 25 Both 5*10-5 1.4132 0.85 <0.001
Arterial area (cm2)       
Right apical bronchus  31 Both 0.0004 1.2099 0.76 <0.001
First branch after rab 30 Both 5,6*10-5 1.5279 0.73 <0.001
Second branch after rab 46 Both 1,9*10-5 1.6145 0.77 <0.001
Third branch after rab 47 Both 4,5*10-6 1.7790 0.86 <0.001
Equations Y=A*XB, except lung weight (Y=A*EXPXB). All equations X=subject height (cm). Lung 
expansion is predicted total lung capacity (TLC) divided by CT measured lung weight, expressed as 
ml gas/g tissue 
 
Airways and arteries 
The LATrachea of our subjects was compared to published normal values (data not 
shown) 46, 47. There is a strong correlation between the trachea (LATrachea) and all the 
other measured airways (R2: LARBI=0.93, LARAB=0.82, LARAB1=0.87 and LARAB2 
=0.91, all p<0.0001). There is also a strong correlation between the arterial dimension 
of the right apical bronchus (AARAB) and all the other measured arteries (R2: AARAB1 
=0.85, AARAB2=0.87 and AARAB3=0.87 all p<0.0001). The relationship between LA 
and subject height for the various generations is shown in Figure 5 (95% confidence 
intervals are not shown). Equations for airway wall and lumen and artery area versus 
subjects’ height are listed in Table 2. 
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Airway versus parenchyma  
The relationship between surface to volume ratio of the lung and surface to volume 
ratio of the various airways is shown in Figure 6. The correlation between surface to 
volume of the lung and surface to volume of the trachea, RBI, RAB, RAB1 and 
RAB2 was 0.62, 0.51, 0.59, 0.42 and 0.44 respectively (all p<0.0001).  
 
Figure 6 Lung surface area to lung volume ratio against airway lumen perimeter to 
airway lumen area for the Columbus subjects 
 
A. The left panel shows data for trachea and right bronchus intermedius. Open diamonds represent 
trachea, solid squares represent right bronchus intermedius. B. The right panel shows data for right 
apical bronchus (RAB), open squares represent first branch after RAB (RAB1), closed circles 
represent second branch after RAB (RAB2). Solid triangles represent RAB, open squares represent 
RAB1, closed circles represent RAB2. Linear regression lines are provided for each generation. The 
linear dimensions of the lung (cm-1) are linearly related to the linear dimensions of the airway (cm-1). 
 
 
Discussion 
 
This study uses CT scans to estimate airway wall and lumen, arterial and parenchyma 
dimensions (lung weight, gas volume, lung expansion, surface to volume ratio) in 
children throughout the growth period. These data show that when lung expansion is 
corrected for predicted TLC, there is only a small gradual change in lung expansion at 
TLC. This suggests that even during the first two years of life when the septation 
process results in rapid alveolar addition, lung weight does not increase as rapidly as 
the gas volume. Using pathologic specimens, Thurlbeck found an increase in lung 
expansion from 3 millilitre of gas per gram tissue (ml/g) at birth to about 8 ml/g at 
age six 3. These values correspond well to our values of approximately 4 ml/g at birth 
and 6 ml/g in adolescence obtained using CT. These findings are markedly different 
from our previous report where we found a decrease in lung expansion during the 
first two years of life, while in the present study lung expansion slightly increased 
during this period 37. This difference can be explained by the difference in lung 
inflation techniques between Columbus and Rotterdam, which produced very 
different pulmonary gas volumes between Rotterdam and Columbus (Figure 3). 
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Therefore, expressing the lung expansion at TLC by dividing measured or predicted 
TLC by CT estimated lung weight may be a more appropriate method to present the 
data (Figure 4). 
  
There was substantial variability in expansion at TLC during the growth period. Part 
of this variation could be caused by differences in scanning technique (slice 
thickness). Most of the variation however is likely to represent variation between 
individuals which might limit its usefulness to study small alterations in lung 
expansion at TLC in disease. 
 
The tracheal lumen area compared favourably to previous CT estimates from 
Griscom et al 46, 47 and to post mortem studies, bronchographic studies and other CT 
studies 48. In the present study we were also able to measure airways smaller than the 
trachea down to the limit that current CT scanners allow (approximately lumen 
diameter of 1 mm). We could not demonstrate differences in airway sizes between 
males and females, which contrast with functional studies in children and adults 8, 9, 11, 
19, 20, 23, 43. This suggests that the changes in function might be due to differences in 
smaller airways that cannot be measured by CT or to type II errors in our study due 
to the small sample size. In addition based on our data one can not determine if the 
conducting airways are relatively larger or smaller in infancy. Potentially (preferably 
longitudinal) CT studies can solve these controversial issues.  
 
We found less variation in the airway wall and lumen and arterial estimates compared 
to lung expansion at TLC. For the variation in airway and arterial measurements at a 
given subject height that we found, there are several possible explanations. The 
measurement program is one source of some of this variation 32, 49 and differences in 
lung inflation between subjects are another 50. But some of the variation likely 
represents the real variability between subjects. We speculate that this could have 
implications for the subsequent development of airway disease or respiratory 
symptoms in subjects with relatively narrow airways 24, 30, however this requires 
further study. 
 
The surface to volume ratio of alveoli was linearly related to the surface to volume 
ratio of the airways suggesting that the growth of the airway and the alveolus is 
closely linked, but longitudinal studies of the same individuals would be required to 
establish this point. Such studies could address if airways grow isotropic or 
dysanaptic. However, the radiation exposure from current CT protocols currently 
limits this approach to subjects that require CT scans of the thorax for other reasons.  
 
The major limitation of this study is that for the safety reasons mentioned above it 
only provides cross sectional information about lung growth. The second limitation is 
that we have neither pathologic validation of the measurements in these subjects, nor 
access to pulmonary function. The third limitation is that the number of subjects 
studied, which made it difficult to analyse differences between males and females. 
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Finally as we only measured airways in the right upper lobe we must assume that the 
growth patterns are the same in other lobes.  
 
In conclusion, these data show that lung expansion is more stable than previously 
reported because lung volume, corrected to TLC, and lung weight increases in such a 
way that overall lung expansion increases surprisingly little between birth and 17 years 
of age. Also in the period of rapid alveolar addition there is only a slightly increase in 
lung expansion at TLC. This suggests that the increase in gas volume associated with 
alveolar addition requires a very limited increase in lung tissue. We did not find 
evidence that CT measured airways are larger in infants or in male subjects, which 
may be related to sample size. Nevertheless, our data provides useful normative 
estimates of airway, artery and maybe parenchyma growth, which may be applicable 
to study alterations in children with pulmonary diseases. 
 
 
References 
 
1.  Thurlbeck WM. Postnatal human lung growth. Thorax 1982; 37(8): 564-71. 
2.  Dunnill M. Postnatal growth of the lung. Thorax 1962; 17: 329-333. 
3.  Thurlbeck WM. Postnatal growth and development of the lung. Am Rev Respir Dis 1975; 111(6): 
803-44. 
4.  Zeltner TB, Burri PH. The postnatal development and growth of the human lung. II. 
Morphology. Respir Physiol 1987; 67(3): 269-82. 
5.  Hislop A, Wigglesworth J, Desai R. Alveolar develoment in the human fetus and infant. Early 
Hum Dev 1986; 13(1): 1-11. 
6.  Reid L. 1976 Edward B.D. Neuhauser lecture: the lung growth and remodeling in health and 
disease. AJR Am J Roentgenol 1977; 129(5): 777-788. 
7.  Hislop AA. Airway and blood vessel interaction during lung development. J Anat 2002; 201(4): 
325-34. 
8.  Jones M, Castile R, Davis S, et al. Forced expiratory flows and volumes in infants. Normative 
data and lung growth. Am J Respir Crit Care Med 2000; 161(2 Pt 1): 353-9. 
9.  Lambert RK, Castile RG, Tepper RS. Model of forced expiratory flows and airway geometry in 
infants. J Appl Physiol 2004; 96(2): 688-92. 
10.  Stocks J. The functional growth and development of the lung during the first year of life. Early 
Hum Dev 1977; 1(3): 285-309. 
11.  Tepper RS, Morgan WJ, Cota K, Wright A, Taussig LM. Physiologic growth and development of 
the lung during the first year of life. Am Rev Respir Dis 1986; 134(3): 513-9. 
12.  Hislop A, Muir DC, Jacobsen M, Simon G, Reid L. Postnatal growth and function of the pre-
acinar airways. Thorax 1972; 27(3): 265-74. 
13.  Horsfield K, Gordon WI, Kemp W, Phillips S. Growth of the bronchial tree in man. Thorax 
1987; 42(5): 383-8. 
14.  Cudmore R, Emery J, Mithal A. Postnatal growth of the bronchi and bronchioles. Arch Dis Child 
1962; Oct(37): 481-484. 
15.  Davies G, Reid L. Growth of the alveoli and pulmonary arteries in childhood. Thorax 1970; 
25(6): 669-81. 
16.  Hogg JC, Williams J, Richardson JB, Macklem PT, Thurlbeck WM. Age as a factor in the 
distribution of lower-airway conductance and in the pathologic anatomy of obstructive lung 
disease. N Engl J Med 1970; 282(23): 1283-7. 
 
MONITORING OF LUNG GROWTH USING COMPUTED TOMOGRAPHY  
 
 
  
 
131
 
17.  Mansell AL, Bryan AC, Levison H. Relationship of lung recoil to lung volume and maximum 
expiratory flow in normal children. J Appl Physiol 1977; 42(6): 817-23. 
18.  Hibbert M, Lannigan A, Raven J, Landau L, Phelan P. Gender differences in lung growth. Pediatr 
Pulmonol 1995; 19(2): 129-34. 
19.  Green M, Mead J, Turner JM. Variability of maximum expiratory flow-volume curves. J Appl 
Physiol 1974; 37(1): 67-74. 
20.  Martin TR, Castile RG, Fredberg JJ, Wohl ME, Mead J. Airway size is related to sex but not lung 
size in normal adults. J Appl Physiol 1987; 63(5): 2042-7. 
21.  Pagtakhan RD, Bjelland JC, Landau LI, et al. Sex differences in growth patterns of the airways 
and lung parenchyma in children. J Appl Physiol 1984; 56(5): 1204-10. 
22.  Martin TR, Feldman HA, Fredberg JJ, Castile RG, Mead J, Wohl ME. Relationship between 
maximal expiratory flows and lung volumes in growing humans. J Appl Physiol 1988; 65(2): 822-8. 
23.  Briscoe W, Dubois A. The relationship between airway resistance, airway conductance and lung 
volume in subjects of different age and body size. J Clin Invest 1958; 37: 1279-1285. 
24.  Merkus PJ, Borsboom GJ, Van Pelt W, et al. Growth of airways and air spaces in teenagers is 
related to sex but not to symptoms. J Appl Physiol 1993; 75(5): 2045-53. 
25.  Merkus PJ, ten Have-Opbroek AA, Quanjer PH. Human lung growth: a review. Pediatr Pulmonol 
1996; 21(6): 383-97. 
26.  Ijsselstijn H, Tibboel D, Hop WJ, Molenaar JC, de Jongste JC. Long-term pulmonary sequelae in 
children with congenital diaphragmatic hernia. Am J Respir Crit Care Med 1997; 155(1): 174-80. 
27.  Tiddens H, Silverman M, Bush A. The role of inflammation in airway disease: remodeling. Am J 
Respir Crit Care Med 2000; 162(2 Pt 2): S7-S10. 
28.  Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children 
with cystic fibrosis. J Pediatr 2004; 144(2): 154-61. 
29.  de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed 
tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004; 23(1): 93-7. 
30.  Hislop AA. Lung growth and computed tomography. Eur Respir J 2003; 22(2): 195-6. 
31.  Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions 
and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 
162(3 Pt 1): 1102-8. 
32.  Nakano Y, Whittall KP, Kalloger SE, Coxson HO, Paré PD, English JC. Development and 
Validation of Human Airway Analysis Algorithm Using Multidetector Row CT. Proceedings of 
SPIE 2002; 4683: 460-469. 
33.  Coxson HO, Mayo JR, Behzad H, et al. Measurement of lung expansion with computed 
tomography and comparison with quantitative histology. J Appl Physiol 1995; 79(5): 1525-30. 
34.  Coxson HO, Rogers RM, Whittall KP, et al. A quantification of the lung surface area in 
emphysema using computed tomography. Am J Respir Crit Care Med 1999; 159(3): 851-6. 
35.  de Jong PA, Ottink MD, Robben SG, et al. Pulmonary disease assessment in cystic fibrosis: 
comparison of CT scoring systems and value of bronchial and arterial dimension measurements. 
Radiology 2004; 231(2): 434-9. 
36.  de Jong PA, Nakano Y, Hop WC, et al. Changes in Airway Dimensions on Computed 
Tomography Scans of Children With Cystic Fibrosis. Am J Respir Crit Care Med 2005. 
37.  de Jong PA, Nakano Y, Lequin MH, et al. Estimation of lung growth using computed 
tomography. Eur Respir J 2003; 22(2): 235-8. 
38.  Long FR, Castile RG. Technique and clinical applications of full-inflation and end-exhalation 
controlled-ventilation chest CT in infants and young children. Pediatr Radiol 2001; 31(6): 413-22. 
39.  Long FR. High-resolution CT of the lungs in infants and young children. J Thorac Imaging 2001; 
16(4): 251-8. 
40. Long FR, Castile RG, Brody AS, et al. Lungs in infants and young children: improved thin-
section CT with a noninvasive controlled-ventilation technique--initial experience. Radiology 1999; 
212(2): 588-93. 
 
MONITORING OF LUNG GROWTH USING COMPUTED TOMOGRAPHY  
 
 
  
 
132
 
41.  Coppoletta J, Wolbach S. Body length and organ weights of infants and children. J Path 1933; 9: 
55-70. 
42.  Bar-Yishay E, Shulman DL, Beardsmore CS, Godfrey S. Functional residual capacity in healthy 
preschool children lying supine. Am Rev Respir Dis 1987; 135(4): 954-6. 
43.  Castile R, Filbrun D, Flucke R, Franklin W, McCoy K. Adult-type pulmonary function tests in 
infants without respiratory disease. Pediatr Pulmonol 2000; 30(3): 215-27. 
44.  Zapletal A, Samanek M, Paul T. Lung Function in Children and Adolescents. Methods, 
Reference Values. Basel: Karger, 1987. 
45.  Amirav I, Kramer SS, Grunstein MM, Hoffman EA. Assessment of methacholine-induced 
airway constriction by ultrafast high-resolution computed tomography. J Appl Physiol 1993; 75(5): 
2239-50. 
46.  Griscom NT, Wohl ME. Dimensions of the growing trachea related to body height. Length, 
anteroposterior and transverse diameters, cross-sectional area, and volume in subjects younger 
than 20 years of age. Am Rev Respir Dis 1985; 131(6): 840-4. 
47.  Griscom NT, Wohl ME, Fenton T. Dimensions of the trachea to age 6 years related to height. 
Pediatr Pulmonol 1989; 6(3): 186-90. 
48.  Effmann EL, Fram EK, Vock P, Kirks DR. Tracheal cross-sectional area in children: CT 
determination. Radiology 1983; 149(1): 137-40. 
49.  Nakano Y, Wong JC, de Jong PA, et al. The prediction of small airway dimensions using 
computed tomography. Am J Respir Crit Care Med 2005; 171(2): 142-6. 
50.  Brown R, W. M. Effect of lung inflation and airway muscle tone on airway diameter in vivo. J 
Appl Physiol 1996; 80(5): 1581-1588. 
 
 
   
 
133
 
 
Chapter 7 
 
Summary, general discussion and future directions 
 
 
 
 
 
 
7.1  Summary  
7.2  General discussion 
7.3  Directions for future research 
 
   
 
134
SUMMARY, GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
  
 
135
7.1 Summary 
 
For clinical management of CF related lung disease to be optimally effective, onset 
and progression of lung disease is commonly closely monitored. This can be done 
either indirectly by measuring lung function or more directly by imaging lung 
structure. Pulmonary function tests (PFTs), such as spirometry and body 
plethysmography, are considered the most important tools for measuring lung 
function routinely from the age of 5-6 years onwards. To image lung structure chest 
radiographs are routinely used. In many centers chest radiographs are made at least 
once yearly and often at times of exacerbations.  
 
Longitudinal data have shown that PFTs are more sensitive than chest radiographs to 
monitor the progression of CF lung disease. Studies in the early nineties have shown 
that computed tomography (CT) scans are more sensitive than chest radiographs for 
the early detection of structural lung abnormalities in CF. In addition, CT scoring 
systems correlated moderately to good with PFTs and structural abnormalities on CT 
scans were detected in some CF patients with normal PFTs.  
 
Many CT scoring systems for the quantification of structural lung abnormalities on 
CT scans of CF patients have been developed. Unfortunately, for several of these 
systems the between and within observer reproducibility was not tested or not 
described. As a comparative evaluation is lacking as well, it is hard to determine 
which system can be used best.  
 
Apart from semi-quantitative scoring, CT scans enable quantitative measurements of 
airway wall and lumen dimensions. Quantitative CT analysis techniques have been 
validated for lung diseases such as chronic obstructive pulmonary disease (COPD) 
and asthma but were not used to study CF.  
 
Longitudinal studies in CF comparing changes in CT scores or quantitative CT 
measures with PFTs are still lacking.  
 
Chapter 1 contains a general introduction to the thesis and states the aim of study.  
 
Chapter 2 describes the rationale of our studies given the current practice of 
monitoring CF lung disease and its limitations. Chapter 2 specifically focuses on the 
benefits and limitations of monitoring lung function and lung structure with the use 
of PFTs, chest radiographs and CT scanning. 
 
Chapter 3 describes the validation and use of CT scoring systems for CF.  
Section 3.1 describes a study that compared thin-section CT scores obtained with five 
scoring systems for the assessment of pulmonary disease in children with cystic 
fibrosis. The additional value of bronchial and arterial dimension measurements was 
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determined as well. Scores obtained with five thin-section CT scoring systems were 
compared. A score of 0 indicates the absence of abnormalities; a higher score means 
that more structural abnormalities were seen. Three observers assigned scores and 
then reassigned scores after intervals varying from 1–2 weeks to 1–2 months of thin-
section CT scans obtained in 25 children with CF. Interobserver and intraobserver 
reliability were calculated with intraclass correlation coefficients. Quantitative 
measurements of bronchial and arterial dimensions were obtained. Thin-section CT 
scores were correlated (Spearman correlation) with bronchial and arterial dimensions 
and with results of PFTs, such as forced expiratory volume in 1 second (FEV1). 
Scores with all five scoring systems were reproducible, with intraclass correlation 
coefficients of 0.74 and higher (P < 0.05), and showed significant correlations with 
FEV1 (R = –0.73 to –0.69, P < 0.01). Ratio of bronchial diameter to accompanying 
pulmonary arterial diameter was correlated with thin-section CT scores but not with 
FEV1. Ratio of bronchial wall thickness to accompanying pulmonary arterial diameter 
was not correlated with thin-section CT scores or PFTs results. To conclude, thin-
section CT scores were reproducible and were correlated with PFTs results. 
Measurements of bronchial dimensions were not significantly related to scores or 
PFTs results. 
 
In Chapter 4 we describe studies that compared the sensitivity of CT to standard 
PFTs for monitoring lung disease in children and adults with CF.  
Section 4.1 describes the finding of progressive damage on high resolution CT 
(HRCT) despite stable PFTs in children with CF. The aim of the study was to 
investigate the ability of HRCT scoring systems and PFTs to detect changes in lung 
disease in CF children (n=48) who had two HRCT scans in combination with two 
PFTs 2 yrs apart. Their scans were scored using five scoring systems (Castile, Brody, 
Helbich, Santamaria and Bhalla). "Sensitivity" was defined as the ability to detect 
disease progression. In this group of children; HRCT scores worsened, whereas PFTs 
remained unchanged or improved. Of the HRCT parameters, mucous plugging and 
the severity, extent and peripheral extension of bronchiectasis worsened significantly. 
Relationships between changes in HRCT scores and PFTs were weak. Substantial 
structural lung damage was evident in some children who had normal lung function. 
These data show that HRCT is more sensitive than PFTs in the detection of early and 
progressive lung disease, and suggest that HRCT may be useful in the follow up of 
CF children and as an outcome measure in studies that aim to reduce lung damage.  
In section 4.2 we describe the longitudinal evaluation of lung structure on CT scans 
and lung function in children and adults with CF. The first aim of this study was to 
investigate whether CT scores would be more sensitive than PFTs to monitor 
structural disease progression in adults with CF. The second aim was to investigate 
whether previous results in children with CF could be reproduced. CT scans and 
PFTs were retrospectively studied in a cohort of CF-patients aged 5 to 52 years for 
whom 2 or 3 CT scans in combination with PFTs (FEV1, FVC, FEV1/FVC, MEF25, 
MEF50, RV, TLC and RV/TLC) at a three-year interval between CT scans were 
available. All CT scans were scored by two observers. PFTs were expressed as 
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percentage predicted and Z-score. Of 119 patients included, 92 patients had two and 
24 had three CT scans. CT scores (composite and components) and PFTs worsened 
significantly (p<0.02). However, peripheral bronchiectasis worsened most by 1.7% 
per year in children (p<0.0001) and by 1.5% per year in adults (p=0.0003). CT scores 
and PFTs showed similar worsening rates for adults and children (p>0.09). 
Therefore, it was concluded that peripheral bronchiectasis score was more sensitive 
than PFTs or composite CT score and other component scores for monitoring lung 
disease progression in this cohort of children and adults with CF.  
In section 4.3 changes in quantitative airway dimensions on CT scans of children 
with CF over a two-year interval were studied. Children with CF (n=23) who had two 
CT scans (CTcf1 and CTcf2) combined with PFTs at a two-year interval between 
measurements were compared to age-matched controls (n=21) who had one CT scan 
(CTcontrol). On cross-sectional cut airway-artery pairs, airway wall area (WA), airway 
lumen area (LA) and perimeter (Pi), and arterial area (AA) were quantified. LA/AA 
(=marker of bronchiectasis), airway wall thickness (AWT) and WA/AA (=markers of 
wall thickness) were calculated. CT scans were scored using 4 different scoring 
systems. PFTs were expressed as percent predicted. Airway wall area to arterial area 
ratio (WA/AA) was 1.45 (p<0.001) and airway lumen area to arterial area ratio 
(LA/AA) was 1.92 times higher (p<0.001) in CF compared to controls. LA/AA and 
WA/AA remained unchanged from CTcf1 to CTcf2 and did not increase with age. 
AWT as a function of airway size increased from CTcf1 to CTcf2 by 2% (0.03 mm; p = 
0.02). The change in AWT was inversely related to the change in FEF25-75 (p=0.002). 
It was concluded, therefore, that in CF quantitative measurements of airways on CT 
scans show an increased ratio between airway lumen and arterial area and progressive 
airway wall thickening; scoring systems show progression of bronchiectasis but 
unchanged airway wall thickness and PFTs remain stable. In conclusion, in the three 
studies described above CT was more sensitive than PFTs to monitor CF related lung 
disease, both in children and in adults.  
 
Chapter 5 focuses on radiation risks associated with CT scanning in CF.  
In section 5.1 we stated that low-dose radiation from CT might increase the risk of 
certain cancers, especially in children. We sought to estimate the excess all-cause and 
cancer-specific mortality associated with serial lifelong CT scanning in CF patients. 
CT scanning dose was calculated for a published CF protocol and the risk per scan 
was estimated from atom-bomb survivor data. A computational model was 
developed to evaluate the effects of background survival, scanning interval and 
scanning doses on radiation-related excess mortality in a CF cohort. The average dose 
per CT scan was 1 milli-Sievert. Survival reduction associated with annual scans from 
age 2 years until death was 1 month and >1 year for CF cohorts with a median 
survival of 26 years and 50 years, respectively. Corresponding cumulative cancer 
mortality was <1% and 6% of the cohort. We concluded that routine lifelong annual 
CT scans carry a low risk of radiation-induced mortality in CF. However, as the 
overall survival for CF patients tend to increase, the risk of radiation-induced 
mortality will become much more meaningful. These data suggest that serial imaging 
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strategies can only be used when lifelong radiation exposure remains below 
acceptable risk levels that outweigh the benefit. 
In section 5.2 we describe a study to determine whether the number of CT images 
and therefore the dose per CT scan could be reduced without any significant loss of 
information in children with CF. A cohort of children with CF was followed with 
biennial surveillance CT scans, obtained in inspiration after a voluntary breath-hold as 
1-mm thick images at 10-mm intervals from lung apex to base. A random set of 20 
baseline CT scans and 10 follow-up CT scans were blinded. Sets of every image (10-
mm interval), every second image (20-mm interval), every third image (30-mm 
interval) and a selection of three and five images were scored randomly using a 
published CT scoring system by one experienced observer. The 20 subjects were 10 
years of age with a range of 3.7-17.6 years at baseline. Fewer CT images resulted in 
significantly lower (less abnormal) CT scores and the number of patients positive for 
abnormalities decreased subsequently. At intervals greater than 20-mm no significant 
changes in CT score over two years could be detected, whereas CT scores at 10-mm 
(p=0.02) and 20-mm (p=0.02) intervals worsened significantly. We concluded that 
reducing the number of inspiratory CT images by increasing the interval between 
images to greater than 10-mm is not a valid option for radiation dose reduction in 
children with CF.  
 
In chapter 6 we examined whether lung growth could be monitored by CT.  
In section 6.1 the gas volume per gram of lung tissue was estimated from 
measurements of lung density obtained from CT scans performed in children 
throughout the growth period. CT scans were performed in 17 boys and 18 girls, 
ranging in age from 15 days–17.6 yrs. CT-measured lung weight was correlated with 
predicted post mortem values and CT measured gas volume with predicted values of 
functional residual capacity. The median value for lung expansion was 1.86 ml*g-1 at 
15 days, decreased to 0.79 ml*g–1 by 2 yrs and then increased steadily to 5.07 ml*g-1 at 
17 yrs. Therefore, CT scans can be used to estimate lung weight, gas volume and 
expansion of normal lungs during the growth period. The increase in lung expansion 
after the age of 2 yrs suggests progressive alveolar expansion with increasing lung 
volume.  
In section 6.2 we aimed to estimate airway, arterial and parenchyma dimensions 
throughout the growth period using CT and to provide normative data to study 
alterations in disease. ‘Normal’ CT scans performed in children for non-pulmonary 
and non-cardiac reasons were included. CT scans were analyzed for lung weight; gas 
volume; lung expansion; lung surface to volume ratio; airway wall area (WA); airway 
lumen area (LA); airway lumen perimeter (Pi); and arterial area (AA) and airway 
surface to volume ratio (Pi/LA). Ages of the 85 subjects ranged from 0 to 17.6 years. 
We found a slight increase in lung expansion for a given subject height in the first 
years of life with little change thereafter. There was substantial variability in lung 
expansion between subjects. Airway and arterial sizes were exponentially associated 
with subjects’ height, but the number of subjects was too small to detect differences 
between sexes. Airway surface to volume ratio (cm-1) was linearly to lung surface to 
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volume ratio (cm-1, R2=0.46-0.66, p<0.001). Our data provide normative CT 
estimates of airway, arterial and parenchyma dimensions throughout the growth 
period that may be useful to study alterations in disease. 
 
 
7.2 General discussion 
 
The studies presented in this thesis demonstrated that chest CT is clearly more 
sensitive than PFTs to follow the progression of the lung disease in children and 
adults who have CF. In addition, CT enabled to detect focal areas of end-stage lung 
disease in many CF patients with normal PFTs. Hence, PFTs, the gold standard for 
monitoring CF patients, are less sensitive to detect early and progressive disease in 
CF children. These findings are likely to have important clinical implications. Firstly, 
the early detection of structural changes on CT allows earlier intervention. Adequate 
treatment might then perhaps prevent irreversible structural damage. There is 
increasing evidence that early and aggressive therapy reduces loss of lung function 
and pulmonary exacerbations and improves quality of life in patients with CF 1-6. 
Therefore, a reasonable case could be made for regular routine CT scans to detect 
airway disease given the current reduced life-expectancy. However, the effect of CT 
on clinical decisions and the magnitude of its benefit remain to be determined. As 
infants or CF patients with end-stage lung disease were not included in our studies, 
we cannot tell whether CT is also more sensitive in these groups. 
 
A second important finding of our studies is that CT scoring in CF for the systems 
tested is generally reproducible between and within observers. We demonstrated that 
five published CT scoring systems all showed good intra- and interobserver 
agreement in two centers. Our scoring system studies indicated that bronchiectasis is 
the most relevant parameter for following CF patients clinically. Bronchiectasis is 
irreversible, while mucous plugging and airway wall thickening can be reversible, 
which may make these parameters less relevant, both clinically and in trials. 
Bronchiectasis is a highly relevant treatment end-point for a clinical trial in CF. In 
order to detect changes the duration of such a trial should be at least one to two 
years. The use of sensitive CT outcome measures is likely to reduce trial costs since 
fewer patients are needed compared to PFT related end points, although the 
increased power remains to be demonstrated. 
 
Third, we demonstrated that quantitative measurements of airway wall and lumen 
dimensions can be used in CF. These measurements revealed an increase in airway 
wall thickness over a two-year period that remained unnoticed in the five CT scoring 
systems. Airway wall thickening is an important CT feature in CF since it is related to 
airway inflammation. Our finding may therefore be relevant for trials that aim to 
reduce airway inflammation in CF.  
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We experienced several limitations in the quantitative studies. First, we used the 
accompanying pulmonary artery to define airway wall thickening and lumen 
dilatation. However, in CF patients the pulmonary artery dimensions themselves may 
have been changed by the disease progress. Secondly, several airways were excluded 
for analysis because of mucous plugging. This is likely to result in an underestimation 
of our findings. Thirdly, severely deformed airways were excluded for analysis since 
the accompanying artery could not be identified or the shape of the airway was too 
much distorted to allow measurement. Fourthly, we were unable to correct for 
inflation volume of the lungs during CT scanning and diseased airways may be more 
sensitive than healthy airways for variation in inflation. Finally, the HRCT protocol 
with 1-cm gaps between images greatly hampered matching of the same airway on 
follow-up CT scans. In spite of these limitations we were able to detect a progressive 
airway wall thickening that remained undetected with the scoring systems.  
 
Our computational model showed that the survival reduction risk of routine lifelong 
CT scans every second year in the CF population was low given the current 
background survival. However, in a fictive cohort of CF patients with an average 
survival of 50 years (expected survival in 2030) the cumulative mortality of radiation 
induced cancers of annual lifelong CT scans was over 6%. It should be stressed that 
possible clinical benefits of the scans were excluded from the model because we were 
only interested in the magnitude of risk. Clearly, scanning protocols should be 
designed in such a way that lifelong radiation dose is within acceptable limits that are 
outweighed by the benefits for patients with CF. The model can help us to design 
such scanning strategies with the lowest risk/benefit ratio. 
 
Finally we made the interesting observation that airway, parenchyma and arterial 
dimensions can be estimated from CT throughout the growth period. Therefore CT 
may enable the estimation of lung growth in health and disease in longitudinal 
studies. A condition for such studies is that their potential benefit must outweigh the 
radiation risks for the general or diseased population. Lung growth may be affected 
by CF lung disease early in life. Hence CT may have a role in studying abnormal lung 
growth patterns in CF. 
 
 
7.3 Directions for Future Research 
 
The studies described in this thesis followed some pioneer work that was published 
in the late eighties and early nineties. Our studies were a next step in this field of 
monitoring CF lung disease and their importance was discussed in the previous 
section. Still further research is needed to determine in more detail the role of CT 
scanning and to design better CT scanning strategies in CF patients clinically and in 
trials. CT provides the opportunity to improve our understanding of the pathogenesis 
of lung disease in CF and to study the impact of CF lung disease on lung growth. 
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Radiologists have the opportunity to move their specialty to the next level; from 
looking at images and providing descriptions of the abnormalities to a full exploit of 
the quantitative nature of their techniques with an evidence-based basis for their 
strategies. The following section aims to propose some directions for future research. 
 
Clinical benefit of CT scanning: Future studies may want to study in more detail 
the potential benefit associated with repetitive CT scanning in CF. It will also be 
clinically relevant to extend our cohort studies to patient groups with less and more 
severe disease. The detection of the earliest stages of disease in infancy, especially 
with quantitative methodology, will be an exciting area and some cross-sectional work 
has already been done 7. Although some studies 8, 9 addressed specifically acute versus 
chronic or reversible versus irreversible changes on CT, further studies in this area are 
required.  
 
Use of CT in intervention trials: A challenge in CF lung disease is to determine 
which therapies change the course of structural lung disease progression. CT may 
provide the opportunity for improved power and therefore fewer patients in trials. 
Fewer patients per trial involve lower costs and in addition more therapies can be 
tested simultaneously in these patients, who almost all participate in trials. An 
additional opportunity is observation of the structural substrate that is changed by the 
therapeutic agent. As previously stated, it may be more meaningful to halt the 
progression of bronchiectasis rather than to reverse or halt mucous plugging or 
airway wall thickening. A relevant study would be investigating the relationship 
between bronchiectasis and quality of life or mortality.  
 
Quantitative CT: More investigations in quantitative measurements of airway wall 
and lumen dimensions as well as air trapping in CF are needed. Some work has 
recently been done in this area in cross-sectional evaluations and a therapeutic trial 
with RhDNase 7, 10, 11. Quantitative CT techniques possibly are able to detect minor 
abnormalities in airway tapering or in airway compliance (difference in airway lumen 
in inspiration and expiration) before bronchiectasis becomes visible. The use of the 
accompanying pulmonary artery as a reference for airway wall and lumen is 
troublesome. Future studies using volumetric full-lung scanning should be able to 
follow the same airway over time without the use of the artery as a size reference. 
Nevertheless the arterial dimension could in itself potentially be an interesting marker 
of lung disease in CF, although further studies are required to establish this point. 
  
Gas trapping: There is an increasing interest in air or gas trapping 10-14. Gas trapping 
is thought to be an early and sensitive measure in CF since it reflects small airway 
obstruction and this is where CF lung disease is thought to begin. Further studies 
demonstrating the variability in the amount of gas trapping within patients over time 
are needed. The optimal numbers of images per expiratory CT scans have to be 
determined. 
 
SUMMARY, GENERAL DISCUSSION AND FUTURE DIRECTIONS 
 
 
  
 
142
 
Correlation with pathology: More studies are needed that correlate abnormalities 
(qualitative or quantitative) to the histopathologic abnormalities in explanted lungs or 
autopsy specimens of end-stage CF lungs. There are only few studies quantifying the 
pathology in CF lungs, and most of which are from an era before modern treatment 
became available. Pathology studies are hampered by their cross-sectional design and 
by the fact that they include mainly end-stage abnormalities. It is important to study 
the better preserved relatively normal areas of lung in these explanted or autopsy 
specimens, which will be possible because of the heterogeneous distribution of the 
disease. These studies will be important to validate CT scores and quantitative 
measurement techniques for CF.  
 
Lung growth: CT could have a role as a research tool to determine the influence of 
CF lung disease on postnatal alveolar and lung growth. 
 
CT scanning protocols: Optimization of CT scanning protocols and strategies with 
respect to dose, scanning technique and optimal interval between CT scans are 
needed in CF. Investigation should aim to determine the optimal dose per CT scan 
required to interpret and quantify the abnormalities and to determine the numbers of 
images needed for in- and expiratory CT scans. The introduction of multi-detector 
CT scanners in the nineties has provided the opportunity to scan the whole lung in a 
single breath hold and this is likely to become the future standard. CT protocols 
might include spirometer triggered CT scans 12, 15. This method is more invasive and 
time-consuming. It seems that those protocols are able to detect more gas trapping 
although no study compared this technique with the conventional technique. It would 
be valuable to study the changes in airway lumen, airway wall and arterial dimensions 
at different lung inflation levels in health and disease. The risk of protocols at various 
doses and intervals can be studied, also with the use of computational modeling 
strategies.  
 
Other modalities to monitor CF lung disease: Several other imaging and non-
imaging modalities are available to potentially monitor the pulmonary status of CF 
patients. There is currently no use for chest radiographs in monitoring structural lung 
disease in CF patients. Chest radiographs have limited sensitivity to detect early 
disease and follow the progression. Neither is there a use currently for magnetic 
resonance imaging (MRI). MRI has the advantage that it involves no radiation. 
Nevertheless MRI visualization of airway wall, airway lumen and mucous plugging is 
presently limited even with the use of hyperpolarized gases. MRI may be more useful 
to study the perfusion, ventilation and diffusion of CF lungs in a research setting. 
Some investigators have used endobronchial ultrasound 16, 17 to measure subdivisions 
of the airway wall down to the right apical bronchus. We feel this technique is too 
invasive to become widespread in CF monitoring. In addition current probes cannot 
visualize smaller airways, which are of main interest. An area of major interest 
involves a non-imaging technique, the measurement of ventilation homogeneity with 
SF6 in multiple breath washout tests 18. These tests have received more attention 
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recently and seem a promising marker of early lung disease in CF. The comparison 
between CT and multiple breath washout tests is highly relevant. Other biomarkers 
of CF lung disease are likely to emerge in the future that may reduce the need for 
imaging lung structure. Such markers may be found in blood, sputum, urine or 
exhaled gas and offer an easily available measurement.  
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Monitoren van longziekte bij cystic fibrosis met 
computed tomografie 
 
“Samenvatting, discussie en verder onderzoek” 
 
 
 
Om de aan cystische fibrose (CF) gerelateerde longziekte zo goed mogelijk te 
behandelen moeten de start en het beloop van de longafwijkingen nauwkeurig 
worden gevolgd. Dit kan op een indirecte manier worden gedaan met behulp van 
longfunctietesten of op een meer directe manier door de longstructuur af te beelden 
met röntgentechnieken. Tot op heden worden longfunctietesten, zoals spirometrie en 
lichaamsplethysmografie metingen, gezien als de belangrijkste methode om 
longafwijkingen op te sporen in CF. Longfunctietesten kunnen routinematig gebruikt 
worden vanaf de leeftijd van 5 of 6 jaar. Om de longstructuur af te beelden wordt 
routinematig gebruik gemaakt van de thoraxfoto. In de meeste CF-centra wordt 
jaarlijks een thoraxfoto gemaakt en soms ook bij een acute verslechtering 
(exacerbatie) van de ziekte.  
 
Onderzoek heeft aangetoond dat longfunctietesten gevoeliger zijn dan thoraxfoto’s 
om de voortgang of verslechtering van de aan CF gerelateerde longziekte te 
vervolgen. In het begin van de jaren negentig werd aangetoond dat computed 
tomografie (CT) scans gevoeliger zijn in vergelijking met thoraxfoto’s om afwijkingen 
in de longstructuur vroeg op te sporen in CF-patiënten.  
 
Er werden diverse CT scoringssystemen ontwikkeld om de afwijkingen op een 
systematische wijze in een getal om te zetten. Deze CT scoringssystemen bleken een 
matig tot goed verband te tonen met longfunctietesten. Een opvallende bevinding 
was dat structurele afwijkingen op CT scans werden gevonden in sommige patiënten 
met CF die een normale longfunctie hadden. Welk CT scoringssysteem het beste was 
om de longafwijkingen te scoren was niet duidelijk omdat de scoringssystemen nooit 
met elkaar vergeleken waren. Het was ook niet duidelijk hoe herhaalbaar 
verschillende beoordelaars één CT scan konden boordelen en hoe herhaalbaar in de 
tijd één beoordelaar één CT scan kon beoordelen. 
  
Naast het gebruik van CT scoringssystemen zijn er ook computersystemen 
ontwikkeld waarmee luchtwegen (wand en lumen) en bloedvaten gemeten kunnen 
worden. Deze computersystemen zijn ontwikkeld voor gebruik bij longziekten zoals 
chronisch bronchitis, longemfyseem, en astma. Deze systemen waren echter nog 
nooit gebruikt voor metingen van luchtwegen op CT scans van CF-patiënten.  
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Verder waren er geen studies gedaan waarbij over een langere tijd de veranderingen in 
de longafwijkingen zoals gemeten met CT scoringssystemen en luchtwegmetingen 
werden vergeleken met veranderingen in longfunctietesten. 
 
Hoewel CT scans gevoeliger zijn dan de thoraxfoto om longafwijkingen bij CF op te 
sporen was er geen onderzoek bekend dat heeft bestudeerd in hoeverre de straling 
verbonden aan CT onderzoek de levensverwachting van CF-patiënten nadelig kon 
beïnvloeden. 
 
Hoofdstuk 1 is een algemene introductie van dit proefschrift waarin ook het doel 
van de studies wordt beschreven. 
 
Hoofdstuk 2 beschrijft de redenen van onze studies in het licht van de huidige 
praktijk van het vervolgen van de aan CF gerelateerde longziekte. Dit hoofdstuk is 
met name gericht op de voor- en nadelen van het bepalen van vroege afwijkingen en 
het vervolgen van afwijkingen met behulp van longfunctietesten, thoraxfoto’s en CT 
scans. 
 
Hoofdstuk 3 beschrijft de vergelijking van CT scoringssystemen in CF. Sectie 3.1 
beschrijft een studie waarin de CT scores van vijf verschillende scoringssystemen 
worden vergeleken. Verder wordt de toegevoegde waarde van metingen van 
luchtwegen en longbloedvaten bepaald. CT score 0 betekende dat er geen afwijkingen 
aanwezig waren en een hogere score dat afwijkingen werden gezien. Drie 
beoordelaars scoorden 25 CT scans van kinderen met CF. Het scoren werd herhaald 
na intervallen van 1-2 weken tot 1-2 maanden. Luchtwegen en bloedvaten werden 
gemeten. De variatie tussen de beoordelaars en binnen één beoordelaar werd 
berekend. Het verband werd bepaald tussen CT scores en afmetingen van luchtwegen 
en bloedvaten en longfunctie parameters zoals uitademingvolume in de eerste 
seconde van de geforceerde uitademing (FEV1). We vonden dat de CT scores 
betrouwbaar tussen en binnen beoordelaars konden worden gescoord met alle vijf de 
systemen. De CT scores toonden een duidelijk verband met de FEV1. De ratio tussen 
luchtweglumen diameter en de diameter van de parallel lopende bloedvaten toonde 
ook een verband met CT scores, maar niet met FEV1. De ratio tussen 
luchtwegwanddikte en de diameter van de parallel lopende bloedvaten toonde met 
beide de CT scores en de FEV1 geen verband. Daarom concludeerden we dat CT 
scores reproduceerbaar waren en een verband toonden met longfunctietesten. 
Metingen van luchtwegdimensies toonden geen verband met CT scores of 
longfunctietesten. 
 
In Hoofdstuk 4 worden de studies beschreven waarin de gevoeligheid van CT 
vergeleken wordt met die van longfunctietesten voor het vervolgen van CF 
gerelateerde longziekte in kinderen en volwassenen. 
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Sectie 4.1 beschrijft de bevinding dat op CT scans van kinderen met CF 
longafwijkingen toenamen terwijl de longfunctie stabiel bleef. Het doel van deze 
studie was om de gevoeligheid van CT scoringssystemen en longfunctietesten te 
vergelijken om veranderingen in longziekte te vervolgen. De studie werd gedaan in 48 
kinderen met CF die allemaal twee CT scans in combinatie met twee 
longfunctietesten hadden ondergaan met een interval van twee jaar tussen de CT 
scans. De CT scans werden gescoord met vijf CT scoringssystemen: Castile, Brody, 
Helbich, Santamaria en Bhalla. Gevoeligheid was gedefinieerd als de mogelijkheid om 
verslechtering vast te stellen. In de groep kinderen verslechterden de CT scores 
terwijl de longfunctietesten stabiel bleven of verbeterden. Op de CT scans was een 
toename van de hoeveelheid slijmproppen te zien. Verder was er een uitbreiding van 
het aantal en van de ernst van bronchiectasieën. Het verband tussen veranderingen in 
CT scores en longfunctietesten was zwak. Substantiële longafwijkingen werden gezien 
op de CT scans van sommige kinderen met een normale longfunctie. Dit onderzoek 
laat dus zien dat CT een gevoeligere test is in vergelijking met longfunctietesten om 
de start en de verslechtering van de longziekte in kinderen met CF op te sporen. Dit 
suggereert dat CT nuttig zou kunnen zijn om longafwijkingen bij CF-patiënten te 
vervolgen. Verder zou CT gebruikt kunnen worden als meetpunt in studies die als 
doel hebben om longschade in CF te verminderen. 
In Sectie 4.2 beschrijven we een vervolgonderzoek van longstructuur en longfunctie 
in kinderen en volwassen patiënten met CF. Het eerste doel van deze studie was om 
te bepalen of CT scores gevoeliger zouden zijn dan longfunctietesten om bij 
volwassen CF-patiënten longafwijkingen te vervolgen. Het tweede doel was om te 
bepalen of de resultaten van de voorgaande studie in kinderen met CF kon worden 
herhaald. CT scans en longfunctietesten werden bestudeerd in een groep Zweedse 
CF-patiënten in de leeftijd van 5 tot 52 jaar. Van iedere patiënt waren 1, 2 of 3 CT-
scans beschikbaar in combinatie met longfunctietesten met een interval van drie jaar 
tussen de CT scans. Alle CT scans werden gescoord door 2 beoordelaars. 
Longfunctietesten werden uitgedrukt als percentage voorspeld en Z-score. 119 
patiënten werden opgenomen in de studie, 92 hadden twee en 24 hadden drie CT 
scans. De CT score (totale en losse componenten) en de longfunctietesten 
verslechterden. Echter, bronchiectasieën verslechterden het meest met 1,7% per jaar 
in kinderen en 1,5% per jaar in volwassenen. CT scores en longfunctietesten 
verslechterden even snel in kinderen als in volwassenen. De score van 
bronchiectasieën was dus gevoeliger dan de longfunctietesten, de totale CT score en 
de scores van de andere componenten van het scoringssysteem om longafwijkingen 
te volgen in deze groep kinderen en volwassen CF-patiënten.  
In Sectie 4.3 werden veranderingen in luchtwegafmetingen op CT scans van kinderen 
met CF gemeten. Drieëntwintig kinderen met CF die twee CT scans (CTcf1 en CTcf2) 
in combinatie met longfunctietesten met een interval van twee jaar tussen de 
metingen hadden werden vergeleken met 21 controles (CTcontroles) van gelijke leeftijd. 
Deze controle-patiënten hadden allen één CT scan die door twee radiologen als 
normaal was beoordeeld. Van alle luchtweg-bloedvat paren werden 
luchtwegwandoppervlakte, luchtweglumenoppervlakte en omtrek, en 
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bloedvatoppervlakte gemeten. Met deze gegevens werden de verhouding tussen 
luchtweglumen- en bloedvatoppervlakte als maat voor bronchiectasieën berekend. 
Als maat voor luchtwegwanddikte werd de verhouding tussen luchtwegwanddikte en 
bloedvatoppervlakte berekend. Verder werden de CT scans met vier verschillende CT 
scoringssystemen gescoord. Resultaten van de longfunctietesten werden uitgedrukt 
als percentage voorspeld. De verhouding tussen luchtwegwanddikte en 
bloedvatoppervlakte was 1,45 en de verhouding tussen luchtweglumen- en 
bloedvatoppervlakte was 1,92 keer hoger in CF-patiënten in vergelijking met 
controles. Luchtwegwanddikte als een functie van luchtweggrootte nam toe van CTcf1 
naar CTcf2 met 0,03 mm (2%). Deze verandering in luchtwegwanddikte toonde een 
duidelijk verband met de verandering in de longfunctie. In CF laten metingen van 
luchtwegen op CT-scans dus een toename zien van de verhouding tussen 
luchtweglumen- en bloedvatoppervlakte en een toename van de luchtwegwanddikte. 
De scoringssystemen laten een toename zien van de bronchiectasieën, maar 
onveranderde luchtwegwanddikte. Longfunctietesten waren stabiel. In de drie 
beschreven studies was CT dus gevoeliger dan longfunctietesten om longafwijkingen 
te vervolgen zowel in kinderen als in volwassen patiënten met CF. 
 
Hoofdstuk 5 concentreert zich op het stralingsrisico dat samenhangt met het maken 
van CT scans in CF-patiënten.  
In Sectie 5.1 stellen wij dat de lage stralingsdosis van CT scans het risico op bepaalde 
soorten kanker zou kunnen vergroten, met name als CT scans op de kindleeftijd 
worden gedaan. Ons doel was om met een rekenkundig computermodel een schatting 
te maken van de totale extra sterfte ten gevolge het doen van herhaalde CT scans in 
patiënten met CF. De stralingsdosis per CT scan werd berekend voor het CT-
protocol dat gebruikt werd in CF-patiënten van het Erasmus MC - Sophia. In het 
computermodel werd gebruik gemaakt van stralingsrisico gegevens afkomstig van de 
Japanse bevolking die de atoombom overleefden. Computersimulaties werden gedaan 
waarin het effect van het interval tussen CT scans en de dosis per CT scan op de 
overleving van CF-patiënten werd berekend. In de simulaties werd er vanuit gegaan 
dat de informatie verkregen van de CT scans de levensverwachting niet veranderde. 
Het doen van een jaarlijkse CT scan vanaf de leeftijd van twee jaar bij een gemiddelde 
overleving van 26 jaar of van 50 jaar gaf een vermindering in overleving van 
respectievelijk een maand tot meer dan een jaar. De bijbehorende extra kankersterfte 
was minder dan 1% en ongeveer 6%. Onze conclusie was dat het doen van een CT 
scan om het jaar een laag risico geeft op stralinggeassocieerde kankersterfte in CF. 
Echter, aangezien de overleving van CF-patiënten lijkt toe te nemen zal dit 
stralingsrisico in betekenis toe nemen. Ons onderzoek suggereert dat herhaald 
röntgenonderzoek gebruikt kan worden om ziekte op te sporen, te vervolgen en te 
behandelen mits de levenslange stralingsbelasting onder een acceptabel risiconiveau 
blijft, waarbij het voordeel groter moet zijn dan het nadeel. 
In Sectie 5.2 beschrijven we een studie om te bepalen of in kinderen met CF het 
aantal afbeeldingen per CT scan, en daarmee de stralingsdosis per CT scan, 
verminderd zou kunnen worden zonder belangrijk verlies van informatie. Met name 
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op de kinderleeftijd is het belangrijk om de stralingsdosis per CT-onderzoek tot het 
absolute minimum te beperken. Voor dit onderzoek werd gebruik gemaakt van een 
groep van CF-patiënten die werden gevolgd met tweejaarlijkse routine CT scans. CT 
scans werden gemaakt tijdens een adempauze bij maximale inademing. Hierbij 
werden 1-mm dikke plakjes gemaakt op intervallen van 10-mm tussen de plakjes van 
de longtop tot de onderkant van de longen. Uit de patiëntengroep werd een 
willekeurige selectie gemaakt van 20 CT scans met voor 10 patiënten ook de vervolg 
CT scan. Sets werden samengesteld van alle plakjes (10-mm interval), ieder tweede 
plakje (20-mm interval), ieder derde plakje (30-mm interval) en van drie en vijf plakjes 
op geselecteerde niveaus. Sets werden in willekeurige volgorde gescoord door een 
ervaren beoordelaar met behulp van een CT scoringssysteem. De 20 CF-patiënten 
waren 10 jaar oud bij het begin van de studie met een spreiding van 3,7 tot 17,6 jaar. 
Als er minder plakjes werden gescoord resulteerde dit in een vermindering van de CT 
score en het aantal patiënten met bepaalde afwijkingen nam af oftewel de longschade 
werd onderschat. Als het interval groter was dan 20-mm kon er geen verslechtering 
van de CT score over een periode van twee jaar worden gevonden. Bij intervallen van 
10-mm en 20-mm werd wel een verslechtering van de CT score over twee jaar 
gevonden. We concludeerden daarom dat vermindering van het aantal plakjes per CT 
scan geen aantrekkelijke optie was om de stralingsdosis per CT scan te verminderen 
bij kinderen met CF.  
 
Hoofdstuk 6 gaat over hoe longgroei gemeten kan worden met CT scans. 
In Sectie 6.1 werd het volume aan gas in de longen per gram longweefsel geschat 
(longuitzetting) door het meten van de longdensiteit op CT scans van kinderen in de 
groeiperiode. CT scans werden gemaakt in 17 jongens en 18 meisjes in de leeftijd van 
15 dagen tot 17,6 jaar. Longgewicht geschat met de CT scan was min of meer 
hetzelfde als het longgewicht van overleden kinderen zoals beschreven in de 
literatuur. Het volume aan gas in de longen was min of meer gelijk aan de voorspelde 
functionele residuale capaciteit. De longuitzetting nam af van 1,85 milliliter gas per 
gram longweefsel op de leeftijd van 15 dagen tot 0,79 milliliter gas per gram 
longweefsel op de leeftijd van 2 jaar. Hierna nam de longuitzetting weer toe tot 5,07 
milliliter gas per gram longweefsel op 17 jaar. CT scans lijken daarom geschikt om 
schattingen te kunnen doen van de groei van longen gedurende de groeiperiode. De 
toename van de longuitzetting na de leeftijd van 2 jaar suggereert een toenemende 
uitzetting van de kleinste longblaasjes (alveoli) als het longvolume toeneemt.  
Het doel van de studie beschreven in sectie 6.2 was om afmetingen van luchtwegen, 
bloedvaten en longblaasjes te schatten op CT scans gemaakt gedurende de 
groeiperiode. Verder om normaalwaarden te bepalen die gebruikt kunnen worden om 
afwijkingen in de groei op te kunnen sporen als gevolg van ziekte. De normale CT 
scans waren afkomstig van kinderen die een CT scan van de longen hadden 
ondergaan zonder dat er sprake bleek te zijn van hart- of longafwijkingen. Op deze 
normale CT scans werden longgewicht; volume aan gas in de longen; longuitzetting; 
de ratio tussen longoppervlakte en longvolume; luchtwegwandoppervlakte; 
luchtweglumenoppervlakte; luchtweglumenomtrek; bloedvatoppervlakte; en de ratio 
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luchtwegomtrek en luchtweglumenoppervlakte gemeten. De leeftijd van de 85 
kinderen varieerde tussen de 0 en 17,6 jaar. We vonden een geringe toename in de 
longuitzetting in de eerste levensjaren die daarna maar weinig meer veranderde. Er 
was een aanzienlijke variatie in longuitzetting tussen de individuen van een bepaalde 
leeftijd. Luchtweg en bloedvatenafmetingen toonden een verband met de 
lichaamslengte. De afmeting van longblaasjes toonde een verband met de afmetingen 
van luchtweglumen. Onze gegevens verschaffen normaalwaarden voor afmetingen 
van luchtwegen, bloedvaten en longblaasjes gedurende de groeiperiode die nuttig 
kunnen zijn bij het bestuderen van afwijkende groei bij ziekte. 
 
 
Discussie 
 
De belangrijkste bevinding van de studies in dit proefschrift is dat CT gevoeliger is 
dan longfunctietesten om de toename van longafwijkingen aan te tonen in kinderen 
en volwassen patiënten met CF. Verder bleek CT in staat om gebiedjes met ernstige 
longafwijkingen aan te tonen in patiënten met normale longfunctietesten. CT scans 
zijn dus gevoeliger dan longfunctietesten om de start en de verslechtering van de 
longziekte in CF aan te tonen. Deze bevindingen hebben waarschijnlijk belangrijke 
gevolgen voor de kliniek. Ten eerste, het vroeg ontdekken van structurele afwijkingen 
op de CT scan maakt het mogelijk om patiënten met CF in een vroege fase en 
gerichter te behandelen. Zo kan geprobeerd worden om onherstelbare schade in de 
longen te voorkomen. Het wordt steeds duidelijker dat vroege en agressieve 
behandeling van patiënten met CF de snelheid van achteruitgang in longfunctie en 
het aantal acute verslechteringen (exacerbaties) vermindert en de levenskwaliteit 
verbetert. Het routinematig maken van CT scans lijkt een goede strategie om de 
verminderde levensverwachting van CF-patiënten verder te verbeteren. Hoe CT 
scans klinische beslissingen beïnvloeden en wat hiervan de invloed is op de 
levensverwachting van de patiënt moet nog verder worden onderzocht. In onze 
studies zoals beschreven in dit proefschrift zijn geen kinderen jonger dan vier jaar en 
slechts enkele patiënten in het eindstadium van de ziekte onderzocht. Daarom 
kunnen we geen uitspraken doen over de gevoeligheid van CT scans in deze 
patiëntengroepen. 
 
Een tweede belangrijke bevinding van ons onderzoek is dat het scoren van CT scans 
met de vijf geteste scoringssystemen betrouwbaar gedaan kan worden. Er bleek 
weinig variatie te zijn tussen verschillende waarnemers die één CT scan scoren en in 
een waarnemer die het scoren van één CT scan na een periode herhaalt. Verder bleek 
dat met name bronchiectasieën op CT scans de meeste relevante afwijking is om 
patiënten met CF te vervolgen in de kliniek. Bronchiectasieën zijn onherstelbaar 
verwijde luchtwegen. Afwijkingen zoals slijmproppen en luchtwegwandverdikking 
zijn daarentegen afwijkingen die nog omkeerbaar kunnen zijn. Bronchiectasieën zijn 
daarom ook meer geschikt dan slijmproppen en luchtwegwandverdikking om als 
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meetpunt te gebruiken in geneesmiddelenonderzoek gericht op de longafwijkingen in 
CF. Door het gebruik van CT scans in geneesmiddelenonderzoek kunnen 
waarschijnlijk de kosten verminderd worden doordat met deze gevoeligere test 
minder patiënten nodig zijn.  
 
Ten derde hebben we aangetoond dat het mogelijk is om met beeldanalysetechnieken 
de luchtwegwanddikte en luchtweglumendiameter te meten in CF. Met dergelijke 
metingen hebben we in 2 jaar tijd een toename in de luchtwegwandverdikking 
kunnen vaststellen. De vijf scoringssystemen bleken niet gevoelig genoeg om deze 
toename op te sporen. Luchtwegwandverdikking is een belangrijk kenmerk in CF-
patiënten omdat dit een maat is voor de ernst van de luchtwegontsteking. Deze 
methode kan daarom belangrijk zijn voor toekomstig onderzoek naar geneesmiddelen 
die er op gericht zijn om de luchtwegontsteking in CF te verminderen. Er waren 
echter nog wel een aantal problemen om met deze technieken de luchtwegen te 
meten. Sommige luchtwegen konden bijvoorbeeld niet gemeten worden omdat er 
slijmproppen in zaten. Andere luchtwegen waren zo ernstig vervormd dat ze niet 
meer gemeten konden worden. Ook is het waarschijnlijk dat het inademingniveau 
tijdens het maken van de CT scan van invloed is op de metingen. Het verder 
ontwikkelen van deze gevoelige beeldanalysetechnieken is aantrekkelijk omdat deze in 
de toekomst geautomatiseerd kunnen worden.  
 
Een vierde belangrijke bevinding kwam uit ons rekenkundig computermodel naar de 
stralingsrisico's van CT. Dit onderzoek liet zien dat met de huidige overleving van 
CF-patiënten het risico van het maken van CT scans iedere twee jaar laag is. Als we in 
de simulaties echter uitgingen van jaarlijkse scans vanaf de peuterleeftijd en van een 
overleving van 50 jaar nam de sterfte ten gevolge van de met stralen samenhangende 
kanker toe tot 6%. Het moet benadrukt worden dat we in ons model net deden alsof 
er geen behandelingsvoordeel zou zijn door de CT scans. Het is duidelijk dat CT-
protocollen op een dusdanige manier ontwikkeld moeten worden dat de risico's van 
de totale levenslange stralenbelasting van een patiënt onder een acceptabele grens 
blijven. Het voordeel van het maken van scans voor patiënten met CF lijkt dus groter 
dan de nadelen. Computermodellen kunnen ons helpen om veilige protocollen te 
ontwikkelen. 
 
Ten slotte deden we de interessante observatie dat met behulp van CT scans de 
longgroei gemeten kan worden in gezonde kinderen. Het is niet onwaarschijnlijk dat 
de longgroei bij CF-patiënten gestoord is. CT zou een rol kunnen spelen om de 
invloed van ziekte op longgroei te bestuderen. 
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Verder onderzoek 
 
Onze studies zoals beschreven in dit proefschrift waren een vervolg op CT-
onderzoek uit eind jaren '80 en begin jaren '90. Onze studies waren een logische 
volgende stap om de aan CF gerelateerde longziekte beter te kunnen vervolgen. 
Verder onderzoek is nodig om de rol van het maken van CT scans in CF-patiënten 
nader te bepalen. Verder moeten betere strategieën voor het maken van CT scans 
worden ontwikkeld. CT geeft ons de mogelijkheid om onze kennis en begrip van het 
ziekteproces te verdiepen en om de invloed van de aan CF gerelateerde longziekte op 
de longgroei te bepalen. De volgende paragraaf heeft als doel om een aantal grote 
lijnen aan te geven voor verder vervolgonderzoek. 
 
Klinisch voordeel van CT scans: Toekomstig onderzoek zou in nog meer detail het 
voordeel van routinematige CT scans bij CF kunnen bestuderen. Het is belangrijk om 
onze studies uit te breiden naar patiëntengroepen met vroegere en latere afwijkingen. 
Met name het meten van de vroege afwijkingen in hele jonge CF-patiënten kan tot 
belangrijke nieuwe inzichten leiden. Verder onderzoek naar de omkeerbaarheid van 
de op CT gevonden afwijkingen is wenselijk. Als laatste is het belangrijk om de relatie 
te bestuderen naar de ernst van de afwijkingen op CT en de kwaliteit van leven en 
overleving van de patiënten. 
 
CT scans en geneesmiddelenonderzoeken: Het is een grote uitdaging in CF om te 
onderzoeken welke behandelingen de toename van de longschade kunnen vertragen. 
Met behulp van CT scans kan worden bepaald of een therapie effectief is. Bovendien 
kan dit worden gedaan met minder patiënten en tegen lagere kosten. Op dit moment 
zijn er veel nieuwe geneesmiddelen voor CF-patiënten in ontwikkeling. Het wordt 
hierdoor steeds moeilijker om voldoende patiënten te vinden om al deze nieuwe 
geneesmiddelen te testen. Door CT scans als meetpunt te gebruiken kan dit probleem 
(deels) opgelost worden. Bovendien kunnen we het effect van behandelingen op de 
longafwijkingen met CT beter bestuderen. Zoals we eerder schreven is het vooral 
belangrijk om het ontstaan en de toename van bronchiectasieën te vertragen. 
 
CT metingen: Verder onderzoek is nodig om beeldanalyse technieken te verbeteren 
voor het opmeten van luchtwegen en van de luchthoudendheid van de longen op CT 
scans. Belangrijk is vooral om technieken te ontwikkelen waarmee subtiele 
afwijkingen opgespoord kunnen worden die kunnen leiden tot afwijkingen zoals 
bronchiectasieën. Toekomstige studies kunnen het beste geen gebruik meer maken 
van bloedvatafmetingen om luchtwegen mee te vergelijken. Met nieuwe CT scanners 
kan de hele long in één adempauze gescand worden. Met deze techniek is het 
eenvoudiger om luchtwegwand dimensies te vervolgen zonder gebruik te hoeven 
maken van de met de luchtwegen meelopende bloedvaten. Op zichzelf zijn de 
afmetingen van de bloedvaten interessant omdat veranderingen in bloedvaten een 
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maat zouden kunnen zijn van de ernst van de aan CF gerelateerde longziekte. 
Aanvullende studies zijn echter nodig om deze veronderstelling te onderbouwen. 
  
Luchthoudendheid: Er is een toenemende interesse in veranderingen in 
luchthoudendheid van de longen in relatie tot de ademhaling. In CF beginnen de 
afwijkingen vooral in de kleine luchtwegen. Als gevolg hiervan kan lucht in bepaalde 
gebieden van de long minder snel of helemaal niet uitgeademd worden. Deze 
gebieden worden 'trapped gas' genoemd en zien er extra zwart uit op de CT scan. Het 
is aannemelijk dat metingen van luchthoudendheid in CF-patiënten een vroege en 
gevoelige ziektemaat zou kunnen zijn. Verder onderzoek is nodig om de variabiliteit 
in de hoeveelheid 'trapped gas' over een bepaalde periode te bepalen. Verder moet 
het aantal uitademing CT plakjes dat nodig is om 'trapped gas' goed aan te tonen nog 
bepaald worden. 
 
Relatie CT en pathologie: Het is nodig om de relatie te bestuderen tussen de 
afwijkingen op CT scans en de afwijkingen van de longen onder de microscoop. Dit 
kan door bij transplantatiepatiënten de CT van voor de operatie te vergelijken met de 
uitgenomen long. Op dit moment zijn er maar weinig zulke studies en de studies die 
er zijn stammen vaak nog uit het tijdperk voordat de huidige antibiotica beschikbaar 
waren. Zulke studies zijn helaas altijd tot op zekere hoogte beperkt om het een 
dwarsdoorsnede betreft van longen in een eindstadium van de ziekte. Een mogelijke 
oplossing is om in zulke longen ook de meer normale gebieden te bestuderen. De 
longafwijkingen in CF zijn immers door de hele long ongelijk in ernst. Studies zijn 
belangrijk om scoringssystemen en CT metingen te verbeteren voor het gebruik in 
CF. 
 
Longgroei: CT kan een rol spelen om de invloed van de aan CF gerelateerde 
longziekte op de groei van longen na de geboorte te bestuderen. 
 
CT protocollen: Verder onderzoek is nodig naar het optimaliseren van CT scanning 
protocollen met betrekking tot de stralendosis, de techniek en het tijdsinterval tussen 
CT scans. Dit onderzoek moet tot doel hebben om met een minimaal aantal CT 
plakjes zoveel mogelijk relevante informatie te verzamelen. Verder is het nodig om 
technieken te ontwikkelen waarmee betere controle kan worden verkregen over het 
longvolume waarbij de CT scan gedaan wordt. Het lijkt erop dat CT scans gemaakt 
met speciale protocollen 'trapped gas' beter kunnen aantonen dan wanneer een 
eenvoudig in- en uitademingcommando wordt gegeven. Deze methode vraagt echter 
meer van de patiënt en is meer tijdrovend. Met deze techniek moet het ook mogelijk 
zijn om veranderingen in luchtweg- en bloedvatafmetingen in relatie tot het 
longvolume te bestuderen in zowel gezonde als zieke personen. De stralingsrisico's 
van de verschillende protocollen kan worden ingeschat met de rekenkundige 
computermodellen  
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Overige testen om longziekte vroeg te ontdekken en te vervolgen in CF: 
Verschillende andere methoden zijn beschikbaar die mogelijk de aan CF gerelateerde 
longziekte zouden kunnen vervolgen. Op dit moment is er geen plaats meer voor het 
gebruik van thoraxfoto’s om CF-patiënten te vervolgen. Deze techniek is te 
ongevoelig om vroege afwijkingen op te sporen en om veranderingen in 
longafwijkingen te vervolgen. Er is op dit moment ook (nog) geen plaats voor MRI 
(magnetic resonance imaging) in het afbeelden van de longen van CF-patiënten. MRI 
heeft als grote voordeel dat er geen röntgenstralen bij betrokken zijn. Echter de 
afbeeldingen van luchtwegen met MRI is op dit moment minder goed dan die van 
CT. MRI zou wel een plaats kunnen hebben om bijvoorbeeld longdoorbloeding te 
besturen. Ook is echografie gebruikt om de luchtwegwand te bestuderen. Deze 
techniek is echter te ingrijpend om op grote schaal toegepast te kunnen worden. De 
echokop moet namelijk via de luchtpijp in de luchtwegen gebracht worden om 
metingen te kunnen doen. Verder zijn de echokoppen op dit moment nog te groot 
om met name kleine luchtwegen af te beelden welke het meest relevant zijn in CF. 
Een ander veelbelovend onderzoeksgebied is het meten van inhomogeniteit van de 
ventilatie met uitademingtesten van bepaalde gassen. Deze functionele testen lijken 
gevoelig te zijn om vroege longafwijkingen in CF op te kunnen sporen. De 
uitkomsten van deze testen moeten vergeleken gaan worden met CT scans.  
 
Door intelligent gebruik van CT technieken is het waarschijnlijk dat we in de nabije 
toekomst veel zullen leren over het ontstaan en de behandeling van CF gerelateerde 
longziekte. 
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